diff --git a/docs/decisions.md b/docs/decisions.md index ae71ab9..0c64a5b 100644 --- a/docs/decisions.md +++ b/docs/decisions.md @@ -103,3 +103,9 @@ Each decision is listed with the date and the reason for it. Settled decisions a | 49 | **V2 is the V1 fit with a physician-cluster-robust SE.** Under V4, physicians without an estimable fixed effect in a phase get probability 0, and the V4 population is restricted to physicians with variation in early PVI. | Same point estimate by construction (D15). | | 50 | **Validation (W0, harm, 40 replicates of 50,000):** CCW A−B1 is +5.12 vs a truth of +5.11 on the disease composite (z = 0.0); sequential ITT is +5.83 vs +5.71 (z = 0.6); MALE and NCO-1 have |z| ≤ 0.7. The model SE is 0–20% below the empirical SE for CCW, so the bootstrap check in D28 still needs doing. | Plan §15 validation (a). | | 51 | **Speed and scale.** The PVI model is fitted once per replicate and variant, and shared by CCW and the sequential trials. CCW clones and weights are built once for all outcomes. The deferred-period PVI model uses every PVI plus a fixed 10% sample of the other person-months, with offset log(10). On W0 validation the estimates are identical to 4 decimals. The main designs take about 39 s per replicate instead of about 130 s. **Scale:** n = 50,000 stays. Draft is 100 replicates; final is 200 replicates (replacing 500 in D29), and the final run extends the draft's replicates 1–100. Total about 12 hours on 11 cores. | User asked for a faster, smaller run. The sample size is not reduced, because CCW's strategy A already depends on about 250 patients treated in month 5 at n = 50,000. With 200 replicates, MCSE of bias ≈ empirical SE / 14 (CCW about 0.2 pp) and MCSE of coverage ≈ 1.5%. | + +## Draft run (2026-10-28) + +| # | Decision | Why | +|---|---|---| +| 52 | **Draft run done:** 8 worlds × 3 scenarios × 100 replicates of 50,000 patients; 9.4 h on 11 cores; 0 errors. 16 of 288,000 estimates are NA (sequential trials, V4, 4 replicates) and are dropped. Summary: `simulations/04_summarise.R` writes `results/summary/`. Report: `reports/draft-report.Rmd`. Two open questions: (Q1) the landmark propensity model adjusts for month-5 severity, a post-PVI mediator, which drives the landmark question gap (W1 own truth about 20 pp vs a reference of 7.2 pp); with baseline covariates only, the 20-replicate oracle mean is 8.1. (Q2) NCO-1 has no severity term in the DGP, contrary to D32, so it cannot detect W5/WR bias. The bootstrap check (D28) waits on Q1/Q2. | Surfaced by the draft results. | diff --git a/reports/draft-report.Rmd b/reports/draft-report.Rmd new file mode 100644 index 0000000..d29b446 --- /dev/null +++ b/reports/draft-report.Rmd @@ -0,0 +1,287 @@ +--- +title: "Early vs delayed PVI for claudication: known-truth simulation, draft results" +subtitle: "Draft scale: n = 50,000 patients, 100 replicates per world x scenario" +date: "`r format(Sys.Date())`" +output: + html_document: + toc: true + toc_float: true + self_contained: true +--- + +```{r setup, include = FALSE} +knitr::opts_chunk$set(echo = FALSE, message = FALSE, warning = FALSE, fig.align = "center", dpi = 120) +suppressPackageStartupMessages({ library(data.table); library(ggplot2); library(patchwork) }) +root <- normalizePath("..") +S <- file.path(root, "results", "summary") +perf <- fread(file.path(S, "perf.csv")); nc <- fread(file.path(S, "nc_reps.csv")) +ncs <- fread(file.path(S, "nc_summary.csv")); reps <- fread(file.path(S, "reps.csv")) + +WORLDS <- c("W0", "W1", "W1_rho0", "W2", "W3", "W4", "W5", "WR") +WLAB <- c(W0 = "W0 Clean", W1 = "W1 Skill", W1_rho0 = "W1 Skill (rho 0)", W2 = "W2 Style", + W3 = "W3 Style -> outcome", W4 = "W4 Deferral", W5 = "W5 Unmeasured severity", WR = "WR Realistic") +VAR <- c(V2_cluster = "Ignore physician (cluster SE)", V3_random = "Random intercept", + V4_within = "Within-physician (FE)", none = "Trial (no adjustment)") +VCOL <- c("Ignore physician (cluster SE)" = "#2a78d6", "Random intercept" = "#eb6834", + "Within-physician (FE)" = "#1baf7a", "Trial (no adjustment)" = "#52514e") +METH <- data.table( + k = c("ccw|A_B1", "ccw|A_B2", "seq|now_not", "landmark|early_none", "naive|early_none", + "rct_realistic|itt", "rct_ideal|itt", "rct_realistic|as_treated", "rct_ideal|as_treated"), + method = c("CCW, A vs B1 (reference)", "CCW, A vs B2", "Sequential trials, ITT", "Landmark at 6 months", + "Naive 'ever early PVI'", "Realistic RCT (n = 240), ITT", "Ideal pragmatic RCT, ITT", + "Realistic RCT, as-treated", "Ideal RCT, as-treated")) +setnames(METH, "k", "key") +pp <- function(x, k = 1) formatC(100 * x, format = "f", digits = k) +theme_set(theme_minimal(base_size = 11) + theme(panel.grid.minor = element_blank(), + panel.grid.major.y = element_blank(), strip.text = element_text(face = "bold", hjust = 0), + legend.position = "bottom")) +perf <- perf[analysis %in% c("main", "rct")] # NCE analyses are used only in Table 4 +perf[, key := paste(design, contrast, sep = "|")] +perf <- merge(perf, METH, by = "key") +perf[, method := factor(method, levels = rev(METH$method))] +perf[, wlab := factor(WLAB[world], levels = WLAB[WORLDS])] +perf[, vlab := factor(VAR[variant], levels = VAR)] +``` + +# Read this first + +* **Run.** 8 worlds × 3 truth scenarios × 100 replicates of 50,000 patients (about 1,500 physicians per + replicate). Each replicate runs naive, landmark, CCW and sequential trials under 4 physician + variants, 3 negative controls, an oracle run, and 2 simulated RCTs. 2,400 replicate files, 0 + errors. 16 of 288,000 estimates are missing (sequential trials with physician fixed effects, 4 + replicates), and these are dropped. +* **Outcome shown.** The headline outcome is the **disease composite (CLTI or major amputation)**, + whose true effect under the null is exactly 0 (D34). MALE is shown where it adds something. +* **Two errors, kept separate (D27).** *Estimation bias* = mean estimate − the method's own truth. + *Question gap* = the method's own truth − the reference truth (CCW A vs B1). *Total error* is the sum. +* **Variants shown.** "Ignore physician" is V1's point estimate with the cluster-robust SE (V2). + The V1 patient-level SE is in the supplement tables. +* **Two open questions** came out of this run (Section 6). They affect the landmark results and the + negative-control results, so treat those parts as provisional. + +# 1. Aim 1: what each method answers (clean world W0) + +```{r tab2} +t2 <- perf[world == "W0" & outcome == "disease" & variant %in% c("V2_cluster", "none") & + !grepl("as_treated", key)] +t2 <- t2[, .(Scenario = scenario, Method = as.character(method), `Reference truth` = pp(ref), + `Own truth` = pp(own), `Question gap` = pp(gap), `Mean estimate` = pp(mean_est), + `Estimation bias (MCSE)` = sprintf("%s (%s)", pp(bias, 2), pp(mcse_bias, 2)), + `Empirical SE` = pp(emp_se), `Coverage of own truth` = sprintf("%.0f%%", 100 * cover_own))] +t2[, Scenario := factor(Scenario, levels = c("null", "harm", "benefit_harm"))] +t2[, Method := factor(Method, levels = METH$method)] +knitr::kable(t2[order(Scenario, Method)], align = "llrrrrrrr", + caption = "Table 2. Disease composite, 5-year risk difference in percentage points, world W0.") +``` + +**What it shows.** + +* Every TTE method is close to unbiased for **its own** truth in W0 (all |bias| < 0.35 pp). H1a holds. +* The methods answer **different questions**. Under harm (reference +5.1 pp): sequential trials target + +5.7, landmark +7.9 and naive +7.2. So the question gap alone is 0.6–2.8 pp. Under the null, naive + has a gap of +1.3 pp from immortal time even with every confounder measured. H1b holds, though the + gap for the sequential trials is small. +* **CCW is right but imprecise.** Its empirical SE is about 2.8 pp at n = 50,000, against about 1.5 pp for + sequential trials. Under the null its 95% CI excludes 0 in 15% of replicates (Section 3). +* The **realistic RCT (n = 240)** is unbiased for its own ITT, but its SE is about 4.2 pp. It detects + the 5-point harm in only 25% of replicates. + +```{r fig1, fig.width = 11, fig.height = 9} +ladder <- function(sc, oc = "disease") { + x <- perf[scenario == sc & outcome == oc & variant != "V1_ignore" & !grepl("as_treated", key)] + r <- reps[scenario == sc & outcome == oc & analysis %in% c("main", "rct") & variant != "V1_ignore" & + variant != "oracle" & !grepl("as_treated", contrast)] + r[, key := paste(design, contrast, sep = "|")] + q <- r[, .(lo = quantile(est, 0.025), hi = quantile(est, 0.975)), by = .(world, key, variant)] + x <- merge(x, q, by = c("world", "key", "variant")) + dodge <- position_dodge(width = 0.6) + ggplot(x, aes(y = method, group = vlab)) + + geom_vline(aes(xintercept = 100 * ref), colour = "#0b0b0b", linewidth = 0.4) + + geom_vline(xintercept = 0, colour = "#c3c2b7", linewidth = 0.3, linetype = 2) + + geom_linerange(aes(xmin = 100 * lo, xmax = 100 * hi, colour = vlab), position = dodge, linewidth = 0.6) + + geom_point(aes(x = 100 * own), position = dodge, shape = 21, size = 2.6, fill = "white", colour = "#0b0b0b") + + geom_point(aes(x = 100 * mean_est, colour = vlab), position = dodge, size = 2) + + facet_wrap(~wlab, ncol = 4) + scale_colour_manual(values = VCOL, name = NULL) + + labs(x = "5-year risk difference, early − delayed (percentage points)", y = NULL, + caption = paste("Filled dot: mean estimate (bar: 2.5th–97.5th percentile across replicates).", + "Hollow dot: the method's own truth. Solid line: the reference truth (CCW A vs B1).")) + + coord_cartesian(xlim = c(-15, 35)) +} +ladder("harm") + ggtitle("Figure 1a. Estimand ladder, harm scenario (disease composite)") +``` + +```{r fig1b, fig.width = 11, fig.height = 9} +ladder("null") + ggtitle("Figure 1b. Estimand ladder, null scenario (disease composite)") +``` + +# 2. Aim 2: surgery-specific threats + +```{r tab3} +x <- perf[scenario == "harm" & outcome == "disease" & analysis == "main" & + variant %in% c("V2_cluster", "V3_random", "V4_within") & key != "ccw|A_B2"] +x[, cell := sprintf("%s (%s)", pp(bias), pp(mcse_bias))] +t3 <- dcast(x, method + vlab ~ wlab, value.var = "cell") +setnames(t3, c("method", "vlab"), c("Method", "Physician variant")) +knitr::kable(t3[order(-as.integer(Method))], caption = paste( + "Table 3. Estimation bias (MCSE) against each method's own truth, percentage points.", + "Harm scenario, disease composite.")) +``` + +```{r tab3b} +x[, cell2 := pp(total)] +t3b <- dcast(x, method + vlab ~ wlab, value.var = "cell2") +setnames(t3b, c("method", "vlab"), c("Method", "Physician variant")) +knitr::kable(t3b[order(-as.integer(Method))], caption = paste( + "Table 3b. Total error against the reference truth (CCW A vs B1), percentage points.", + "Harm scenario, disease composite.")) +``` + +**What it shows.** + +* **Surgeon skill (W1).** CCW and sequential trials stay within about 1 pp, and the FE variant brings + them to 0.2–0.3 pp. The **landmark is badly off (total error about 14–16 pp)**. Almost all of that is + question gap, not estimation bias, and Section 6 (Q1) explains why. +* **Practice style (W2).** It only harms the **naive** design (bias −9 to −12 pp). The TTE designs + absorb style through their time-varying PVI models. +* **Style that also changes the outcome coding (W3).** It biases landmark and sequential trials by + about 1.5 pp when the physician is ignored. A random intercept or FE removes most of it, which + supports H2b. +* **Deferral / crossover (W4).** No design bias. The TTE designs handle crossover by design. +* **Unmeasured severity (W5).** It biases **every** observational design by about 2.5–5.5 pp, and no + physician variant helps (H2c holds). +* **Realistic world (WR).** CCW is biased by +6 to +7 pp and sequential trials by +7 to +9 pp. FE helps + only a little. Unmeasured severity dominates. + +# 3. False alarms under the null (headline for clinicians) + +```{r fig2, fig.width = 10, fig.height = 5.2} +fa <- perf[scenario == "null" & outcome == "disease" & analysis == "main" & key != "ccw|A_B2" & variant != "V1_ignore"] +fa[, row := factor(paste0(method, " · ", sub(" \\(.*", "", vlab)))] +fa[, row := factor(row, levels = rev(sort(levels(row))))] +p1 <- ggplot(fa, aes(wlab, row, fill = 100 * reject0)) + geom_tile(colour = "white", linewidth = 1) + + geom_text(aes(label = sprintf("%.0f", 100 * reject0), colour = reject0 > 0.5), size = 3) + + scale_colour_manual(values = c(`TRUE` = "white", `FALSE` = "#0b0b0b"), guide = "none") + + scale_fill_gradient(low = "#eef4fc", high = "#0d3d78", limits = c(0, 100), name = "% of replicates\nCI excludes 0") + + labs(x = NULL, y = NULL, title = "Figure 2. False-alarm rate, null scenario (disease composite; nominal 5%)") + + theme(axis.text.x = element_text(angle = 30, hjust = 1), panel.grid = element_blank(), legend.position = "right") +p1 +``` + +```{r fig2b, fig.width = 8, fig.height = 3} +m0 <- perf[scenario == "null" & world == "W0" & variant %in% c("V2_cluster", "none") & + outcome %in% c("male", "disease") & !grepl("as_treated", key) & key != "ccw|A_B2"] +m0[, oc := factor(ifelse(outcome == "male", "MALE", "Disease composite"), levels = c("Disease composite", "MALE"))] +ggplot(m0, aes(100 * mean_est, method, colour = oc, group = oc)) + + geom_vline(xintercept = 0, colour = "#c3c2b7") + + geom_errorbarh(aes(xmin = 100 * (mean_est - 1.96 * emp_se), xmax = 100 * (mean_est + 1.96 * emp_se)), height = 0, linewidth = 0.6, position = position_dodge(width = 0.5)) + + geom_point(size = 2, position = position_dodge(width = 0.5)) + scale_colour_manual(values = c("Disease composite" = "#2a78d6", MALE = "#eb6834"), name = NULL) + + labs(x = "Risk difference (pp), W0 null", y = NULL, + title = "Figure 2 inset. Sharp null: disease 0, yet MALE about +14 pp") +``` + +**What it shows.** + +* In the clean, skill and deferral worlds, landmark, sequential trials and naive are near 5%. **CCW + is at 10–15% in W0/W1**, mainly because its SE is slightly underestimated in the null scenario + (model/empirical SE 0.86 in W0) and its estimate sits slightly low (−0.33 pp, 1.3 MCSE). The + bootstrap check (D28) is meant to settle this. +* Style that changes outcome coding (W3) pushes naive to 51–55% and sequential trials to 25% when the + physician is ignored. A random intercept or FE brings that back to 8–16%. +* Unmeasured severity (W5, WR) gives **80–100% false alarms** for landmark, sequential trials and + naive. CCW stays at 15–24%, but only because its SE is wide. FE lowers the landmark and sequential + rates in WR (31% and 60%). +* **MALE under the sharp null:** +14 pp for CCW, purely because only treated patients can have a + repeat revascularization. Every design "detects harm" on MALE in 93–100% of replicates. + +# 4. Aim 3: do negative controls detect bias? + +```{r tab4} +s <- ncs[level == "cell"] +s[, cell := ifelse(is.na(sens), "–", sprintf("%.0f%% / %s", 100 * sens, ifelse(is.na(spec), "–", sprintf("%.0f%%", 100 * spec))))] +s[, control := factor(c(nco1 = "NCO-1 (hip fracture / pneumonia)", nco2 = "NCO-2 (vein ablation)", + nce = "NCE (early low-value procedure)", any_nc = "Any of the three")[control], + levels = c("NCO-1 (hip fracture / pneumonia)", "NCO-2 (vein ablation)", + "NCE (early low-value procedure)", "Any of the three"))] +s[, wl := factor(c(WLAB, all = "All worlds")[world], levels = c(WLAB[WORLDS], "All worlds"))] +knitr::kable(dcast(s, control ~ wl, value.var = "cell"), caption = paste( + "Table 4. Sensitivity / specificity of each negative control for MALE bias > 1 pp.", + "A cell (world × scenario × method × variant) counts as biased when its mean MALE bias exceeds 1 pp;", + "a replicate is flagged when the control's 95% CI excludes 0. '–': no biased (or no clean) cells in that world.")) +``` + +```{r fig3, fig.width = 10, fig.height = 4.5} +nc[, design_lab := factor(c(ccw = "CCW", seq = "Sequential", landmark = "Landmark", naive = "Naive")[design], + levels = c("CCW", "Sequential", "Landmark", "Naive"))] +nc[, flag := factor(ifelse(any_nc, "A negative control flagged", "All negative controls clean"), + levels = c("All negative controls clean", "A negative control flagged"))] +nc[, wlab := factor(WLAB[world], levels = WLAB[WORLDS])] +cb <- nc[, .(absbias = abs(mean(err))), by = .(world, wlab, scenario, design_lab, variant, flag)] +ggplot(cb, aes(wlab, 100 * absbias, colour = flag)) + + geom_point(position = position_jitterdodge(jitter.width = 0.15, dodge.width = 0.6), size = 1.4, alpha = 0.8) + + geom_hline(yintercept = 1, linetype = 2, colour = "#52514e") + + scale_colour_manual(values = c("All negative controls clean" = "#1baf7a", "A negative control flagged" = "#eb6834"), name = NULL) + + facet_wrap(~design_lab, nrow = 1) + + labs(x = NULL, y = "|mean MALE bias| (pp)", title = "Figure 3. How much bias sits behind a clean negative control") + + theme(axis.text.x = element_text(angle = 45, hjust = 1)) +``` + +**What it shows (provisional, see Q2).** + +* **NCO-1 almost never flags (sensitivity about 12%), even with unmeasured severity (W5).** In the + current DGP, NCO-1 depends on frailty, smoking and age but **not on claudication severity**, so it + cannot see the main source of bias. H3a fails, by construction. +* **NCO-2 is the working detector (48% sensitivity overall, 65–67% in WR).** It also fires when style + does no harm (specificity 26–45% in W2/W3), which supports H3b. +* **The NCE almost never flags (about 5–9%).** It is adjusted for early PVI (D36), and it shares style + and frailty, not severity. +* **Bias hides behind clean controls.** In WR, the cells with clean negative controls still have a + median |MALE bias| of 8.5 pp (H3c). + +# 5. Simulated RCTs + +```{r tabrct} +r <- perf[analysis == "rct" & outcome == "disease" & scenario != "null"] +r <- r[, .(World = wlab, Scenario = scenario, Trial = method, `Reference` = pp(ref), `Own ITT truth` = pp(own), + `Mean estimate` = pp(mean_est), `Empirical SE` = pp(emp_se), `Power (CI excludes 0)` = sprintf("%.0f%%", 100 * reject0))] +knitr::kable(r[order(World, Scenario, Trial)], caption = "Table 5. Simulated trials, disease composite (pp).") +``` + +* **Surgeon selection changes the answer.** In WR, a realistic trial recruits hospital-based, + top-third-skill, low-style surgeons. Its own ITT truth is **+2.1 pp under harm and −1.4 pp under + benefit-then-harm**, while the population effects are +6.9 and +7.7. A well-run trial answers a + question about selected surgeons (H1c). +* **Small trials are uninformative.** With n = 240 the SE is about 4 pp, giving 6–29% power against + effects of 5–8 pp. +* The ideal pragmatic RCT (n = 50,000) recovers its truth with an SE of about 0.3–0.6 pp. + +# 6. Open questions raised by the draft run + +**Q1. Landmark adjusts for severity at month 5, after the PVI.** As specified in D13, the landmark +propensity model uses covariates at diagnosis **and at month W−1**. For treated patients, month-5 +severity is already changed by the PVI (relief, then faster progression), so it is a mediator. +Conditioning on it gives extreme weights (effective treated sample about 110–140) and a large own-truth +shift when the harm varies between patients (W1: own truth about 20 pp vs a reference of 7 pp). +A check on 20 oracle replicates gave these landmark estimates: + +| World (harm) | Adjust for month-5 severity | Baseline covariates only | Reference | +|---|---|---|---| +| W0 | 8.6 (SD 3.4) | 5.6 (SD 1.4) | 5.1 | +| W1 | 14.6 (SD 4.3) | 8.1 (SD 1.6) | 7.2 | + +**Q2. NCO-1 does not depend on severity.** D32 says NCO-1 "shares the latent patient frailty, +severity and smoking", but the DGP's NCO-1 model has no severity term. That is why it misses the +W5/WR bias. + +**Also pending:** the physician-cluster bootstrap check of SEs (D28). Model-to-empirical SE ratios +are near 1 for CCW (0.96–1.07, except WR 0.87). They are 0.83–0.92 for landmark and sequential trials +in W0, and 0.58 for landmark in W1. + +# Supplement: full performance table + +```{r supp} +x <- perf[analysis == "main" & outcome %in% c("disease", "male")] +knitr::kable(x[order(outcome, scenario, world, method, variant), + .(outcome, scenario, world, method = as.character(method), variant, est = pp(mean_est, 2), own = pp(own, 2), + ref = pp(ref, 2), bias = pp(bias, 2), mcse = pp(mcse_bias, 2), gap = pp(gap, 2), emp_se = pp(emp_se, 2), + se_ratio = round(se_ratio, 2), cover = round(cover_own, 2), reject0 = round(reject0, 2))]) +``` diff --git a/reports/draft-report.html b/reports/draft-report.html new file mode 100644 index 0000000..fe715bf --- /dev/null +++ b/reports/draft-report.html @@ -0,0 +1,19479 @@ + + + + +
+ + + + + + + + + +| Scenario | +Method | +Reference truth | +Own truth | +Question gap | +Mean estimate | +Estimation bias (MCSE) | +Empirical SE | +Coverage of own truth | +
|---|---|---|---|---|---|---|---|---|
| null | +CCW, A vs B1 (reference) | +0.0 | +0.0 | +0.0 | +-0.3 | +-0.33 (0.26) | +2.6 | +85% | +
| null | +CCW, A vs B2 | +0.0 | +0.0 | +0.0 | +-0.3 | +-0.33 (0.26) | +2.6 | +85% | +
| null | +Sequential trials, ITT | +0.0 | +0.0 | +0.0 | +-0.0 | +-0.02 (0.10) | +1.0 | +94% | +
| null | +Landmark at 6 months | +0.0 | +-0.3 | +-0.3 | +-0.2 | +0.14 (0.06) | +1.0 | +97% | +
| null | +Naive ‘ever early PVI’ | +0.0 | +1.3 | +1.3 | +1.1 | +-0.20 (0.06) | +1.2 | +95% | +
| null | +Realistic RCT (n = 240), ITT | +0.0 | +0.0 | +0.0 | +-0.1 | +-0.07 (0.39) | +3.9 | +94% | +
| null | +Ideal pragmatic RCT, ITT | +0.0 | +0.0 | +0.0 | +-0.1 | +-0.05 (0.03) | +0.3 | +95% | +
| harm | +CCW, A vs B1 (reference) | +5.1 | +5.1 | +0.0 | +5.3 | +0.17 (0.28) | +2.8 | +96% | +
| harm | +CCW, A vs B2 | +5.1 | +5.2 | +0.0 | +5.3 | +0.17 (0.28) | +2.8 | +96% | +
| harm | +Sequential trials, ITT | +5.1 | +5.7 | +0.6 | +5.7 | +-0.01 (0.15) | +1.5 | +91% | +
| harm | +Landmark at 6 months | +5.1 | +7.9 | +2.8 | +7.8 | +-0.10 (0.16) | +3.6 | +92% | +
| harm | +Naive ‘ever early PVI’ | +5.1 | +7.2 | +2.1 | +6.9 | +-0.29 (0.06) | +1.6 | +88% | +
| harm | +Realistic RCT (n = 240), ITT | +5.1 | +5.3 | +0.2 | +5.5 | +0.21 (0.43) | +4.3 | +97% | +
| harm | +Ideal pragmatic RCT, ITT | +5.1 | +5.2 | +0.0 | +5.2 | +0.04 (0.03) | +0.3 | +95% | +
| benefit_harm | +CCW, A vs B1 (reference) | +3.1 | +3.1 | +0.0 | +3.3 | +0.28 (0.29) | +2.9 | +89% | +
| benefit_harm | +CCW, A vs B2 | +3.1 | +3.0 | +-0.0 | +3.3 | +0.28 (0.29) | +2.9 | +89% | +
| benefit_harm | +Sequential trials, ITT | +3.1 | +4.0 | +0.9 | +4.2 | +0.26 (0.11) | +1.1 | +99% | +
| benefit_harm | +Landmark at 6 months | +3.1 | +5.3 | +2.3 | +5.4 | +0.03 (0.19) | +3.5 | +95% | +
| benefit_harm | +Naive ‘ever early PVI’ | +3.1 | +5.7 | +2.6 | +5.4 | +-0.26 (0.07) | +1.2 | +97% | +
| benefit_harm | +Realistic RCT (n = 240), ITT | +3.1 | +3.9 | +0.8 | +3.8 | +-0.08 (0.43) | +4.3 | +94% | +
| benefit_harm | +Ideal pragmatic RCT, ITT | +3.1 | +3.9 | +0.8 | +3.9 | +0.01 (0.03) | +0.3 | +92% | +
What it shows.
+| Method | +Physician variant | +W0 Clean | +W1 Skill | +W1 Skill (rho 0) | +W2 Style | +W3 Style -> outcome | +W4 Deferral | +W5 Unmeasured severity | +WR Realistic | +
|---|---|---|---|---|---|---|---|---|---|
| CCW, A vs B1 (reference) | +Ignore physician (cluster SE) | +0.2 (0.3) | +1.1 (0.3) | +0.2 (0.3) | +0.2 (0.3) | +0.7 (0.3) | +-0.0 (0.3) | +4.4 (0.2) | +7.1 (0.4) | +
| CCW, A vs B1 (reference) | +Random intercept | +0.2 (0.3) | +0.9 (0.3) | +0.4 (0.3) | +0.1 (0.4) | +0.1 (0.4) | +0.0 (0.3) | +4.4 (0.3) | +6.4 (0.4) | +
| CCW, A vs B1 (reference) | +Within-physician (FE) | +0.1 (0.4) | +0.3 (0.4) | +0.2 (0.4) | +-0.2 (0.5) | +-0.3 (0.4) | +-0.1 (0.3) | +4.4 (0.3) | +6.1 (0.4) | +
| Sequential trials, ITT | +Ignore physician (cluster SE) | +-0.0 (0.1) | +1.2 (0.1) | +0.1 (0.1) | +0.2 (0.1) | +1.4 (0.1) | +-0.1 (0.1) | +4.9 (0.1) | +9.3 (0.2) | +
| Sequential trials, ITT | +Random intercept | +-0.0 (0.2) | +0.9 (0.1) | +0.1 (0.1) | +0.0 (0.2) | +0.2 (0.2) | +-0.2 (0.1) | +5.0 (0.1) | +7.4 (0.2) | +
| Sequential trials, ITT | +Within-physician (FE) | +-0.3 (0.2) | +0.2 (0.2) | +-0.1 (0.2) | +-0.3 (0.2) | +-0.5 (0.2) | +-0.5 (0.1) | +4.9 (0.1) | +6.7 (0.2) | +
| Landmark at 6 months | +Ignore physician (cluster SE) | +-0.1 (0.2) | +3.9 (0.4) | +1.1 (0.3) | +0.1 (0.8) | +1.5 (0.7) | +-0.0 (0.2) | +2.5 (0.4) | +1.2 (1.1) | +
| Landmark at 6 months | +Random intercept | +-0.2 (0.2) | +2.7 (0.3) | +0.8 (0.3) | +-0.3 (0.7) | +0.3 (0.5) | +0.0 (0.1) | +2.6 (0.4) | +-0.5 (1.1) | +
| Landmark at 6 months | +Within-physician (FE) | +-0.7 (0.3) | +1.5 (0.5) | +0.8 (0.5) | +-1.1 (0.7) | +-1.0 (0.6) | +-0.4 (0.3) | +2.5 (0.4) | +-1.3 (1.1) | +
| Naive ‘ever early PVI’ | +Ignore physician (cluster SE) | +-0.3 (0.1) | +0.5 (0.1) | +-0.3 (0.1) | +-10.5 (1.0) | +-6.4 (0.9) | +-0.2 (0.1) | +5.5 (0.1) | +1.5 (1.0) | +
| Naive ‘ever early PVI’ | +Random intercept | +-0.2 (0.1) | +0.4 (0.1) | +-0.2 (0.1) | +-9.0 (0.9) | +-6.1 (0.9) | +-0.1 (0.1) | +5.6 (0.1) | +0.6 (1.0) | +
| Naive ‘ever early PVI’ | +Within-physician (FE) | +-0.9 (0.1) | +-0.7 (0.1) | +-0.8 (0.1) | +-11.5 (1.0) | +-8.9 (0.9) | +-1.0 (0.1) | +5.3 (0.1) | +-1.0 (1.0) | +
| Method | +Physician variant | +W0 Clean | +W1 Skill | +W1 Skill (rho 0) | +W2 Style | +W3 Style -> outcome | +W4 Deferral | +W5 Unmeasured severity | +WR Realistic | +
|---|---|---|---|---|---|---|---|---|---|
| CCW, A vs B1 (reference) | +Ignore physician (cluster SE) | +0.2 | +1.1 | +0.2 | +0.2 | +0.7 | +-0.0 | +4.4 | +7.1 | +
| CCW, A vs B1 (reference) | +Random intercept | +0.2 | +0.9 | +0.4 | +0.1 | +0.1 | +0.0 | +4.4 | +6.4 | +
| CCW, A vs B1 (reference) | +Within-physician (FE) | +0.1 | +0.3 | +0.2 | +-0.2 | +-0.3 | +-0.1 | +4.4 | +6.1 | +
| Sequential trials, ITT | +Ignore physician (cluster SE) | +0.6 | +2.0 | +0.9 | +0.8 | +2.0 | +0.5 | +5.5 | +10.0 | +
| Sequential trials, ITT | +Random intercept | +0.6 | +1.7 | +0.9 | +0.6 | +0.8 | +0.5 | +5.6 | +8.2 | +
| Sequential trials, ITT | +Within-physician (FE) | +0.3 | +1.0 | +0.7 | +0.3 | +0.1 | +0.1 | +5.5 | +7.4 | +
| Landmark at 6 months | +Ignore physician (cluster SE) | +2.7 | +16.5 | +14.1 | +3.2 | +3.5 | +2.4 | +5.6 | +9.8 | +
| Landmark at 6 months | +Random intercept | +2.7 | +15.4 | +13.7 | +2.9 | +2.2 | +2.4 | +5.6 | +8.1 | +
| Landmark at 6 months | +Within-physician (FE) | +2.2 | +14.2 | +13.7 | +2.0 | +1.0 | +2.0 | +5.5 | +7.3 | +
| Naive ‘ever early PVI’ | +Ignore physician (cluster SE) | +1.8 | +3.1 | +2.1 | +2.1 | +3.2 | +1.7 | +7.6 | +11.8 | +
| Naive ‘ever early PVI’ | +Random intercept | +1.9 | +3.0 | +2.2 | +3.6 | +3.5 | +1.8 | +7.7 | +10.9 | +
| Naive ‘ever early PVI’ | +Within-physician (FE) | +1.2 | +1.9 | +1.6 | +1.1 | +0.7 | +0.9 | +7.4 | +9.3 | +
What it shows.
+What it shows.
+| control | +W0 Clean | +W1 Skill | +W1 Skill (rho 0) | +W2 Style | +W3 Style -> outcome | +W4 Deferral | +W5 Unmeasured severity | +WR Realistic | +All worlds | +
|---|---|---|---|---|---|---|---|---|---|
| NCO-1 (hip fracture / pneumonia) | +– | +11% / 94% | +19% / 89% | +13% / 87% | +13% / 89% | +12% / 92% | +10% / – | +12% / 88% | +12% / 90% | +
| NCO-2 (vein ablation) | +– | +25% / 78% | +7% / 75% | +54% / 45% | +52% / 26% | +11% / 74% | +42% / – | +67% / 92% | +48% / 70% | +
| NCE (early low-value procedure) | +– | +4% / 94% | +6% / 96% | +5% / 95% | +9% / 88% | +7% / 94% | +6% / – | +9% / 93% | +7% / 94% | +
| Any of the three | +– | +37% / 72% | +30% / 65% | +63% / 36% | +61% / 20% | +25% / 65% | +50% / – | +73% / 78% | +57% / 61% | +
What it shows (provisional, see Q2).
+| World | +Scenario | +Trial | +Reference | +Own ITT truth | +Mean estimate | +Empirical SE | +Power (CI excludes 0) | +
|---|---|---|---|---|---|---|---|
| W0 Clean | +benefit_harm | +Ideal RCT, as-treated | +3.1 | +NA | +4.9 | +0.3 | +100% | +
| W0 Clean | +benefit_harm | +Realistic RCT, as-treated | +3.1 | +NA | +4.7 | +4.1 | +19% | +
| W0 Clean | +benefit_harm | +Ideal pragmatic RCT, ITT | +3.1 | +3.9 | +3.9 | +0.3 | +100% | +
| W0 Clean | +benefit_harm | +Realistic RCT (n = 240), ITT | +3.1 | +3.9 | +3.8 | +4.3 | +13% | +
| W0 Clean | +harm | +Ideal RCT, as-treated | +5.1 | +NA | +6.5 | +0.3 | +100% | +
| W0 Clean | +harm | +Realistic RCT, as-treated | +5.1 | +NA | +6.7 | +4.0 | +29% | +
| W0 Clean | +harm | +Ideal pragmatic RCT, ITT | +5.1 | +5.2 | +5.2 | +0.3 | +100% | +
| W0 Clean | +harm | +Realistic RCT (n = 240), ITT | +5.1 | +5.3 | +5.5 | +4.3 | +25% | +
| W1 Skill | +benefit_harm | +Ideal RCT, as-treated | +7.9 | +NA | +10.7 | +0.8 | +100% | +
| W1 Skill | +benefit_harm | +Realistic RCT, as-treated | +7.9 | +NA | +-2.0 | +4.0 | +10% | +
| W1 Skill | +benefit_harm | +Ideal pragmatic RCT, ITT | +7.9 | +8.7 | +8.7 | +0.7 | +100% | +
| W1 Skill | +benefit_harm | +Realistic RCT (n = 240), ITT | +7.9 | +-1.4 | +-2.1 | +4.0 | +9% | +
| W1 Skill | +harm | +Ideal RCT, as-treated | +7.2 | +NA | +9.1 | +0.5 | +100% | +
| W1 Skill | +harm | +Realistic RCT, as-treated | +7.2 | +NA | +2.3 | +4.4 | +6% | +
| W1 Skill | +harm | +Ideal pragmatic RCT, ITT | +7.2 | +7.3 | +7.3 | +0.4 | +100% | +
| W1 Skill | +harm | +Realistic RCT (n = 240), ITT | +7.2 | +2.1 | +2.0 | +4.5 | +8% | +
| W1 Skill (rho 0) | +benefit_harm | +Ideal RCT, as-treated | +7.9 | +NA | +10.7 | +0.7 | +100% | +
| W1 Skill (rho 0) | +benefit_harm | +Realistic RCT, as-treated | +7.9 | +NA | +-1.7 | +3.4 | +9% | +
| W1 Skill (rho 0) | +benefit_harm | +Ideal pragmatic RCT, ITT | +7.9 | +8.8 | +8.8 | +0.6 | +100% | +
| W1 Skill (rho 0) | +benefit_harm | +Realistic RCT (n = 240), ITT | +7.9 | +-1.1 | +-1.6 | +3.4 | +6% | +
| W1 Skill (rho 0) | +harm | +Ideal RCT, as-treated | +7.1 | +NA | +8.9 | +0.4 | +100% | +
| W1 Skill (rho 0) | +harm | +Realistic RCT, as-treated | +7.1 | +NA | +2.1 | +4.7 | +10% | +
| W1 Skill (rho 0) | +harm | +Ideal pragmatic RCT, ITT | +7.1 | +7.3 | +7.3 | +0.4 | +100% | +
| W1 Skill (rho 0) | +harm | +Realistic RCT (n = 240), ITT | +7.1 | +2.3 | +1.8 | +4.7 | +12% | +
| W2 Style | +benefit_harm | +Ideal RCT, as-treated | +3.0 | +NA | +4.9 | +0.3 | +100% | +
| W2 Style | +benefit_harm | +Realistic RCT, as-treated | +3.0 | +NA | +4.8 | +4.5 | +18% | +
| W2 Style | +benefit_harm | +Ideal pragmatic RCT, ITT | +3.0 | +3.9 | +4.0 | +0.3 | +100% | +
| W2 Style | +benefit_harm | +Realistic RCT (n = 240), ITT | +3.0 | +3.9 | +4.3 | +4.3 | +18% | +
| W2 Style | +harm | +Ideal RCT, as-treated | +5.1 | +NA | +6.4 | +0.3 | +100% | +
| W2 Style | +harm | +Realistic RCT, as-treated | +5.1 | +NA | +5.9 | +4.6 | +25% | +
| W2 Style | +harm | +Ideal pragmatic RCT, ITT | +5.1 | +5.2 | +5.2 | +0.3 | +100% | +
| W2 Style | +harm | +Realistic RCT (n = 240), ITT | +5.1 | +5.4 | +5.3 | +4.5 | +22% | +
| W3 Style -> outcome | +benefit_harm | +Ideal RCT, as-treated | +3.0 | +NA | +4.8 | +0.3 | +100% | +
| W3 Style -> outcome | +benefit_harm | +Realistic RCT, as-treated | +3.0 | +NA | +4.8 | +4.4 | +26% | +
| W3 Style -> outcome | +benefit_harm | +Ideal pragmatic RCT, ITT | +3.0 | +3.8 | +3.9 | +0.3 | +100% | +
| W3 Style -> outcome | +benefit_harm | +Realistic RCT (n = 240), ITT | +3.0 | +3.9 | +4.0 | +4.0 | +15% | +
| W3 Style -> outcome | +harm | +Ideal RCT, as-treated | +5.0 | +NA | +6.3 | +0.3 | +100% | +
| W3 Style -> outcome | +harm | +Realistic RCT, as-treated | +5.0 | +NA | +6.0 | +4.6 | +31% | +
| W3 Style -> outcome | +harm | +Ideal pragmatic RCT, ITT | +5.0 | +5.0 | +5.1 | +0.3 | +100% | +
| W3 Style -> outcome | +harm | +Realistic RCT (n = 240), ITT | +5.0 | +5.3 | +5.9 | +4.4 | +28% | +
| W4 Deferral | +benefit_harm | +Ideal RCT, as-treated | +3.3 | +NA | +5.1 | +0.3 | +100% | +
| W4 Deferral | +benefit_harm | +Realistic RCT, as-treated | +3.3 | +NA | +4.6 | +4.8 | +17% | +
| W4 Deferral | +benefit_harm | +Ideal pragmatic RCT, ITT | +3.3 | +4.1 | +4.1 | +0.3 | +100% | +
| W4 Deferral | +benefit_harm | +Realistic RCT (n = 240), ITT | +3.3 | +4.0 | +4.1 | +4.7 | +17% | +
| W4 Deferral | +harm | +Ideal RCT, as-treated | +4.8 | +NA | +6.2 | +0.3 | +100% | +
| W4 Deferral | +harm | +Realistic RCT, as-treated | +4.8 | +NA | +6.4 | +4.3 | +25% | +
| W4 Deferral | +harm | +Ideal pragmatic RCT, ITT | +4.8 | +4.9 | +4.9 | +0.3 | +100% | +
| W4 Deferral | +harm | +Realistic RCT (n = 240), ITT | +4.8 | +5.2 | +5.3 | +3.9 | +19% | +
| W5 Unmeasured severity | +benefit_harm | +Ideal RCT, as-treated | +3.1 | +NA | +4.9 | +0.3 | +100% | +
| W5 Unmeasured severity | +benefit_harm | +Realistic RCT, as-treated | +3.1 | +NA | +4.6 | +4.3 | +18% | +
| W5 Unmeasured severity | +benefit_harm | +Ideal pragmatic RCT, ITT | +3.1 | +3.9 | +3.9 | +0.3 | +100% | +
| W5 Unmeasured severity | +benefit_harm | +Realistic RCT (n = 240), ITT | +3.1 | +3.9 | +3.9 | +4.3 | +13% | +
| W5 Unmeasured severity | +harm | +Ideal RCT, as-treated | +5.1 | +NA | +6.4 | +0.4 | +100% | +
| W5 Unmeasured severity | +harm | +Realistic RCT, as-treated | +5.1 | +NA | +6.2 | +4.8 | +29% | +
| W5 Unmeasured severity | +harm | +Ideal pragmatic RCT, ITT | +5.1 | +5.2 | +5.1 | +0.3 | +100% | +
| W5 Unmeasured severity | +harm | +Realistic RCT (n = 240), ITT | +5.1 | +5.3 | +5.9 | +4.7 | +33% | +
| WR Realistic | +benefit_harm | +Ideal RCT, as-treated | +7.7 | +NA | +10.6 | +0.8 | +100% | +
| WR Realistic | +benefit_harm | +Realistic RCT, as-treated | +7.7 | +NA | +-1.6 | +3.7 | +8% | +
| WR Realistic | +benefit_harm | +Ideal pragmatic RCT, ITT | +7.7 | +8.4 | +8.4 | +0.6 | +100% | +
| WR Realistic | +benefit_harm | +Realistic RCT (n = 240), ITT | +7.7 | +-1.4 | +-1.3 | +3.7 | +6% | +
| WR Realistic | +harm | +Ideal RCT, as-treated | +6.9 | +NA | +8.8 | +0.5 | +100% | +
| WR Realistic | +harm | +Realistic RCT, as-treated | +6.9 | +NA | +1.8 | +4.4 | +11% | +
| WR Realistic | +harm | +Ideal pragmatic RCT, ITT | +6.9 | +7.0 | +7.0 | +0.4 | +100% | +
| WR Realistic | +harm | +Realistic RCT (n = 240), ITT | +6.9 | +2.1 | +1.7 | +4.2 | +9% | +
Q1. Landmark adjusts for severity at month 5, after the +PVI. As specified in D13, the landmark propensity model uses +covariates at diagnosis and at month W−1. For treated +patients, month-5 severity is already changed by the PVI (relief, then +faster progression), so it is a mediator. Conditioning on it gives +extreme weights (effective treated sample about 110–140) and a large +own-truth shift when the harm varies between patients (W1: own truth +about 20 pp vs a reference of 7 pp). A check on 20 oracle replicates +gave these landmark estimates:
+| World (harm) | +Adjust for month-5 severity | +Baseline covariates only | +Reference | +
|---|---|---|---|
| W0 | +8.6 (SD 3.4) | +5.6 (SD 1.4) | +5.1 | +
| W1 | +14.6 (SD 4.3) | +8.1 (SD 1.6) | +7.2 | +
Q2. NCO-1 does not depend on severity. D32 says +NCO-1 “shares the latent patient frailty, severity and smoking”, but the +DGP’s NCO-1 model has no severity term. That is why it misses the W5/WR +bias.
+Also pending: the physician-cluster bootstrap check +of SEs (D28). Model-to-empirical SE ratios are near 1 for CCW +(0.96–1.07, except WR 0.87). They are 0.83–0.92 for landmark and +sequential trials in W0, and 0.58 for landmark in W1.
+| outcome | +scenario | +world | +method | +variant | +est | +own | +ref | +bias | +mcse | +gap | +emp_se | +se_ratio | +cover | +reject0 | +
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| disease | +benefit_harm | +W0 | +Naive ‘ever early PVI’ | +V1_ignore | +5.43 | +5.69 | +3.05 | +-0.26 | +0.07 | +2.64 | +1.22 | +1.15 | +0.97 | +1.00 | +
| disease | +benefit_harm | +W0 | +Naive ‘ever early PVI’ | +V2_cluster | +5.43 | +5.69 | +3.05 | +-0.26 | +0.07 | +2.64 | +1.22 | +1.15 | +0.97 | +1.00 | +
| disease | +benefit_harm | +W0 | +Naive ‘ever early PVI’ | +V3_random | +5.55 | +5.69 | +3.05 | +-0.14 | +0.07 | +2.64 | +1.29 | +1.11 | +0.96 | +1.00 | +
| disease | +benefit_harm | +W0 | +Naive ‘ever early PVI’ | +V4_within | +4.92 | +5.69 | +3.05 | +-0.78 | +0.13 | +2.64 | +1.80 | +0.95 | +0.84 | +0.89 | +
| disease | +benefit_harm | +W0 | +Landmark at 6 months | +V1_ignore | +5.38 | +5.35 | +3.05 | +0.03 | +0.19 | +2.30 | +3.52 | +1.10 | +0.95 | +0.24 | +
| disease | +benefit_harm | +W0 | +Landmark at 6 months | +V2_cluster | +5.38 | +5.35 | +3.05 | +0.03 | +0.19 | +2.30 | +3.52 | +1.10 | +0.95 | +0.24 | +
| disease | +benefit_harm | +W0 | +Landmark at 6 months | +V3_random | +5.38 | +5.35 | +3.05 | +0.03 | +0.19 | +2.30 | +3.55 | +1.09 | +0.95 | +0.24 | +
| disease | +benefit_harm | +W0 | +Landmark at 6 months | +V4_within | +5.87 | +5.35 | +3.05 | +0.52 | +0.45 | +2.30 | +6.47 | +0.83 | +0.90 | +0.14 | +
| disease | +benefit_harm | +W0 | +Sequential trials, ITT | +V1_ignore | +4.25 | +3.98 | +3.05 | +0.26 | +0.11 | +0.93 | +1.07 | +1.15 | +0.99 | +0.96 | +
| disease | +benefit_harm | +W0 | +Sequential trials, ITT | +V2_cluster | +4.25 | +3.98 | +3.05 | +0.26 | +0.11 | +0.93 | +1.07 | +1.15 | +0.99 | +0.96 | +
| disease | +benefit_harm | +W0 | +Sequential trials, ITT | +V3_random | +4.22 | +3.98 | +3.05 | +0.24 | +0.11 | +0.93 | +1.13 | +1.10 | +0.99 | +0.96 | +
| disease | +benefit_harm | +W0 | +Sequential trials, ITT | +V4_within | +4.05 | +3.98 | +3.05 | +0.07 | +0.17 | +0.93 | +1.70 | +0.87 | +0.89 | +0.79 | +
| disease | +benefit_harm | +W0 | +CCW, A vs B2 | +V1_ignore | +3.31 | +3.03 | +3.05 | +0.28 | +0.29 | +-0.02 | +2.88 | +0.93 | +0.87 | +0.20 | +
| disease | +benefit_harm | +W0 | +CCW, A vs B2 | +V2_cluster | +3.31 | +3.03 | +3.05 | +0.28 | +0.29 | +-0.02 | +2.88 | +0.93 | +0.89 | +0.18 | +
| disease | +benefit_harm | +W0 | +CCW, A vs B2 | +V3_random | +3.36 | +3.03 | +3.05 | +0.33 | +0.28 | +-0.02 | +2.85 | +0.94 | +0.90 | +0.19 | +
| disease | +benefit_harm | +W0 | +CCW, A vs B2 | +V4_within | +3.28 | +3.03 | +3.05 | +0.25 | +0.31 | +-0.02 | +3.12 | +0.99 | +0.92 | +0.15 | +
| disease | +benefit_harm | +W0 | +CCW, A vs B1 (reference) | +V1_ignore | +3.33 | +3.05 | +3.05 | +0.28 | +0.29 | +0.00 | +2.88 | +0.93 | +0.87 | +0.20 | +
| disease | +benefit_harm | +W0 | +CCW, A vs B1 (reference) | +V2_cluster | +3.33 | +3.05 | +3.05 | +0.28 | +0.29 | +0.00 | +2.88 | +0.92 | +0.89 | +0.18 | +
| disease | +benefit_harm | +W0 | +CCW, A vs B1 (reference) | +V3_random | +3.38 | +3.05 | +3.05 | +0.33 | +0.28 | +0.00 | +2.85 | +0.94 | +0.91 | +0.19 | +
| disease | +benefit_harm | +W0 | +CCW, A vs B1 (reference) | +V4_within | +3.29 | +3.05 | +3.05 | +0.24 | +0.31 | +0.00 | +3.12 | +0.99 | +0.92 | +0.15 | +
| disease | +benefit_harm | +W1 | +Naive ‘ever early PVI’ | +V1_ignore | +12.25 | +10.68 | +7.94 | +1.57 | +0.10 | +2.73 | +1.69 | +0.94 | +0.83 | +1.00 | +
| disease | +benefit_harm | +W1 | +Naive ‘ever early PVI’ | +V2_cluster | +12.25 | +10.68 | +7.94 | +1.57 | +0.10 | +2.73 | +1.69 | +1.04 | +0.91 | +1.00 | +
| disease | +benefit_harm | +W1 | +Naive ‘ever early PVI’ | +V3_random | +11.84 | +10.68 | +7.94 | +1.16 | +0.08 | +2.73 | +1.63 | +1.05 | +0.92 | +1.00 | +
| disease | +benefit_harm | +W1 | +Naive ‘ever early PVI’ | +V4_within | +10.51 | +10.68 | +7.94 | +-0.17 | +0.12 | +2.73 | +1.87 | +1.06 | +0.98 | +1.00 | +
| disease | +benefit_harm | +W1 | +Landmark at 6 months | +V1_ignore | +11.96 | +8.86 | +7.94 | +3.10 | +0.24 | +0.91 | +5.33 | +0.82 | +0.85 | +0.82 | +
| disease | +benefit_harm | +W1 | +Landmark at 6 months | +V2_cluster | +11.96 | +8.86 | +7.94 | +3.10 | +0.24 | +0.91 | +5.33 | +0.84 | +0.86 | +0.81 | +
| disease | +benefit_harm | +W1 | +Landmark at 6 months | +V3_random | +11.71 | +8.86 | +7.94 | +2.85 | +0.23 | +0.91 | +5.26 | +0.84 | +0.87 | +0.81 | +
| disease | +benefit_harm | +W1 | +Landmark at 6 months | +V4_within | +10.13 | +8.86 | +7.94 | +1.27 | +0.44 | +0.91 | +6.85 | +0.76 | +0.85 | +0.54 | +
| disease | +benefit_harm | +W1 | +Sequential trials, ITT | +V1_ignore | +11.22 | +9.26 | +7.94 | +1.97 | +0.16 | +1.31 | +1.63 | +0.90 | +0.73 | +1.00 | +
| disease | +benefit_harm | +W1 | +Sequential trials, ITT | +V2_cluster | +11.22 | +9.26 | +7.94 | +1.97 | +0.16 | +1.31 | +1.63 | +1.02 | +0.83 | +1.00 | +
| disease | +benefit_harm | +W1 | +Sequential trials, ITT | +V3_random | +10.67 | +9.26 | +7.94 | +1.41 | +0.16 | +1.31 | +1.55 | +1.04 | +0.90 | +1.00 | +
| disease | +benefit_harm | +W1 | +Sequential trials, ITT | +V4_within | +9.78 | +9.26 | +7.94 | +0.52 | +0.17 | +1.31 | +1.74 | +1.05 | +0.97 | +1.00 | +
| disease | +benefit_harm | +W1 | +CCW, A vs B2 | +V1_ignore | +9.63 | +7.99 | +7.94 | +1.64 | +0.37 | +0.04 | +3.72 | +0.87 | +0.90 | +0.89 | +
| disease | +benefit_harm | +W1 | +CCW, A vs B2 | +V2_cluster | +9.63 | +7.99 | +7.94 | +1.64 | +0.37 | +0.04 | +3.72 | +0.89 | +0.91 | +0.89 | +
| disease | +benefit_harm | +W1 | +CCW, A vs B2 | +V3_random | +9.17 | +7.99 | +7.94 | +1.18 | +0.37 | +0.04 | +3.70 | +0.87 | +0.93 | +0.86 | +
| disease | +benefit_harm | +W1 | +CCW, A vs B2 | +V4_within | +8.52 | +7.99 | +7.94 | +0.53 | +0.43 | +0.04 | +4.34 | +0.84 | +0.87 | +0.66 | +
| disease | +benefit_harm | +W1 | +CCW, A vs B1 (reference) | +V1_ignore | +9.58 | +7.94 | +7.94 | +1.64 | +0.37 | +0.00 | +3.72 | +0.87 | +0.90 | +0.88 | +
| disease | +benefit_harm | +W1 | +CCW, A vs B1 (reference) | +V2_cluster | +9.58 | +7.94 | +7.94 | +1.64 | +0.37 | +0.00 | +3.72 | +0.89 | +0.92 | +0.89 | +
| disease | +benefit_harm | +W1 | +CCW, A vs B1 (reference) | +V3_random | +9.12 | +7.94 | +7.94 | +1.18 | +0.37 | +0.00 | +3.70 | +0.87 | +0.93 | +0.86 | +
| disease | +benefit_harm | +W1 | +CCW, A vs B1 (reference) | +V4_within | +8.46 | +7.94 | +7.94 | +0.52 | +0.43 | +0.00 | +4.34 | +0.84 | +0.87 | +0.65 | +
| disease | +benefit_harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V1_ignore | +10.48 | +10.72 | +7.92 | +-0.23 | +0.09 | +2.80 | +1.67 | +0.92 | +0.94 | +1.00 | +
| disease | +benefit_harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V2_cluster | +10.48 | +10.72 | +7.92 | +-0.23 | +0.09 | +2.80 | +1.67 | +1.00 | +0.95 | +1.00 | +
| disease | +benefit_harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V3_random | +10.62 | +10.72 | +7.92 | +-0.09 | +0.08 | +2.80 | +1.74 | +0.97 | +0.95 | +1.00 | +
| disease | +benefit_harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V4_within | +9.98 | +10.72 | +7.92 | +-0.74 | +0.12 | +2.80 | +2.22 | +0.93 | +0.88 | +1.00 | +
| disease | +benefit_harm | +W1_rho0 | +Landmark at 6 months | +V1_ignore | +11.09 | +10.12 | +7.92 | +0.97 | +0.24 | +2.21 | +5.20 | +0.89 | +0.95 | +0.79 | +
| disease | +benefit_harm | +W1_rho0 | +Landmark at 6 months | +V2_cluster | +11.09 | +10.12 | +7.92 | +0.97 | +0.24 | +2.21 | +5.20 | +0.91 | +0.95 | +0.79 | +
| disease | +benefit_harm | +W1_rho0 | +Landmark at 6 months | +V3_random | +11.03 | +10.12 | +7.92 | +0.91 | +0.23 | +2.21 | +5.19 | +0.90 | +0.94 | +0.79 | +
| disease | +benefit_harm | +W1_rho0 | +Landmark at 6 months | +V4_within | +10.22 | +10.12 | +7.92 | +0.10 | +0.58 | +2.21 | +7.21 | +0.85 | +0.82 | +0.46 | +
| disease | +benefit_harm | +W1_rho0 | +Sequential trials, ITT | +V1_ignore | +9.36 | +9.28 | +7.92 | +0.08 | +0.16 | +1.36 | +1.56 | +0.91 | +0.95 | +1.00 | +
| disease | +benefit_harm | +W1_rho0 | +Sequential trials, ITT | +V2_cluster | +9.36 | +9.28 | +7.92 | +0.08 | +0.16 | +1.36 | +1.56 | +1.00 | +0.95 | +1.00 | +
| disease | +benefit_harm | +W1_rho0 | +Sequential trials, ITT | +V3_random | +9.36 | +9.28 | +7.92 | +0.08 | +0.16 | +1.36 | +1.63 | +0.96 | +0.95 | +1.00 | +
| disease | +benefit_harm | +W1_rho0 | +Sequential trials, ITT | +V4_within | +9.14 | +9.28 | +7.92 | +-0.14 | +0.21 | +1.36 | +2.07 | +0.90 | +0.92 | +1.00 | +
| disease | +benefit_harm | +W1_rho0 | +CCW, A vs B2 | +V1_ignore | +7.81 | +7.94 | +7.92 | +-0.13 | +0.30 | +0.02 | +3.04 | +1.01 | +0.95 | +0.82 | +
| disease | +benefit_harm | +W1_rho0 | +CCW, A vs B2 | +V2_cluster | +7.81 | +7.94 | +7.92 | +-0.13 | +0.30 | +0.02 | +3.04 | +1.02 | +0.95 | +0.80 | +
| disease | +benefit_harm | +W1_rho0 | +CCW, A vs B2 | +V3_random | +7.91 | +7.94 | +7.92 | +-0.03 | +0.33 | +0.02 | +3.34 | +0.95 | +0.93 | +0.76 | +
| disease | +benefit_harm | +W1_rho0 | +CCW, A vs B2 | +V4_within | +8.05 | +7.94 | +7.92 | +0.11 | +0.45 | +0.02 | +4.47 | +0.86 | +0.91 | +0.60 | +
| disease | +benefit_harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V1_ignore | +7.78 | +7.92 | +7.92 | +-0.14 | +0.30 | +0.00 | +3.04 | +1.01 | +0.95 | +0.79 | +
| disease | +benefit_harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V2_cluster | +7.78 | +7.92 | +7.92 | +-0.14 | +0.30 | +0.00 | +3.04 | +1.02 | +0.95 | +0.79 | +
| disease | +benefit_harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V3_random | +7.88 | +7.92 | +7.92 | +-0.04 | +0.33 | +0.00 | +3.34 | +0.95 | +0.93 | +0.75 | +
| disease | +benefit_harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V4_within | +8.03 | +7.92 | +7.92 | +0.11 | +0.45 | +0.00 | +4.47 | +0.86 | +0.91 | +0.60 | +
| disease | +benefit_harm | +W2 | +Naive ‘ever early PVI’ | +V1_ignore | +5.70 | +14.36 | +3.05 | +-8.66 | +0.99 | +11.31 | +1.37 | +1.03 | +0.00 | +1.00 | +
| disease | +benefit_harm | +W2 | +Naive ‘ever early PVI’ | +V2_cluster | +5.70 | +14.36 | +3.05 | +-8.66 | +0.99 | +11.31 | +1.37 | +1.03 | +0.00 | +1.00 | +
| disease | +benefit_harm | +W2 | +Naive ‘ever early PVI’ | +V3_random | +6.98 | +14.36 | +3.05 | +-7.38 | +0.96 | +11.31 | +2.11 | +1.14 | +0.15 | +0.94 | +
| disease | +benefit_harm | +W2 | +Naive ‘ever early PVI’ | +V4_within | +4.65 | +14.36 | +3.05 | +-9.71 | +1.03 | +11.31 | +2.40 | +1.05 | +0.06 | +0.54 | +
| disease | +benefit_harm | +W2 | +Landmark at 6 months | +V1_ignore | +4.88 | +4.29 | +3.05 | +0.59 | +0.83 | +1.24 | +3.49 | +1.06 | +0.94 | +0.18 | +
| disease | +benefit_harm | +W2 | +Landmark at 6 months | +V2_cluster | +4.88 | +4.29 | +3.05 | +0.59 | +0.83 | +1.24 | +3.49 | +1.05 | +0.95 | +0.18 | +
| disease | +benefit_harm | +W2 | +Landmark at 6 months | +V3_random | +5.23 | +4.29 | +3.05 | +0.94 | +0.81 | +1.24 | +3.84 | +1.02 | +0.97 | +0.16 | +
| disease | +benefit_harm | +W2 | +Landmark at 6 months | +V4_within | +4.95 | +4.29 | +3.05 | +0.66 | +0.88 | +1.24 | +5.55 | +0.96 | +0.91 | +0.05 | +
| disease | +benefit_harm | +W2 | +Sequential trials, ITT | +V1_ignore | +4.39 | +3.98 | +3.05 | +0.41 | +0.13 | +0.93 | +1.28 | +0.96 | +0.92 | +0.98 | +
| disease | +benefit_harm | +W2 | +Sequential trials, ITT | +V2_cluster | +4.39 | +3.98 | +3.05 | +0.41 | +0.13 | +0.93 | +1.28 | +0.96 | +0.91 | +0.99 | +
| disease | +benefit_harm | +W2 | +Sequential trials, ITT | +V3_random | +4.15 | +3.98 | +3.05 | +0.18 | +0.17 | +0.93 | +1.65 | +1.02 | +0.97 | +0.74 | +
| disease | +benefit_harm | +W2 | +Sequential trials, ITT | +V4_within | +3.88 | +3.98 | +3.05 | +-0.10 | +0.19 | +0.93 | +1.86 | +1.01 | +0.94 | +0.49 | +
| disease | +benefit_harm | +W2 | +CCW, A vs B2 | +V1_ignore | +3.13 | +3.03 | +3.05 | +0.09 | +0.25 | +-0.02 | +2.45 | +1.13 | +0.96 | +0.11 | +
| disease | +benefit_harm | +W2 | +CCW, A vs B2 | +V2_cluster | +3.13 | +3.03 | +3.05 | +0.09 | +0.25 | +-0.02 | +2.45 | +1.12 | +0.97 | +0.14 | +
| disease | +benefit_harm | +W2 | +CCW, A vs B2 | +V3_random | +3.50 | +3.03 | +3.05 | +0.47 | +0.32 | +-0.02 | +3.16 | +1.14 | +0.92 | +0.07 | +
| disease | +benefit_harm | +W2 | +CCW, A vs B2 | +V4_within | +3.44 | +3.03 | +3.05 | +0.41 | +0.40 | +-0.02 | +3.95 | +1.05 | +0.90 | +0.05 | +
| disease | +benefit_harm | +W2 | +CCW, A vs B1 (reference) | +V1_ignore | +3.15 | +3.05 | +3.05 | +0.10 | +0.25 | +0.00 | +2.45 | +1.13 | +0.96 | +0.11 | +
| disease | +benefit_harm | +W2 | +CCW, A vs B1 (reference) | +V2_cluster | +3.15 | +3.05 | +3.05 | +0.10 | +0.25 | +0.00 | +2.45 | +1.12 | +0.97 | +0.14 | +
| disease | +benefit_harm | +W2 | +CCW, A vs B1 (reference) | +V3_random | +3.52 | +3.05 | +3.05 | +0.47 | +0.32 | +0.00 | +3.16 | +1.14 | +0.92 | +0.07 | +
| disease | +benefit_harm | +W2 | +CCW, A vs B1 (reference) | +V4_within | +3.44 | +3.05 | +3.05 | +0.39 | +0.40 | +0.00 | +3.97 | +1.05 | +0.90 | +0.05 | +
| disease | +benefit_harm | +W3 | +Naive ‘ever early PVI’ | +V1_ignore | +6.92 | +14.67 | +2.98 | +-7.75 | +0.92 | +11.69 | +1.61 | +0.92 | +0.00 | +1.00 | +
| disease | +benefit_harm | +W3 | +Naive ‘ever early PVI’ | +V2_cluster | +6.92 | +14.67 | +2.98 | +-7.75 | +0.92 | +11.69 | +1.61 | +0.91 | +0.00 | +1.00 | +
| disease | +benefit_harm | +W3 | +Naive ‘ever early PVI’ | +V3_random | +7.38 | +14.67 | +2.98 | +-7.29 | +0.86 | +11.69 | +2.70 | +0.90 | +0.23 | +0.93 | +
| disease | +benefit_harm | +W3 | +Naive ‘ever early PVI’ | +V4_within | +4.69 | +14.67 | +2.98 | +-9.97 | +0.92 | +11.69 | +2.78 | +0.93 | +0.08 | +0.50 | +
| disease | +benefit_harm | +W3 | +Landmark at 6 months | +V1_ignore | +5.81 | +4.11 | +2.98 | +1.70 | +0.56 | +1.13 | +3.83 | +1.04 | +0.98 | +0.23 | +
| disease | +benefit_harm | +W3 | +Landmark at 6 months | +V2_cluster | +5.81 | +4.11 | +2.98 | +1.70 | +0.56 | +1.13 | +3.83 | +1.04 | +0.98 | +0.26 | +
| disease | +benefit_harm | +W3 | +Landmark at 6 months | +V3_random | +5.53 | +4.11 | +2.98 | +1.42 | +0.49 | +1.13 | +3.73 | +1.07 | +0.95 | +0.17 | +
| disease | +benefit_harm | +W3 | +Landmark at 6 months | +V4_within | +4.54 | +4.11 | +2.98 | +0.43 | +0.59 | +1.13 | +5.28 | +0.92 | +0.89 | +0.11 | +
| disease | +benefit_harm | +W3 | +Sequential trials, ITT | +V1_ignore | +5.52 | +3.88 | +2.98 | +1.64 | +0.14 | +0.90 | +1.41 | +0.92 | +0.74 | +1.00 | +
| disease | +benefit_harm | +W3 | +Sequential trials, ITT | +V2_cluster | +5.52 | +3.88 | +2.98 | +1.64 | +0.14 | +0.90 | +1.41 | +0.91 | +0.74 | +1.00 | +
| disease | +benefit_harm | +W3 | +Sequential trials, ITT | +V3_random | +4.44 | +3.88 | +2.98 | +0.56 | +0.19 | +0.90 | +1.94 | +0.90 | +0.95 | +0.75 | +
| disease | +benefit_harm | +W3 | +Sequential trials, ITT | +V4_within | +3.85 | +3.88 | +2.98 | +-0.03 | +0.23 | +0.90 | +2.25 | +0.86 | +0.90 | +0.52 | +
| disease | +benefit_harm | +W3 | +CCW, A vs B2 | +V1_ignore | +3.70 | +2.96 | +2.98 | +0.74 | +0.30 | +-0.01 | +3.00 | +0.98 | +0.96 | +0.23 | +
| disease | +benefit_harm | +W3 | +CCW, A vs B2 | +V2_cluster | +3.70 | +2.96 | +2.98 | +0.74 | +0.30 | +-0.01 | +3.00 | +0.99 | +0.96 | +0.24 | +
| disease | +benefit_harm | +W3 | +CCW, A vs B2 | +V3_random | +3.22 | +2.96 | +2.98 | +0.26 | +0.40 | +-0.01 | +4.01 | +0.95 | +0.88 | +0.07 | +
| disease | +benefit_harm | +W3 | +CCW, A vs B2 | +V4_within | +2.83 | +2.96 | +2.98 | +-0.13 | +0.47 | +-0.01 | +4.74 | +0.90 | +0.82 | +0.06 | +
| disease | +benefit_harm | +W3 | +CCW, A vs B1 (reference) | +V1_ignore | +3.71 | +2.98 | +2.98 | +0.73 | +0.30 | +0.00 | +3.00 | +0.98 | +0.96 | +0.22 | +
| disease | +benefit_harm | +W3 | +CCW, A vs B1 (reference) | +V2_cluster | +3.71 | +2.98 | +2.98 | +0.73 | +0.30 | +0.00 | +3.00 | +0.99 | +0.96 | +0.23 | +
| disease | +benefit_harm | +W3 | +CCW, A vs B1 (reference) | +V3_random | +3.23 | +2.98 | +2.98 | +0.25 | +0.40 | +0.00 | +4.02 | +0.95 | +0.88 | +0.07 | +
| disease | +benefit_harm | +W3 | +CCW, A vs B1 (reference) | +V4_within | +2.87 | +2.98 | +2.98 | +-0.11 | +0.47 | +0.00 | +4.75 | +0.90 | +0.82 | +0.07 | +
| disease | +benefit_harm | +W4 | +Naive ‘ever early PVI’ | +V1_ignore | +5.47 | +5.75 | +3.29 | +-0.27 | +0.08 | +2.45 | +1.34 | +1.04 | +0.93 | +0.99 | +
| disease | +benefit_harm | +W4 | +Naive ‘ever early PVI’ | +V2_cluster | +5.47 | +5.75 | +3.29 | +-0.27 | +0.08 | +2.45 | +1.34 | +1.04 | +0.92 | +0.99 | +
| disease | +benefit_harm | +W4 | +Naive ‘ever early PVI’ | +V3_random | +5.63 | +5.75 | +3.29 | +-0.11 | +0.07 | +2.45 | +1.39 | +1.04 | +0.94 | +0.99 | +
| disease | +benefit_harm | +W4 | +Naive ‘ever early PVI’ | +V4_within | +5.01 | +5.75 | +3.29 | +-0.73 | +0.13 | +2.45 | +1.63 | +1.06 | +0.88 | +0.92 | +
| disease | +benefit_harm | +W4 | +Landmark at 6 months | +V1_ignore | +4.93 | +4.77 | +3.29 | +0.16 | +0.14 | +1.48 | +3.43 | +1.03 | +0.94 | +0.22 | +
| disease | +benefit_harm | +W4 | +Landmark at 6 months | +V2_cluster | +4.93 | +4.77 | +3.29 | +0.16 | +0.14 | +1.48 | +3.43 | +1.03 | +0.95 | +0.23 | +
| disease | +benefit_harm | +W4 | +Landmark at 6 months | +V3_random | +4.90 | +4.77 | +3.29 | +0.13 | +0.13 | +1.48 | +3.42 | +1.03 | +0.95 | +0.23 | +
| disease | +benefit_harm | +W4 | +Landmark at 6 months | +V4_within | +4.10 | +4.77 | +3.29 | +-0.67 | +0.28 | +1.48 | +4.42 | +0.97 | +0.82 | +0.09 | +
| disease | +benefit_harm | +W4 | +Sequential trials, ITT | +V1_ignore | +4.32 | +4.22 | +3.29 | +0.10 | +0.12 | +0.93 | +1.19 | +1.04 | +0.94 | +0.94 | +
| disease | +benefit_harm | +W4 | +Sequential trials, ITT | +V2_cluster | +4.32 | +4.22 | +3.29 | +0.10 | +0.12 | +0.93 | +1.19 | +1.04 | +0.94 | +0.95 | +
| disease | +benefit_harm | +W4 | +Sequential trials, ITT | +V3_random | +4.34 | +4.22 | +3.29 | +0.13 | +0.12 | +0.93 | +1.24 | +1.02 | +0.94 | +0.95 | +
| disease | +benefit_harm | +W4 | +Sequential trials, ITT | +V4_within | +4.20 | +4.22 | +3.29 | +-0.02 | +0.15 | +0.93 | +1.54 | +0.97 | +0.93 | +0.85 | +
| disease | +benefit_harm | +W4 | +CCW, A vs B2 | +V1_ignore | +2.86 | +3.04 | +3.29 | +-0.18 | +0.26 | +-0.25 | +2.64 | +0.98 | +0.91 | +0.17 | +
| disease | +benefit_harm | +W4 | +CCW, A vs B2 | +V2_cluster | +2.86 | +3.04 | +3.29 | +-0.18 | +0.26 | +-0.25 | +2.64 | +0.97 | +0.91 | +0.17 | +
| disease | +benefit_harm | +W4 | +CCW, A vs B2 | +V3_random | +2.92 | +3.04 | +3.29 | +-0.12 | +0.27 | +-0.25 | +2.74 | +0.95 | +0.91 | +0.17 | +
| disease | +benefit_harm | +W4 | +CCW, A vs B2 | +V4_within | +2.65 | +3.04 | +3.29 | +-0.39 | +0.32 | +-0.25 | +3.20 | +0.92 | +0.87 | +0.13 | +
| disease | +benefit_harm | +W4 | +CCW, A vs B1 (reference) | +V1_ignore | +3.12 | +3.29 | +3.29 | +-0.17 | +0.26 | +0.00 | +2.64 | +0.98 | +0.91 | +0.18 | +
| disease | +benefit_harm | +W4 | +CCW, A vs B1 (reference) | +V2_cluster | +3.12 | +3.29 | +3.29 | +-0.17 | +0.26 | +0.00 | +2.64 | +0.97 | +0.91 | +0.18 | +
| disease | +benefit_harm | +W4 | +CCW, A vs B1 (reference) | +V3_random | +3.14 | +3.29 | +3.29 | +-0.16 | +0.27 | +0.00 | +2.73 | +0.95 | +0.91 | +0.20 | +
| disease | +benefit_harm | +W4 | +CCW, A vs B1 (reference) | +V4_within | +2.91 | +3.29 | +3.29 | +-0.38 | +0.32 | +0.00 | +3.19 | +0.92 | +0.87 | +0.14 | +
| disease | +benefit_harm | +W5 | +Naive ‘ever early PVI’ | +V1_ignore | +10.21 | +5.18 | +3.05 | +5.03 | +0.15 | +2.13 | +1.26 | +0.89 | +0.00 | +1.00 | +
| disease | +benefit_harm | +W5 | +Naive ‘ever early PVI’ | +V2_cluster | +10.21 | +5.18 | +3.05 | +5.03 | +0.15 | +2.13 | +1.26 | +0.89 | +0.01 | +1.00 | +
| disease | +benefit_harm | +W5 | +Naive ‘ever early PVI’ | +V3_random | +10.27 | +5.18 | +3.05 | +5.09 | +0.14 | +2.13 | +1.28 | +0.89 | +0.00 | +1.00 | +
| disease | +benefit_harm | +W5 | +Naive ‘ever early PVI’ | +V4_within | +10.02 | +5.18 | +3.05 | +4.84 | +0.15 | +2.13 | +1.47 | +0.94 | +0.06 | +1.00 | +
| disease | +benefit_harm | +W5 | +Landmark at 6 months | +V1_ignore | +10.29 | +5.09 | +3.05 | +5.19 | +0.40 | +2.04 | +1.29 | +0.89 | +0.01 | +1.00 | +
| disease | +benefit_harm | +W5 | +Landmark at 6 months | +V2_cluster | +10.29 | +5.09 | +3.05 | +5.19 | +0.40 | +2.04 | +1.29 | +0.89 | +0.01 | +1.00 | +
| disease | +benefit_harm | +W5 | +Landmark at 6 months | +V3_random | +10.30 | +5.09 | +3.05 | +5.20 | +0.40 | +2.04 | +1.30 | +0.90 | +0.00 | +1.00 | +
| disease | +benefit_harm | +W5 | +Landmark at 6 months | +V4_within | +10.32 | +5.09 | +3.05 | +5.22 | +0.41 | +2.04 | +1.54 | +0.92 | +0.04 | +1.00 | +
| disease | +benefit_harm | +W5 | +Sequential trials, ITT | +V1_ignore | +8.37 | +3.98 | +3.05 | +4.39 | +0.12 | +0.93 | +1.22 | +0.91 | +0.00 | +1.00 | +
| disease | +benefit_harm | +W5 | +Sequential trials, ITT | +V2_cluster | +8.37 | +3.98 | +3.05 | +4.39 | +0.12 | +0.93 | +1.22 | +0.91 | +0.00 | +1.00 | +
| disease | +benefit_harm | +W5 | +Sequential trials, ITT | +V3_random | +8.34 | +3.98 | +3.05 | +4.36 | +0.13 | +0.93 | +1.26 | +0.90 | +0.01 | +1.00 | +
| disease | +benefit_harm | +W5 | +Sequential trials, ITT | +V4_within | +8.29 | +3.98 | +3.05 | +4.31 | +0.15 | +0.93 | +1.47 | +0.92 | +0.12 | +1.00 | +
| disease | +benefit_harm | +W5 | +CCW, A vs B2 | +V1_ignore | +6.81 | +3.03 | +3.05 | +3.77 | +0.25 | +-0.02 | +2.46 | +0.97 | +0.75 | +0.88 | +
| disease | +benefit_harm | +W5 | +CCW, A vs B2 | +V2_cluster | +6.81 | +3.03 | +3.05 | +3.77 | +0.25 | +-0.02 | +2.46 | +0.97 | +0.74 | +0.88 | +
| disease | +benefit_harm | +W5 | +CCW, A vs B2 | +V3_random | +6.83 | +3.03 | +3.05 | +3.80 | +0.25 | +-0.02 | +2.54 | +0.96 | +0.76 | +0.87 | +
| disease | +benefit_harm | +W5 | +CCW, A vs B2 | +V4_within | +6.86 | +3.03 | +3.05 | +3.83 | +0.30 | +-0.02 | +3.03 | +0.96 | +0.82 | +0.71 | +
| disease | +benefit_harm | +W5 | +CCW, A vs B1 (reference) | +V1_ignore | +6.83 | +3.05 | +3.05 | +3.78 | +0.25 | +0.00 | +2.46 | +0.97 | +0.75 | +0.89 | +
| disease | +benefit_harm | +W5 | +CCW, A vs B1 (reference) | +V2_cluster | +6.83 | +3.05 | +3.05 | +3.78 | +0.25 | +0.00 | +2.46 | +0.97 | +0.74 | +0.89 | +
| disease | +benefit_harm | +W5 | +CCW, A vs B1 (reference) | +V3_random | +6.85 | +3.05 | +3.05 | +3.80 | +0.25 | +0.00 | +2.54 | +0.96 | +0.77 | +0.88 | +
| disease | +benefit_harm | +W5 | +CCW, A vs B1 (reference) | +V4_within | +6.88 | +3.05 | +3.05 | +3.83 | +0.30 | +0.00 | +3.03 | +0.96 | +0.82 | +0.71 | +
| disease | +benefit_harm | +WR | +Naive ‘ever early PVI’ | +V1_ignore | +22.13 | +20.66 | +7.74 | +1.47 | +1.12 | +12.92 | +1.93 | +0.76 | +0.76 | +1.00 | +
| disease | +benefit_harm | +WR | +Naive ‘ever early PVI’ | +V2_cluster | +22.13 | +20.66 | +7.74 | +1.47 | +1.12 | +12.92 | +1.93 | +1.11 | +0.92 | +1.00 | +
| disease | +benefit_harm | +WR | +Naive ‘ever early PVI’ | +V3_random | +19.89 | +20.66 | +7.74 | +-0.77 | +1.06 | +12.92 | +1.91 | +1.08 | +0.96 | +1.00 | +
| disease | +benefit_harm | +WR | +Naive ‘ever early PVI’ | +V4_within | +17.98 | +20.66 | +7.74 | +-2.68 | +1.08 | +12.92 | +2.18 | +1.04 | +0.75 | +1.00 | +
| disease | +benefit_harm | +WR | +Landmark at 6 months | +V1_ignore | +22.24 | +11.10 | +7.74 | +11.14 | +1.05 | +3.36 | +1.93 | +0.79 | +0.00 | +1.00 | +
| disease | +benefit_harm | +WR | +Landmark at 6 months | +V2_cluster | +22.24 | +11.10 | +7.74 | +11.14 | +1.05 | +3.36 | +1.93 | +1.12 | +0.00 | +1.00 | +
| disease | +benefit_harm | +WR | +Landmark at 6 months | +V3_random | +19.13 | +11.10 | +7.74 | +8.03 | +1.03 | +3.36 | +1.95 | +1.06 | +0.00 | +1.00 | +
| disease | +benefit_harm | +WR | +Landmark at 6 months | +V4_within | +18.42 | +11.10 | +7.74 | +7.32 | +1.03 | +3.36 | +2.23 | +1.05 | +0.03 | +1.00 | +
| disease | +benefit_harm | +WR | +Sequential trials, ITT | +V1_ignore | +20.35 | +8.93 | +7.74 | +11.41 | +0.20 | +1.19 | +1.99 | +0.74 | +0.00 | +1.00 | +
| disease | +benefit_harm | +WR | +Sequential trials, ITT | +V2_cluster | +20.35 | +8.93 | +7.74 | +11.41 | +0.20 | +1.19 | +1.99 | +1.08 | +0.00 | +1.00 | +
| disease | +benefit_harm | +WR | +Sequential trials, ITT | +V3_random | +17.09 | +8.93 | +7.74 | +8.16 | +0.20 | +1.19 | +1.99 | +1.01 | +0.00 | +1.00 | +
| disease | +benefit_harm | +WR | +Sequential trials, ITT | +V4_within | +16.17 | +8.93 | +7.74 | +7.23 | +0.22 | +1.19 | +2.23 | +0.99 | +0.07 | +1.00 | +
| disease | +benefit_harm | +WR | +CCW, A vs B2 | +V1_ignore | +17.14 | +7.84 | +7.74 | +9.30 | +0.43 | +0.10 | +4.27 | +0.79 | +0.24 | +1.00 | +
| disease | +benefit_harm | +WR | +CCW, A vs B2 | +V2_cluster | +17.14 | +7.84 | +7.74 | +9.30 | +0.43 | +0.10 | +4.27 | +0.85 | +0.27 | +1.00 | +
| disease | +benefit_harm | +WR | +CCW, A vs B2 | +V3_random | +14.96 | +7.84 | +7.74 | +7.12 | +0.46 | +0.10 | +4.56 | +0.88 | +0.64 | +1.00 | +
| disease | +benefit_harm | +WR | +CCW, A vs B2 | +V4_within | +14.66 | +7.84 | +7.74 | +6.82 | +0.50 | +0.10 | +5.00 | +0.90 | +0.71 | +0.95 | +
| disease | +benefit_harm | +WR | +CCW, A vs B1 (reference) | +V1_ignore | +17.04 | +7.74 | +7.74 | +9.30 | +0.43 | +0.00 | +4.27 | +0.79 | +0.23 | +1.00 | +
| disease | +benefit_harm | +WR | +CCW, A vs B1 (reference) | +V2_cluster | +17.04 | +7.74 | +7.74 | +9.30 | +0.43 | +0.00 | +4.27 | +0.85 | +0.28 | +1.00 | +
| disease | +benefit_harm | +WR | +CCW, A vs B1 (reference) | +V3_random | +14.83 | +7.74 | +7.74 | +7.09 | +0.46 | +0.00 | +4.56 | +0.88 | +0.62 | +1.00 | +
| disease | +benefit_harm | +WR | +CCW, A vs B1 (reference) | +V4_within | +14.44 | +7.74 | +7.74 | +6.70 | +0.50 | +0.00 | +5.00 | +0.90 | +0.72 | +0.95 | +
| disease | +harm | +W0 | +Naive ‘ever early PVI’ | +V1_ignore | +6.89 | +7.18 | +5.11 | +-0.29 | +0.06 | +2.07 | +1.65 | +0.85 | +0.88 | +1.00 | +
| disease | +harm | +W0 | +Naive ‘ever early PVI’ | +V2_cluster | +6.89 | +7.18 | +5.11 | +-0.29 | +0.06 | +2.07 | +1.65 | +0.85 | +0.88 | +1.00 | +
| disease | +harm | +W0 | +Naive ‘ever early PVI’ | +V3_random | +7.02 | +7.18 | +5.11 | +-0.16 | +0.06 | +2.07 | +1.69 | +0.85 | +0.89 | +1.00 | +
| disease | +harm | +W0 | +Naive ‘ever early PVI’ | +V4_within | +6.28 | +7.18 | +5.11 | +-0.90 | +0.12 | +2.07 | +2.03 | +0.87 | +0.80 | +0.98 | +
| disease | +harm | +W0 | +Landmark at 6 months | +V1_ignore | +7.85 | +7.95 | +5.11 | +-0.10 | +0.16 | +2.84 | +3.61 | +0.92 | +0.92 | +0.81 | +
| disease | +harm | +W0 | +Landmark at 6 months | +V2_cluster | +7.85 | +7.95 | +5.11 | +-0.10 | +0.16 | +2.84 | +3.61 | +0.92 | +0.92 | +0.80 | +
| disease | +harm | +W0 | +Landmark at 6 months | +V3_random | +7.80 | +7.95 | +5.11 | +-0.15 | +0.15 | +2.84 | +3.62 | +0.91 | +0.91 | +0.78 | +
| disease | +harm | +W0 | +Landmark at 6 months | +V4_within | +7.29 | +7.95 | +5.11 | +-0.66 | +0.29 | +2.84 | +4.59 | +0.88 | +0.87 | +0.50 | +
| disease | +harm | +W0 | +Sequential trials, ITT | +V1_ignore | +5.70 | +5.71 | +5.11 | +-0.01 | +0.15 | +0.61 | +1.46 | +0.86 | +0.91 | +0.99 | +
| disease | +harm | +W0 | +Sequential trials, ITT | +V2_cluster | +5.70 | +5.71 | +5.11 | +-0.01 | +0.15 | +0.61 | +1.46 | +0.86 | +0.91 | +0.99 | +
| disease | +harm | +W0 | +Sequential trials, ITT | +V3_random | +5.68 | +5.71 | +5.11 | +-0.03 | +0.16 | +0.61 | +1.55 | +0.83 | +0.91 | +0.99 | +
| disease | +harm | +W0 | +Sequential trials, ITT | +V4_within | +5.43 | +5.71 | +5.11 | +-0.29 | +0.19 | +0.61 | +1.86 | +0.83 | +0.89 | +0.94 | +
| disease | +harm | +W0 | +CCW, A vs B2 | +V1_ignore | +5.32 | +5.15 | +5.11 | +0.17 | +0.28 | +0.05 | +2.81 | +1.03 | +0.96 | +0.44 | +
| disease | +harm | +W0 | +CCW, A vs B2 | +V2_cluster | +5.32 | +5.15 | +5.11 | +0.17 | +0.28 | +0.05 | +2.81 | +1.03 | +0.96 | +0.46 | +
| disease | +harm | +W0 | +CCW, A vs B2 | +V3_random | +5.38 | +5.15 | +5.11 | +0.23 | +0.29 | +0.05 | +2.91 | +1.02 | +0.97 | +0.43 | +
| disease | +harm | +W0 | +CCW, A vs B2 | +V4_within | +5.29 | +5.15 | +5.11 | +0.13 | +0.36 | +0.05 | +3.61 | +0.96 | +0.93 | +0.32 | +
| disease | +harm | +W0 | +CCW, A vs B1 (reference) | +V1_ignore | +5.28 | +5.11 | +5.11 | +0.17 | +0.28 | +0.00 | +2.82 | +1.03 | +0.96 | +0.44 | +
| disease | +harm | +W0 | +CCW, A vs B1 (reference) | +V2_cluster | +5.28 | +5.11 | +5.11 | +0.17 | +0.28 | +0.00 | +2.82 | +1.03 | +0.96 | +0.46 | +
| disease | +harm | +W0 | +CCW, A vs B1 (reference) | +V3_random | +5.34 | +5.11 | +5.11 | +0.23 | +0.29 | +0.00 | +2.91 | +1.02 | +0.97 | +0.43 | +
| disease | +harm | +W0 | +CCW, A vs B1 (reference) | +V4_within | +5.24 | +5.11 | +5.11 | +0.13 | +0.36 | +0.00 | +3.61 | +0.96 | +0.93 | +0.32 | +
| disease | +harm | +W1 | +Naive ‘ever early PVI’ | +V1_ignore | +10.33 | +9.80 | +7.18 | +0.52 | +0.10 | +2.62 | +1.51 | +1.02 | +0.95 | +1.00 | +
| disease | +harm | +W1 | +Naive ‘ever early PVI’ | +V2_cluster | +10.33 | +9.80 | +7.18 | +0.52 | +0.10 | +2.62 | +1.51 | +1.06 | +0.96 | +1.00 | +
| disease | +harm | +W1 | +Naive ‘ever early PVI’ | +V3_random | +10.19 | +9.80 | +7.18 | +0.39 | +0.08 | +2.62 | +1.54 | +1.04 | +0.97 | +1.00 | +
| disease | +harm | +W1 | +Naive ‘ever early PVI’ | +V4_within | +9.11 | +9.80 | +7.18 | +-0.70 | +0.14 | +2.62 | +2.13 | +0.90 | +0.85 | +1.00 | +
| disease | +harm | +W1 | +Landmark at 6 months | +V1_ignore | +23.70 | +19.85 | +7.18 | +3.85 | +0.38 | +12.67 | +12.66 | +0.55 | +0.84 | +0.96 | +
| disease | +harm | +W1 | +Landmark at 6 months | +V2_cluster | +23.70 | +19.85 | +7.18 | +3.85 | +0.38 | +12.67 | +12.66 | +0.58 | +0.84 | +0.96 | +
| disease | +harm | +W1 | +Landmark at 6 months | +V3_random | +22.54 | +19.85 | +7.18 | +2.69 | +0.32 | +12.67 | +12.59 | +0.56 | +0.83 | +0.96 | +
| disease | +harm | +W1 | +Landmark at 6 months | +V4_within | +21.36 | +19.85 | +7.18 | +1.51 | +0.53 | +12.67 | +13.13 | +0.58 | +0.83 | +0.94 | +
| disease | +harm | +W1 | +Sequential trials, ITT | +V1_ignore | +9.17 | +7.98 | +7.18 | +1.19 | +0.15 | +0.80 | +1.47 | +0.96 | +0.91 | +1.00 | +
| disease | +harm | +W1 | +Sequential trials, ITT | +V2_cluster | +9.17 | +7.98 | +7.18 | +1.19 | +0.15 | +0.80 | +1.47 | +1.01 | +0.92 | +1.00 | +
| disease | +harm | +W1 | +Sequential trials, ITT | +V3_random | +8.89 | +7.98 | +7.18 | +0.92 | +0.15 | +0.80 | +1.48 | +1.00 | +0.95 | +1.00 | +
| disease | +harm | +W1 | +Sequential trials, ITT | +V4_within | +8.20 | +7.98 | +7.18 | +0.22 | +0.20 | +0.80 | +1.95 | +0.88 | +0.89 | +1.00 | +
| disease | +harm | +W1 | +CCW, A vs B2 | +V1_ignore | +8.36 | +7.26 | +7.18 | +1.11 | +0.28 | +0.07 | +2.85 | +1.07 | +0.96 | +0.85 | +
| disease | +harm | +W1 | +CCW, A vs B2 | +V2_cluster | +8.36 | +7.26 | +7.18 | +1.11 | +0.28 | +0.07 | +2.85 | +1.07 | +0.96 | +0.85 | +
| disease | +harm | +W1 | +CCW, A vs B2 | +V3_random | +8.15 | +7.26 | +7.18 | +0.89 | +0.30 | +0.07 | +2.95 | +1.04 | +0.96 | +0.81 | +
| disease | +harm | +W1 | +CCW, A vs B2 | +V4_within | +7.61 | +7.26 | +7.18 | +0.35 | +0.36 | +0.07 | +3.58 | +0.97 | +0.94 | +0.67 | +
| disease | +harm | +W1 | +CCW, A vs B1 (reference) | +V1_ignore | +8.29 | +7.18 | +7.18 | +1.11 | +0.28 | +0.00 | +2.85 | +1.07 | +0.96 | +0.85 | +
| disease | +harm | +W1 | +CCW, A vs B1 (reference) | +V2_cluster | +8.29 | +7.18 | +7.18 | +1.11 | +0.28 | +0.00 | +2.85 | +1.07 | +0.96 | +0.85 | +
| disease | +harm | +W1 | +CCW, A vs B1 (reference) | +V3_random | +8.08 | +7.18 | +7.18 | +0.90 | +0.30 | +0.00 | +2.95 | +1.04 | +0.96 | +0.81 | +
| disease | +harm | +W1 | +CCW, A vs B1 (reference) | +V4_within | +7.53 | +7.18 | +7.18 | +0.34 | +0.36 | +0.00 | +3.57 | +0.97 | +0.94 | +0.66 | +
| disease | +harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V1_ignore | +9.20 | +9.50 | +7.12 | +-0.31 | +0.08 | +2.38 | +1.41 | +1.07 | +0.95 | +1.00 | +
| disease | +harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V2_cluster | +9.20 | +9.50 | +7.12 | +-0.31 | +0.08 | +2.38 | +1.41 | +1.09 | +0.96 | +1.00 | +
| disease | +harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V3_random | +9.35 | +9.50 | +7.12 | +-0.16 | +0.07 | +2.38 | +1.45 | +1.08 | +0.97 | +1.00 | +
| disease | +harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V4_within | +8.70 | +9.50 | +7.12 | +-0.81 | +0.13 | +2.38 | +1.84 | +1.04 | +0.92 | +1.00 | +
| disease | +harm | +W1_rho0 | +Landmark at 6 months | +V1_ignore | +21.20 | +20.08 | +7.12 | +1.12 | +0.35 | +12.96 | +11.58 | +0.62 | +0.80 | +0.95 | +
| disease | +harm | +W1_rho0 | +Landmark at 6 months | +V2_cluster | +21.20 | +20.08 | +7.12 | +1.12 | +0.35 | +12.96 | +11.58 | +0.64 | +0.78 | +0.96 | +
| disease | +harm | +W1_rho0 | +Landmark at 6 months | +V3_random | +20.83 | +20.08 | +7.12 | +0.75 | +0.28 | +12.96 | +11.51 | +0.63 | +0.75 | +0.94 | +
| disease | +harm | +W1_rho0 | +Landmark at 6 months | +V4_within | +20.85 | +20.08 | +7.12 | +0.77 | +0.52 | +12.96 | +13.19 | +0.62 | +0.72 | +0.86 | +
| disease | +harm | +W1_rho0 | +Sequential trials, ITT | +V1_ignore | +8.03 | +7.97 | +7.12 | +0.06 | +0.13 | +0.84 | +1.25 | +1.09 | +0.97 | +1.00 | +
| disease | +harm | +W1_rho0 | +Sequential trials, ITT | +V2_cluster | +8.03 | +7.97 | +7.12 | +0.06 | +0.13 | +0.84 | +1.25 | +1.12 | +0.98 | +1.00 | +
| disease | +harm | +W1_rho0 | +Sequential trials, ITT | +V3_random | +8.04 | +7.97 | +7.12 | +0.07 | +0.13 | +0.84 | +1.30 | +1.10 | +0.98 | +1.00 | +
| disease | +harm | +W1_rho0 | +Sequential trials, ITT | +V4_within | +7.83 | +7.97 | +7.12 | +-0.14 | +0.18 | +0.84 | +1.75 | +0.98 | +0.96 | +1.00 | +
| disease | +harm | +W1_rho0 | +CCW, A vs B2 | +V1_ignore | +7.42 | +7.19 | +7.12 | +0.23 | +0.30 | +0.06 | +2.96 | +1.03 | +0.92 | +0.78 | +
| disease | +harm | +W1_rho0 | +CCW, A vs B2 | +V2_cluster | +7.42 | +7.19 | +7.12 | +0.23 | +0.30 | +0.06 | +2.96 | +1.03 | +0.92 | +0.77 | +
| disease | +harm | +W1_rho0 | +CCW, A vs B2 | +V3_random | +7.55 | +7.19 | +7.12 | +0.36 | +0.31 | +0.06 | +3.10 | +1.02 | +0.90 | +0.75 | +
| disease | +harm | +W1_rho0 | +CCW, A vs B2 | +V4_within | +7.43 | +7.19 | +7.12 | +0.25 | +0.38 | +0.06 | +3.77 | +0.97 | +0.90 | +0.61 | +
| disease | +harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V1_ignore | +7.36 | +7.12 | +7.12 | +0.23 | +0.30 | +0.00 | +2.97 | +1.03 | +0.92 | +0.77 | +
| disease | +harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V2_cluster | +7.36 | +7.12 | +7.12 | +0.23 | +0.30 | +0.00 | +2.97 | +1.03 | +0.92 | +0.76 | +
| disease | +harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V3_random | +7.49 | +7.12 | +7.12 | +0.37 | +0.31 | +0.00 | +3.10 | +1.01 | +0.91 | +0.75 | +
| disease | +harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V4_within | +7.37 | +7.12 | +7.12 | +0.24 | +0.38 | +0.00 | +3.78 | +0.97 | +0.90 | +0.60 | +
| disease | +harm | +W2 | +Naive ‘ever early PVI’ | +V1_ignore | +7.23 | +17.68 | +5.09 | +-10.45 | +1.00 | +12.59 | +1.51 | +0.97 | +0.00 | +1.00 | +
| disease | +harm | +W2 | +Naive ‘ever early PVI’ | +V2_cluster | +7.23 | +17.68 | +5.09 | +-10.45 | +1.00 | +12.59 | +1.51 | +0.98 | +0.00 | +1.00 | +
| disease | +harm | +W2 | +Naive ‘ever early PVI’ | +V3_random | +8.71 | +17.68 | +5.09 | +-8.97 | +0.94 | +12.59 | +2.64 | +0.96 | +0.13 | +0.99 | +
| disease | +harm | +W2 | +Naive ‘ever early PVI’ | +V4_within | +6.22 | +17.68 | +5.09 | +-11.46 | +1.03 | +12.59 | +2.81 | +0.89 | +0.06 | +0.78 | +
| disease | +harm | +W2 | +Landmark at 6 months | +V1_ignore | +8.27 | +8.20 | +5.09 | +0.07 | +0.79 | +3.11 | +4.25 | +0.92 | +0.91 | +0.76 | +
| disease | +harm | +W2 | +Landmark at 6 months | +V2_cluster | +8.27 | +8.20 | +5.09 | +0.07 | +0.79 | +3.11 | +4.25 | +0.91 | +0.90 | +0.79 | +
| disease | +harm | +W2 | +Landmark at 6 months | +V3_random | +7.95 | +8.20 | +5.09 | +-0.25 | +0.70 | +3.11 | +5.01 | +0.86 | +0.88 | +0.52 | +
| disease | +harm | +W2 | +Landmark at 6 months | +V4_within | +7.12 | +8.20 | +5.09 | +-1.08 | +0.70 | +3.11 | +5.84 | +0.82 | +0.82 | +0.30 | +
| disease | +harm | +W2 | +Sequential trials, ITT | +V1_ignore | +5.91 | +5.72 | +5.09 | +0.19 | +0.14 | +0.63 | +1.40 | +0.92 | +0.92 | +1.00 | +
| disease | +harm | +W2 | +Sequential trials, ITT | +V2_cluster | +5.91 | +5.72 | +5.09 | +0.19 | +0.14 | +0.63 | +1.40 | +0.93 | +0.95 | +1.00 | +
| disease | +harm | +W2 | +Sequential trials, ITT | +V3_random | +5.72 | +5.72 | +5.09 | +0.00 | +0.20 | +0.63 | +2.02 | +0.87 | +0.86 | +0.93 | +
| disease | +harm | +W2 | +Sequential trials, ITT | +V4_within | +5.43 | +5.72 | +5.09 | +-0.29 | +0.23 | +0.63 | +2.29 | +0.85 | +0.85 | +0.84 | +
| disease | +harm | +W2 | +CCW, A vs B2 | +V1_ignore | +5.28 | +5.15 | +5.09 | +0.13 | +0.31 | +0.06 | +3.10 | +0.98 | +0.90 | +0.36 | +
| disease | +harm | +W2 | +CCW, A vs B2 | +V2_cluster | +5.28 | +5.15 | +5.09 | +0.13 | +0.31 | +0.06 | +3.10 | +0.97 | +0.91 | +0.39 | +
| disease | +harm | +W2 | +CCW, A vs B2 | +V3_random | +5.23 | +5.15 | +5.09 | +0.08 | +0.40 | +0.06 | +3.97 | +0.96 | +0.93 | +0.20 | +
| disease | +harm | +W2 | +CCW, A vs B2 | +V4_within | +5.03 | +5.15 | +5.09 | +-0.12 | +0.48 | +0.06 | +4.83 | +0.87 | +0.91 | +0.19 | +
| disease | +harm | +W2 | +CCW, A vs B1 (reference) | +V1_ignore | +5.24 | +5.09 | +5.09 | +0.15 | +0.31 | +0.00 | +3.10 | +0.98 | +0.90 | +0.35 | +
| disease | +harm | +W2 | +CCW, A vs B1 (reference) | +V2_cluster | +5.24 | +5.09 | +5.09 | +0.15 | +0.31 | +0.00 | +3.10 | +0.97 | +0.91 | +0.38 | +
| disease | +harm | +W2 | +CCW, A vs B1 (reference) | +V3_random | +5.18 | +5.09 | +5.09 | +0.09 | +0.40 | +0.00 | +3.98 | +0.96 | +0.93 | +0.20 | +
| disease | +harm | +W2 | +CCW, A vs B1 (reference) | +V4_within | +4.94 | +5.09 | +5.09 | +-0.15 | +0.48 | +0.00 | +4.84 | +0.87 | +0.91 | +0.16 | +
| disease | +harm | +W3 | +Naive ‘ever early PVI’ | +V1_ignore | +8.16 | +14.58 | +4.97 | +-6.42 | +0.94 | +9.62 | +1.39 | +1.08 | +0.02 | +1.00 | +
| disease | +harm | +W3 | +Naive ‘ever early PVI’ | +V2_cluster | +8.16 | +14.58 | +4.97 | +-6.42 | +0.94 | +9.62 | +1.39 | +1.08 | +0.02 | +1.00 | +
| disease | +harm | +W3 | +Naive ‘ever early PVI’ | +V3_random | +8.48 | +14.58 | +4.97 | +-6.10 | +0.87 | +9.62 | +2.34 | +1.05 | +0.25 | +1.00 | +
| disease | +harm | +W3 | +Naive ‘ever early PVI’ | +V4_within | +5.66 | +14.58 | +4.97 | +-8.93 | +0.95 | +9.62 | +2.37 | +0.98 | +0.13 | +0.72 | +
| disease | +harm | +W3 | +Landmark at 6 months | +V1_ignore | +8.43 | +6.90 | +4.97 | +1.52 | +0.67 | +1.94 | +3.39 | +1.00 | +0.96 | +0.87 | +
| disease | +harm | +W3 | +Landmark at 6 months | +V2_cluster | +8.43 | +6.90 | +4.97 | +1.52 | +0.67 | +1.94 | +3.39 | +0.98 | +0.95 | +0.87 | +
| disease | +harm | +W3 | +Landmark at 6 months | +V3_random | +7.17 | +6.90 | +4.97 | +0.27 | +0.54 | +1.94 | +3.81 | +0.92 | +0.94 | +0.58 | +
| disease | +harm | +W3 | +Landmark at 6 months | +V4_within | +5.95 | +6.90 | +4.97 | +-0.95 | +0.56 | +1.94 | +4.36 | +0.92 | +0.87 | +0.34 | +
| disease | +harm | +W3 | +Sequential trials, ITT | +V1_ignore | +6.94 | +5.58 | +4.97 | +1.36 | +0.13 | +0.62 | +1.29 | +1.05 | +0.93 | +1.00 | +
| disease | +harm | +W3 | +Sequential trials, ITT | +V2_cluster | +6.94 | +5.58 | +4.97 | +1.36 | +0.13 | +0.62 | +1.29 | +1.05 | +0.90 | +1.00 | +
| disease | +harm | +W3 | +Sequential trials, ITT | +V3_random | +5.77 | +5.58 | +4.97 | +0.19 | +0.17 | +0.62 | +1.65 | +1.04 | +0.96 | +0.99 | +
| disease | +harm | +W3 | +Sequential trials, ITT | +V4_within | +5.07 | +5.58 | +4.97 | +-0.51 | +0.20 | +0.62 | +1.99 | +0.97 | +0.90 | +0.82 | +
| disease | +harm | +W3 | +CCW, A vs B2 | +V1_ignore | +5.71 | +5.02 | +4.97 | +0.70 | +0.28 | +0.05 | +2.84 | +1.07 | +0.96 | +0.49 | +
| disease | +harm | +W3 | +CCW, A vs B2 | +V2_cluster | +5.71 | +5.02 | +4.97 | +0.70 | +0.28 | +0.05 | +2.84 | +1.08 | +0.96 | +0.47 | +
| disease | +harm | +W3 | +CCW, A vs B2 | +V3_random | +5.14 | +5.02 | +4.97 | +0.12 | +0.38 | +0.05 | +3.75 | +0.97 | +0.93 | +0.19 | +
| disease | +harm | +W3 | +CCW, A vs B2 | +V4_within | +4.73 | +5.02 | +4.97 | +-0.29 | +0.44 | +0.05 | +4.42 | +0.92 | +0.90 | +0.15 | +
| disease | +harm | +W3 | +CCW, A vs B1 (reference) | +V1_ignore | +5.66 | +4.97 | +4.97 | +0.69 | +0.28 | +0.00 | +2.84 | +1.07 | +0.96 | +0.49 | +
| disease | +harm | +W3 | +CCW, A vs B1 (reference) | +V2_cluster | +5.66 | +4.97 | +4.97 | +0.69 | +0.28 | +0.00 | +2.84 | +1.08 | +0.96 | +0.46 | +
| disease | +harm | +W3 | +CCW, A vs B1 (reference) | +V3_random | +5.09 | +4.97 | +4.97 | +0.12 | +0.38 | +0.00 | +3.75 | +0.97 | +0.93 | +0.19 | +
| disease | +harm | +W3 | +CCW, A vs B1 (reference) | +V4_within | +4.65 | +4.97 | +4.97 | +-0.32 | +0.44 | +0.00 | +4.42 | +0.92 | +0.91 | +0.14 | +
| disease | +harm | +W4 | +Naive ‘ever early PVI’ | +V1_ignore | +6.51 | +6.73 | +4.80 | +-0.23 | +0.07 | +1.93 | +1.37 | +1.03 | +0.93 | +1.00 | +
| disease | +harm | +W4 | +Naive ‘ever early PVI’ | +V2_cluster | +6.51 | +6.73 | +4.80 | +-0.23 | +0.07 | +1.93 | +1.37 | +1.02 | +0.93 | +1.00 | +
| disease | +harm | +W4 | +Naive ‘ever early PVI’ | +V3_random | +6.62 | +6.73 | +4.80 | +-0.12 | +0.07 | +1.93 | +1.46 | +0.99 | +0.95 | +1.00 | +
| disease | +harm | +W4 | +Naive ‘ever early PVI’ | +V4_within | +5.70 | +6.73 | +4.80 | +-1.03 | +0.11 | +1.93 | +1.60 | +1.09 | +0.88 | +0.97 | +
| disease | +harm | +W4 | +Landmark at 6 months | +V1_ignore | +7.18 | +7.23 | +4.80 | +-0.05 | +0.16 | +2.43 | +3.08 | +1.04 | +0.93 | +0.70 | +
| disease | +harm | +W4 | +Landmark at 6 months | +V2_cluster | +7.18 | +7.23 | +4.80 | +-0.05 | +0.16 | +2.43 | +3.08 | +1.04 | +0.93 | +0.71 | +
| disease | +harm | +W4 | +Landmark at 6 months | +V3_random | +7.25 | +7.23 | +4.80 | +0.01 | +0.14 | +2.43 | +3.34 | +1.00 | +0.95 | +0.71 | +
| disease | +harm | +W4 | +Landmark at 6 months | +V4_within | +6.84 | +7.23 | +4.80 | +-0.39 | +0.34 | +2.43 | +5.38 | +0.83 | +0.90 | +0.35 | +
| disease | +harm | +W4 | +Sequential trials, ITT | +V1_ignore | +5.32 | +5.42 | +4.80 | +-0.10 | +0.12 | +0.62 | +1.24 | +1.01 | +0.93 | +1.00 | +
| disease | +harm | +W4 | +Sequential trials, ITT | +V2_cluster | +5.32 | +5.42 | +4.80 | +-0.10 | +0.12 | +0.62 | +1.24 | +1.01 | +0.92 | +1.00 | +
| disease | +harm | +W4 | +Sequential trials, ITT | +V3_random | +5.26 | +5.42 | +4.80 | +-0.16 | +0.13 | +0.62 | +1.30 | +0.99 | +0.92 | +1.00 | +
| disease | +harm | +W4 | +Sequential trials, ITT | +V4_within | +4.88 | +5.42 | +4.80 | +-0.54 | +0.14 | +0.62 | +1.44 | +1.05 | +0.92 | +0.96 | +
| disease | +harm | +W4 | +CCW, A vs B2 | +V1_ignore | +5.11 | +5.16 | +4.80 | +-0.05 | +0.27 | +0.36 | +2.71 | +1.04 | +0.94 | +0.40 | +
| disease | +harm | +W4 | +CCW, A vs B2 | +V2_cluster | +5.11 | +5.16 | +4.80 | +-0.05 | +0.27 | +0.36 | +2.71 | +1.03 | +0.94 | +0.42 | +
| disease | +harm | +W4 | +CCW, A vs B2 | +V3_random | +5.22 | +5.16 | +4.80 | +0.05 | +0.28 | +0.36 | +2.80 | +1.02 | +0.95 | +0.42 | +
| disease | +harm | +W4 | +CCW, A vs B2 | +V4_within | +5.15 | +5.16 | +4.80 | +-0.02 | +0.34 | +0.36 | +3.37 | +1.00 | +0.90 | +0.29 | +
| disease | +harm | +W4 | +CCW, A vs B1 (reference) | +V1_ignore | +4.79 | +4.80 | +4.80 | +-0.01 | +0.27 | +0.00 | +2.70 | +1.04 | +0.94 | +0.38 | +
| disease | +harm | +W4 | +CCW, A vs B1 (reference) | +V2_cluster | +4.79 | +4.80 | +4.80 | +-0.01 | +0.27 | +0.00 | +2.70 | +1.03 | +0.94 | +0.37 | +
| disease | +harm | +W4 | +CCW, A vs B1 (reference) | +V3_random | +4.84 | +4.80 | +4.80 | +0.04 | +0.28 | +0.00 | +2.80 | +1.02 | +0.95 | +0.35 | +
| disease | +harm | +W4 | +CCW, A vs B1 (reference) | +V4_within | +4.75 | +4.80 | +4.80 | +-0.05 | +0.34 | +0.00 | +3.38 | +1.00 | +0.90 | +0.25 | +
| disease | +harm | +W5 | +Naive ‘ever early PVI’ | +V1_ignore | +12.74 | +7.23 | +5.11 | +5.51 | +0.11 | +2.13 | +1.09 | +1.08 | +0.00 | +1.00 | +
| disease | +harm | +W5 | +Naive ‘ever early PVI’ | +V2_cluster | +12.74 | +7.23 | +5.11 | +5.51 | +0.11 | +2.13 | +1.09 | +1.08 | +0.00 | +1.00 | +
| disease | +harm | +W5 | +Naive ‘ever early PVI’ | +V3_random | +12.83 | +7.23 | +5.11 | +5.60 | +0.11 | +2.13 | +1.10 | +1.09 | +0.00 | +1.00 | +
| disease | +harm | +W5 | +Naive ‘ever early PVI’ | +V4_within | +12.55 | +7.23 | +5.11 | +5.32 | +0.12 | +2.13 | +1.28 | +1.12 | +0.01 | +1.00 | +
| disease | +harm | +W5 | +Landmark at 6 months | +V1_ignore | +10.68 | +8.16 | +5.11 | +2.52 | +0.36 | +3.06 | +1.11 | +1.08 | +0.43 | +1.00 | +
| disease | +harm | +W5 | +Landmark at 6 months | +V2_cluster | +10.68 | +8.16 | +5.11 | +2.52 | +0.36 | +3.06 | +1.11 | +1.07 | +0.41 | +1.00 | +
| disease | +harm | +W5 | +Landmark at 6 months | +V3_random | +10.72 | +8.16 | +5.11 | +2.55 | +0.36 | +3.06 | +1.11 | +1.10 | +0.44 | +1.00 | +
| disease | +harm | +W5 | +Landmark at 6 months | +V4_within | +10.65 | +8.16 | +5.11 | +2.48 | +0.37 | +3.06 | +1.30 | +1.13 | +0.66 | +1.00 | +
| disease | +harm | +W5 | +Sequential trials, ITT | +V1_ignore | +10.66 | +5.71 | +5.11 | +4.94 | +0.11 | +0.61 | +1.09 | +1.08 | +0.00 | +1.00 | +
| disease | +harm | +W5 | +Sequential trials, ITT | +V2_cluster | +10.66 | +5.71 | +5.11 | +4.94 | +0.11 | +0.61 | +1.09 | +1.07 | +0.00 | +1.00 | +
| disease | +harm | +W5 | +Sequential trials, ITT | +V3_random | +10.68 | +5.71 | +5.11 | +4.96 | +0.11 | +0.61 | +1.08 | +1.11 | +0.00 | +1.00 | +
| disease | +harm | +W5 | +Sequential trials, ITT | +V4_within | +10.63 | +5.71 | +5.11 | +4.92 | +0.12 | +0.61 | +1.22 | +1.17 | +0.04 | +1.00 | +
| disease | +harm | +W5 | +CCW, A vs B2 | +V1_ignore | +9.58 | +5.15 | +5.11 | +4.42 | +0.25 | +0.05 | +2.49 | +1.05 | +0.60 | +0.99 | +
| disease | +harm | +W5 | +CCW, A vs B2 | +V2_cluster | +9.58 | +5.15 | +5.11 | +4.42 | +0.25 | +0.05 | +2.49 | +1.05 | +0.60 | +0.98 | +
| disease | +harm | +W5 | +CCW, A vs B2 | +V3_random | +9.55 | +5.15 | +5.11 | +4.40 | +0.26 | +0.05 | +2.58 | +1.02 | +0.61 | +0.99 | +
| disease | +harm | +W5 | +CCW, A vs B2 | +V4_within | +9.58 | +5.15 | +5.11 | +4.43 | +0.30 | +0.05 | +3.05 | +1.00 | +0.68 | +0.96 | +
| disease | +harm | +W5 | +CCW, A vs B1 (reference) | +V1_ignore | +9.54 | +5.11 | +5.11 | +4.43 | +0.25 | +0.00 | +2.49 | +1.05 | +0.61 | +0.98 | +
| disease | +harm | +W5 | +CCW, A vs B1 (reference) | +V2_cluster | +9.54 | +5.11 | +5.11 | +4.43 | +0.25 | +0.00 | +2.49 | +1.05 | +0.61 | +0.98 | +
| disease | +harm | +W5 | +CCW, A vs B1 (reference) | +V3_random | +9.51 | +5.11 | +5.11 | +4.41 | +0.26 | +0.00 | +2.58 | +1.02 | +0.61 | +0.99 | +
| disease | +harm | +W5 | +CCW, A vs B1 (reference) | +V4_within | +9.54 | +5.11 | +5.11 | +4.43 | +0.31 | +0.00 | +3.05 | +1.00 | +0.68 | +0.96 | +
| disease | +harm | +WR | +Naive ‘ever early PVI’ | +V1_ignore | +18.78 | +17.32 | +6.93 | +1.46 | +0.98 | +10.39 | +1.62 | +0.88 | +0.81 | +1.00 | +
| disease | +harm | +WR | +Naive ‘ever early PVI’ | +V2_cluster | +18.78 | +17.32 | +6.93 | +1.46 | +0.98 | +10.39 | +1.62 | +1.08 | +0.90 | +1.00 | +
| disease | +harm | +WR | +Naive ‘ever early PVI’ | +V3_random | +17.88 | +17.32 | +6.93 | +0.56 | +0.97 | +10.39 | +2.05 | +0.94 | +0.93 | +1.00 | +
| disease | +harm | +WR | +Naive ‘ever early PVI’ | +V4_within | +16.28 | +17.32 | +6.93 | +-1.04 | +1.00 | +10.39 | +2.33 | +0.92 | +0.84 | +1.00 | +
| disease | +harm | +WR | +Landmark at 6 months | +V1_ignore | +16.73 | +15.52 | +6.93 | +1.21 | +1.07 | +8.59 | +1.66 | +0.88 | +0.83 | +1.00 | +
| disease | +harm | +WR | +Landmark at 6 months | +V2_cluster | +16.73 | +15.52 | +6.93 | +1.21 | +1.07 | +8.59 | +1.66 | +1.07 | +0.93 | +1.00 | +
| disease | +harm | +WR | +Landmark at 6 months | +V3_random | +15.00 | +15.52 | +6.93 | +-0.52 | +1.07 | +8.59 | +1.97 | +0.98 | +0.95 | +1.00 | +
| disease | +harm | +WR | +Landmark at 6 months | +V4_within | +14.26 | +15.52 | +6.93 | +-1.26 | +1.08 | +8.59 | +2.31 | +0.97 | +0.86 | +1.00 | +
| disease | +harm | +WR | +Sequential trials, ITT | +V1_ignore | +16.93 | +7.68 | +6.93 | +9.25 | +0.16 | +0.75 | +1.58 | +0.91 | +0.00 | +1.00 | +
| disease | +harm | +WR | +Sequential trials, ITT | +V2_cluster | +16.93 | +7.68 | +6.93 | +9.25 | +0.16 | +0.75 | +1.58 | +1.11 | +0.00 | +1.00 | +
| disease | +harm | +WR | +Sequential trials, ITT | +V3_random | +15.11 | +7.68 | +6.93 | +7.43 | +0.20 | +0.75 | +2.00 | +0.93 | +0.00 | +1.00 | +
| disease | +harm | +WR | +Sequential trials, ITT | +V4_within | +14.35 | +7.68 | +6.93 | +6.67 | +0.23 | +0.75 | +2.35 | +0.88 | +0.12 | +1.00 | +
| disease | +harm | +WR | +CCW, A vs B2 | +V1_ignore | +14.14 | +7.08 | +6.93 | +7.06 | +0.39 | +0.15 | +3.88 | +0.84 | +0.48 | +1.00 | +
| disease | +harm | +WR | +CCW, A vs B2 | +V2_cluster | +14.14 | +7.08 | +6.93 | +7.06 | +0.39 | +0.15 | +3.88 | +0.87 | +0.50 | +1.00 | +
| disease | +harm | +WR | +CCW, A vs B2 | +V3_random | +13.49 | +7.08 | +6.93 | +6.41 | +0.39 | +0.15 | +3.94 | +1.01 | +0.73 | +1.00 | +
| disease | +harm | +WR | +CCW, A vs B2 | +V4_within | +13.31 | +7.08 | +6.93 | +6.24 | +0.43 | +0.15 | +4.34 | +1.04 | +0.79 | +0.94 | +
| disease | +harm | +WR | +CCW, A vs B1 (reference) | +V1_ignore | +13.99 | +6.93 | +6.93 | +7.06 | +0.39 | +0.00 | +3.87 | +0.85 | +0.48 | +1.00 | +
| disease | +harm | +WR | +CCW, A vs B1 (reference) | +V2_cluster | +13.99 | +6.93 | +6.93 | +7.06 | +0.39 | +0.00 | +3.87 | +0.87 | +0.50 | +1.00 | +
| disease | +harm | +WR | +CCW, A vs B1 (reference) | +V3_random | +13.31 | +6.93 | +6.93 | +6.38 | +0.39 | +0.00 | +3.94 | +1.01 | +0.73 | +1.00 | +
| disease | +harm | +WR | +CCW, A vs B1 (reference) | +V4_within | +13.00 | +6.93 | +6.93 | +6.07 | +0.43 | +0.00 | +4.34 | +1.04 | +0.80 | +0.93 | +
| disease | +null | +W0 | +Naive ‘ever early PVI’ | +V1_ignore | +1.06 | +1.25 | +0.00 | +-0.20 | +0.06 | +1.25 | +1.15 | +1.03 | +0.94 | +0.07 | +
| disease | +null | +W0 | +Naive ‘ever early PVI’ | +V2_cluster | +1.06 | +1.25 | +0.00 | +-0.20 | +0.06 | +1.25 | +1.15 | +1.02 | +0.95 | +0.07 | +
| disease | +null | +W0 | +Naive ‘ever early PVI’ | +V3_random | +1.16 | +1.25 | +0.00 | +-0.10 | +0.06 | +1.25 | +1.19 | +1.03 | +0.92 | +0.13 | +
| disease | +null | +W0 | +Naive ‘ever early PVI’ | +V4_within | +0.54 | +1.25 | +0.00 | +-0.71 | +0.10 | +1.25 | +1.45 | +0.98 | +0.84 | +0.03 | +
| disease | +null | +W0 | +Landmark at 6 months | +V1_ignore | +-0.16 | +-0.30 | +0.00 | +0.14 | +0.06 | +-0.30 | +0.99 | +1.06 | +0.97 | +0.06 | +
| disease | +null | +W0 | +Landmark at 6 months | +V2_cluster | +-0.16 | +-0.30 | +0.00 | +0.14 | +0.06 | +-0.30 | +0.99 | +1.06 | +0.97 | +0.06 | +
| disease | +null | +W0 | +Landmark at 6 months | +V3_random | +-0.12 | +-0.30 | +0.00 | +0.18 | +0.05 | +-0.30 | +1.02 | +1.05 | +0.97 | +0.06 | +
| disease | +null | +W0 | +Landmark at 6 months | +V4_within | +-0.33 | +-0.30 | +0.00 | +-0.04 | +0.07 | +-0.30 | +1.26 | +1.01 | +0.94 | +0.08 | +
| disease | +null | +W0 | +Sequential trials, ITT | +V1_ignore | +-0.02 | +0.00 | +0.00 | +-0.02 | +0.10 | +0.00 | +0.96 | +1.06 | +0.95 | +0.05 | +
| disease | +null | +W0 | +Sequential trials, ITT | +V2_cluster | +-0.02 | +0.00 | +0.00 | +-0.02 | +0.10 | +0.00 | +0.96 | +1.06 | +0.94 | +0.06 | +
| disease | +null | +W0 | +Sequential trials, ITT | +V3_random | +-0.03 | +0.00 | +0.00 | +-0.03 | +0.10 | +0.00 | +0.98 | +1.06 | +0.95 | +0.05 | +
| disease | +null | +W0 | +Sequential trials, ITT | +V4_within | +-0.12 | +0.00 | +0.00 | +-0.12 | +0.12 | +0.00 | +1.19 | +1.03 | +0.91 | +0.09 | +
| disease | +null | +W0 | +CCW, A vs B2 | +V1_ignore | +-0.33 | +0.00 | +0.00 | +-0.33 | +0.26 | +0.00 | +2.56 | +0.86 | +0.85 | +0.15 | +
| disease | +null | +W0 | +CCW, A vs B2 | +V2_cluster | +-0.33 | +0.00 | +0.00 | +-0.33 | +0.26 | +0.00 | +2.56 | +0.86 | +0.85 | +0.15 | +
| disease | +null | +W0 | +CCW, A vs B2 | +V3_random | +-0.21 | +0.00 | +0.00 | +-0.21 | +0.27 | +0.00 | +2.69 | +0.86 | +0.86 | +0.14 | +
| disease | +null | +W0 | +CCW, A vs B2 | +V4_within | +-0.14 | +0.00 | +0.00 | +-0.14 | +0.31 | +0.00 | +3.11 | +0.89 | +0.89 | +0.11 | +
| disease | +null | +W0 | +CCW, A vs B1 (reference) | +V1_ignore | +-0.33 | +0.00 | +0.00 | +-0.33 | +0.26 | +0.00 | +2.56 | +0.86 | +0.86 | +0.14 | +
| disease | +null | +W0 | +CCW, A vs B1 (reference) | +V2_cluster | +-0.33 | +0.00 | +0.00 | +-0.33 | +0.26 | +0.00 | +2.56 | +0.86 | +0.85 | +0.15 | +
| disease | +null | +W0 | +CCW, A vs B1 (reference) | +V3_random | +-0.21 | +0.00 | +0.00 | +-0.21 | +0.27 | +0.00 | +2.69 | +0.86 | +0.86 | +0.14 | +
| disease | +null | +W0 | +CCW, A vs B1 (reference) | +V4_within | +-0.14 | +0.00 | +0.00 | +-0.14 | +0.31 | +0.00 | +3.11 | +0.89 | +0.89 | +0.11 | +
| disease | +null | +W1 | +Naive ‘ever early PVI’ | +V1_ignore | +1.13 | +1.40 | +0.00 | +-0.27 | +0.07 | +1.40 | +1.37 | +0.92 | +0.89 | +0.10 | +
| disease | +null | +W1 | +Naive ‘ever early PVI’ | +V2_cluster | +1.13 | +1.40 | +0.00 | +-0.27 | +0.07 | +1.40 | +1.37 | +0.92 | +0.88 | +0.11 | +
| disease | +null | +W1 | +Naive ‘ever early PVI’ | +V3_random | +1.28 | +1.40 | +0.00 | +-0.12 | +0.06 | +1.40 | +1.42 | +0.92 | +0.93 | +0.12 | +
| disease | +null | +W1 | +Naive ‘ever early PVI’ | +V4_within | +0.69 | +1.40 | +0.00 | +-0.71 | +0.12 | +1.40 | +1.66 | +0.95 | +0.85 | +0.09 | +
| disease | +null | +W1 | +Landmark at 6 months | +V1_ignore | +-0.17 | +-0.28 | +0.00 | +0.11 | +0.05 | +-0.28 | +0.99 | +1.10 | +0.98 | +0.05 | +
| disease | +null | +W1 | +Landmark at 6 months | +V2_cluster | +-0.17 | +-0.28 | +0.00 | +0.11 | +0.05 | +-0.28 | +0.99 | +1.09 | +0.97 | +0.05 | +
| disease | +null | +W1 | +Landmark at 6 months | +V3_random | +-0.12 | +-0.28 | +0.00 | +0.16 | +0.05 | +-0.28 | +1.03 | +1.06 | +0.97 | +0.04 | +
| disease | +null | +W1 | +Landmark at 6 months | +V4_within | +-0.22 | +-0.28 | +0.00 | +0.06 | +0.09 | +-0.28 | +1.35 | +1.04 | +0.92 | +0.11 | +
| disease | +null | +W1 | +Sequential trials, ITT | +V1_ignore | +-0.11 | +0.00 | +0.00 | +-0.11 | +0.10 | +0.00 | +0.96 | +1.07 | +0.94 | +0.06 | +
| disease | +null | +W1 | +Sequential trials, ITT | +V2_cluster | +-0.11 | +0.00 | +0.00 | +-0.11 | +0.10 | +0.00 | +0.96 | +1.07 | +0.94 | +0.06 | +
| disease | +null | +W1 | +Sequential trials, ITT | +V3_random | +-0.11 | +0.00 | +0.00 | +-0.11 | +0.10 | +0.00 | +0.99 | +1.05 | +0.94 | +0.06 | +
| disease | +null | +W1 | +Sequential trials, ITT | +V4_within | +-0.12 | +0.00 | +0.00 | +-0.12 | +0.13 | +0.00 | +1.26 | +1.02 | +0.92 | +0.08 | +
| disease | +null | +W1 | +CCW, A vs B2 | +V1_ignore | +-0.01 | +0.00 | +0.00 | +-0.01 | +0.25 | +0.00 | +2.51 | +0.95 | +0.88 | +0.12 | +
| disease | +null | +W1 | +CCW, A vs B2 | +V2_cluster | +-0.01 | +0.00 | +0.00 | +-0.01 | +0.25 | +0.00 | +2.51 | +0.95 | +0.88 | +0.12 | +
| disease | +null | +W1 | +CCW, A vs B2 | +V3_random | +0.02 | +0.00 | +0.00 | +0.02 | +0.27 | +0.00 | +2.67 | +0.91 | +0.88 | +0.12 | +
| disease | +null | +W1 | +CCW, A vs B2 | +V4_within | +0.22 | +0.00 | +0.00 | +0.22 | +0.36 | +0.00 | +3.61 | +0.84 | +0.84 | +0.16 | +
| disease | +null | +W1 | +CCW, A vs B1 (reference) | +V1_ignore | +-0.01 | +0.00 | +0.00 | +-0.01 | +0.25 | +0.00 | +2.51 | +0.95 | +0.88 | +0.12 | +
| disease | +null | +W1 | +CCW, A vs B1 (reference) | +V2_cluster | +-0.01 | +0.00 | +0.00 | +-0.01 | +0.25 | +0.00 | +2.51 | +0.95 | +0.88 | +0.12 | +
| disease | +null | +W1 | +CCW, A vs B1 (reference) | +V3_random | +0.02 | +0.00 | +0.00 | +0.02 | +0.27 | +0.00 | +2.67 | +0.91 | +0.88 | +0.12 | +
| disease | +null | +W1 | +CCW, A vs B1 (reference) | +V4_within | +0.21 | +0.00 | +0.00 | +0.21 | +0.36 | +0.00 | +3.61 | +0.84 | +0.85 | +0.15 | +
| disease | +null | +W1_rho0 | +Naive ‘ever early PVI’ | +V1_ignore | +0.95 | +1.11 | +0.00 | +-0.16 | +0.06 | +1.11 | +1.19 | +1.01 | +0.91 | +0.12 | +
| disease | +null | +W1_rho0 | +Naive ‘ever early PVI’ | +V2_cluster | +0.95 | +1.11 | +0.00 | +-0.16 | +0.06 | +1.11 | +1.19 | +1.00 | +0.91 | +0.12 | +
| disease | +null | +W1_rho0 | +Naive ‘ever early PVI’ | +V3_random | +1.07 | +1.11 | +0.00 | +-0.04 | +0.06 | +1.11 | +1.28 | +0.97 | +0.92 | +0.14 | +
| disease | +null | +W1_rho0 | +Naive ‘ever early PVI’ | +V4_within | +0.46 | +1.11 | +0.00 | +-0.65 | +0.11 | +1.11 | +1.43 | +1.01 | +0.89 | +0.08 | +
| disease | +null | +W1_rho0 | +Landmark at 6 months | +V1_ignore | +-0.31 | +-0.46 | +0.00 | +0.15 | +0.05 | +-0.46 | +0.98 | +1.06 | +0.95 | +0.11 | +
| disease | +null | +W1_rho0 | +Landmark at 6 months | +V2_cluster | +-0.31 | +-0.46 | +0.00 | +0.15 | +0.05 | +-0.46 | +0.98 | +1.05 | +0.94 | +0.11 | +
| disease | +null | +W1_rho0 | +Landmark at 6 months | +V3_random | +-0.29 | +-0.46 | +0.00 | +0.18 | +0.05 | +-0.46 | +1.02 | +1.03 | +0.93 | +0.10 | +
| disease | +null | +W1_rho0 | +Landmark at 6 months | +V4_within | +-0.49 | +-0.46 | +0.00 | +-0.02 | +0.08 | +-0.46 | +1.27 | +1.00 | +0.90 | +0.13 | +
| disease | +null | +W1_rho0 | +Sequential trials, ITT | +V1_ignore | +-0.16 | +0.00 | +0.00 | +-0.16 | +0.10 | +0.00 | +1.03 | +0.98 | +0.91 | +0.09 | +
| disease | +null | +W1_rho0 | +Sequential trials, ITT | +V2_cluster | +-0.16 | +0.00 | +0.00 | +-0.16 | +0.10 | +0.00 | +1.03 | +0.98 | +0.91 | +0.09 | +
| disease | +null | +W1_rho0 | +Sequential trials, ITT | +V3_random | +-0.19 | +0.00 | +0.00 | +-0.19 | +0.11 | +0.00 | +1.06 | +0.97 | +0.91 | +0.09 | +
| disease | +null | +W1_rho0 | +Sequential trials, ITT | +V4_within | +-0.29 | +0.00 | +0.00 | +-0.29 | +0.12 | +0.00 | +1.23 | +0.99 | +0.90 | +0.10 | +
| disease | +null | +W1_rho0 | +CCW, A vs B2 | +V1_ignore | +-0.03 | +0.00 | +0.00 | +-0.03 | +0.25 | +0.00 | +2.48 | +0.91 | +0.90 | +0.10 | +
| disease | +null | +W1_rho0 | +CCW, A vs B2 | +V2_cluster | +-0.03 | +0.00 | +0.00 | +-0.03 | +0.25 | +0.00 | +2.48 | +0.91 | +0.88 | +0.12 | +
| disease | +null | +W1_rho0 | +CCW, A vs B2 | +V3_random | +-0.10 | +0.00 | +0.00 | +-0.10 | +0.24 | +0.00 | +2.45 | +0.92 | +0.90 | +0.10 | +
| disease | +null | +W1_rho0 | +CCW, A vs B2 | +V4_within | +-0.27 | +0.00 | +0.00 | +-0.27 | +0.26 | +0.00 | +2.61 | +0.98 | +0.88 | +0.12 | +
| disease | +null | +W1_rho0 | +CCW, A vs B1 (reference) | +V1_ignore | +-0.03 | +0.00 | +0.00 | +-0.03 | +0.25 | +0.00 | +2.48 | +0.91 | +0.90 | +0.10 | +
| disease | +null | +W1_rho0 | +CCW, A vs B1 (reference) | +V2_cluster | +-0.03 | +0.00 | +0.00 | +-0.03 | +0.25 | +0.00 | +2.48 | +0.91 | +0.88 | +0.12 | +
| disease | +null | +W1_rho0 | +CCW, A vs B1 (reference) | +V3_random | +-0.10 | +0.00 | +0.00 | +-0.10 | +0.24 | +0.00 | +2.45 | +0.92 | +0.90 | +0.10 | +
| disease | +null | +W1_rho0 | +CCW, A vs B1 (reference) | +V4_within | +-0.27 | +0.00 | +0.00 | +-0.27 | +0.26 | +0.00 | +2.61 | +0.97 | +0.88 | +0.12 | +
| disease | +null | +W2 | +Naive ‘ever early PVI’ | +V1_ignore | +1.70 | +12.65 | +0.00 | +-10.94 | +1.12 | +12.65 | +1.27 | +1.04 | +0.00 | +0.16 | +
| disease | +null | +W2 | +Naive ‘ever early PVI’ | +V2_cluster | +1.70 | +12.65 | +0.00 | +-10.94 | +1.12 | +12.65 | +1.27 | +1.04 | +0.00 | +0.14 | +
| disease | +null | +W2 | +Naive ‘ever early PVI’ | +V3_random | +3.27 | +12.65 | +0.00 | +-9.37 | +1.10 | +12.65 | +2.44 | +1.07 | +0.07 | +0.20 | +
| disease | +null | +W2 | +Naive ‘ever early PVI’ | +V4_within | +0.82 | +12.65 | +0.00 | +-11.83 | +1.19 | +12.65 | +2.96 | +0.89 | +0.02 | +0.06 | +
| disease | +null | +W2 | +Landmark at 6 months | +V1_ignore | +0.32 | +0.03 | +0.00 | +0.29 | +0.32 | +0.03 | +1.08 | +1.05 | +0.92 | +0.08 | +
| disease | +null | +W2 | +Landmark at 6 months | +V2_cluster | +0.32 | +0.03 | +0.00 | +0.29 | +0.32 | +0.03 | +1.08 | +1.05 | +0.93 | +0.07 | +
| disease | +null | +W2 | +Landmark at 6 months | +V3_random | +0.18 | +0.03 | +0.00 | +0.15 | +0.29 | +0.03 | +1.96 | +0.96 | +0.93 | +0.06 | +
| disease | +null | +W2 | +Landmark at 6 months | +V4_within | +-0.18 | +0.03 | +0.00 | +-0.21 | +0.33 | +0.03 | +2.86 | +0.84 | +0.91 | +0.09 | +
| disease | +null | +W2 | +Sequential trials, ITT | +V1_ignore | +0.44 | +0.00 | +0.00 | +0.44 | +0.11 | +0.00 | +1.06 | +1.03 | +0.92 | +0.08 | +
| disease | +null | +W2 | +Sequential trials, ITT | +V2_cluster | +0.44 | +0.00 | +0.00 | +0.44 | +0.11 | +0.00 | +1.06 | +1.03 | +0.93 | +0.07 | +
| disease | +null | +W2 | +Sequential trials, ITT | +V3_random | +0.14 | +0.00 | +0.00 | +0.14 | +0.16 | +0.00 | +1.56 | +0.94 | +0.92 | +0.08 | +
| disease | +null | +W2 | +Sequential trials, ITT | +V4_within | +-0.03 | +0.00 | +0.00 | +-0.03 | +0.19 | +0.00 | +1.88 | +0.84 | +0.93 | +0.07 | +
| disease | +null | +W2 | +CCW, A vs B2 | +V1_ignore | +0.83 | +0.00 | +0.00 | +0.83 | +0.28 | +0.00 | +2.85 | +0.97 | +0.95 | +0.05 | +
| disease | +null | +W2 | +CCW, A vs B2 | +V2_cluster | +0.83 | +0.00 | +0.00 | +0.83 | +0.28 | +0.00 | +2.85 | +0.96 | +0.95 | +0.05 | +
| disease | +null | +W2 | +CCW, A vs B2 | +V3_random | +0.96 | +0.00 | +0.00 | +0.96 | +0.55 | +0.00 | +5.45 | +0.70 | +0.92 | +0.08 | +
| disease | +null | +W2 | +CCW, A vs B2 | +V4_within | +0.78 | +0.00 | +0.00 | +0.78 | +0.66 | +0.00 | +6.64 | +0.60 | +0.90 | +0.10 | +
| disease | +null | +W2 | +CCW, A vs B1 (reference) | +V1_ignore | +0.84 | +0.00 | +0.00 | +0.84 | +0.28 | +0.00 | +2.84 | +0.97 | +0.95 | +0.05 | +
| disease | +null | +W2 | +CCW, A vs B1 (reference) | +V2_cluster | +0.84 | +0.00 | +0.00 | +0.84 | +0.28 | +0.00 | +2.84 | +0.96 | +0.95 | +0.05 | +
| disease | +null | +W2 | +CCW, A vs B1 (reference) | +V3_random | +0.96 | +0.00 | +0.00 | +0.96 | +0.54 | +0.00 | +5.45 | +0.70 | +0.92 | +0.08 | +
| disease | +null | +W2 | +CCW, A vs B1 (reference) | +V4_within | +0.79 | +0.00 | +0.00 | +0.79 | +0.66 | +0.00 | +6.63 | +0.60 | +0.89 | +0.11 | +
| disease | +null | +W3 | +Naive ‘ever early PVI’ | +V1_ignore | +2.63 | +10.69 | +0.00 | +-8.07 | +0.79 | +10.69 | +1.45 | +0.90 | +0.00 | +0.51 | +
| disease | +null | +W3 | +Naive ‘ever early PVI’ | +V2_cluster | +2.63 | +10.69 | +0.00 | +-8.07 | +0.79 | +10.69 | +1.45 | +0.89 | +0.00 | +0.55 | +
| disease | +null | +W3 | +Naive ‘ever early PVI’ | +V3_random | +3.19 | +10.69 | +0.00 | +-7.50 | +0.75 | +10.69 | +2.27 | +0.99 | +0.10 | +0.27 | +
| disease | +null | +W3 | +Naive ‘ever early PVI’ | +V4_within | +0.47 | +10.69 | +0.00 | +-10.22 | +0.81 | +10.69 | +2.16 | +0.95 | +0.03 | +0.08 | +
| disease | +null | +W3 | +Landmark at 6 months | +V1_ignore | +1.18 | +0.13 | +0.00 | +1.05 | +0.36 | +0.13 | +1.28 | +0.90 | +0.85 | +0.17 | +
| disease | +null | +W3 | +Landmark at 6 months | +V2_cluster | +1.18 | +0.13 | +0.00 | +1.05 | +0.36 | +0.13 | +1.28 | +0.89 | +0.85 | +0.19 | +
| disease | +null | +W3 | +Landmark at 6 months | +V3_random | +0.19 | +0.13 | +0.00 | +0.07 | +0.32 | +0.13 | +1.70 | +0.88 | +0.92 | +0.08 | +
| disease | +null | +W3 | +Landmark at 6 months | +V4_within | +-0.55 | +0.13 | +0.00 | +-0.68 | +0.33 | +0.13 | +2.00 | +0.88 | +0.84 | +0.15 | +
| disease | +null | +W3 | +Sequential trials, ITT | +V1_ignore | +1.34 | +0.00 | +0.00 | +1.34 | +0.13 | +0.00 | +1.25 | +0.90 | +0.74 | +0.26 | +
| disease | +null | +W3 | +Sequential trials, ITT | +V2_cluster | +1.34 | +0.00 | +0.00 | +1.34 | +0.13 | +0.00 | +1.25 | +0.89 | +0.75 | +0.25 | +
| disease | +null | +W3 | +Sequential trials, ITT | +V3_random | +0.27 | +0.00 | +0.00 | +0.27 | +0.17 | +0.00 | +1.68 | +0.84 | +0.87 | +0.13 | +
| disease | +null | +W3 | +Sequential trials, ITT | +V4_within | +-0.19 | +0.00 | +0.00 | +-0.19 | +0.19 | +0.00 | +1.90 | +0.82 | +0.84 | +0.16 | +
| disease | +null | +W3 | +CCW, A vs B2 | +V1_ignore | +0.88 | +0.00 | +0.00 | +0.88 | +0.28 | +0.00 | +2.77 | +0.94 | +0.93 | +0.07 | +
| disease | +null | +W3 | +CCW, A vs B2 | +V2_cluster | +0.88 | +0.00 | +0.00 | +0.88 | +0.28 | +0.00 | +2.77 | +0.95 | +0.93 | +0.07 | +
| disease | +null | +W3 | +CCW, A vs B2 | +V3_random | +0.21 | +0.00 | +0.00 | +0.21 | +0.34 | +0.00 | +3.40 | +0.91 | +0.85 | +0.15 | +
| disease | +null | +W3 | +CCW, A vs B2 | +V4_within | +-0.26 | +0.00 | +0.00 | +-0.26 | +0.37 | +0.00 | +3.68 | +0.94 | +0.81 | +0.19 | +
| disease | +null | +W3 | +CCW, A vs B1 (reference) | +V1_ignore | +0.86 | +0.00 | +0.00 | +0.86 | +0.28 | +0.00 | +2.77 | +0.94 | +0.93 | +0.07 | +
| disease | +null | +W3 | +CCW, A vs B1 (reference) | +V2_cluster | +0.86 | +0.00 | +0.00 | +0.86 | +0.28 | +0.00 | +2.77 | +0.95 | +0.93 | +0.07 | +
| disease | +null | +W3 | +CCW, A vs B1 (reference) | +V3_random | +0.20 | +0.00 | +0.00 | +0.20 | +0.34 | +0.00 | +3.40 | +0.91 | +0.85 | +0.15 | +
| disease | +null | +W3 | +CCW, A vs B1 (reference) | +V4_within | +-0.26 | +0.00 | +0.00 | +-0.26 | +0.37 | +0.00 | +3.67 | +0.94 | +0.81 | +0.19 | +
| disease | +null | +W4 | +Naive ‘ever early PVI’ | +V1_ignore | +1.09 | +1.48 | +0.00 | +-0.39 | +0.08 | +1.48 | +1.25 | +0.97 | +0.90 | +0.12 | +
| disease | +null | +W4 | +Naive ‘ever early PVI’ | +V2_cluster | +1.09 | +1.48 | +0.00 | +-0.39 | +0.08 | +1.48 | +1.25 | +0.97 | +0.90 | +0.12 | +
| disease | +null | +W4 | +Naive ‘ever early PVI’ | +V3_random | +1.19 | +1.48 | +0.00 | +-0.29 | +0.07 | +1.48 | +1.28 | +0.97 | +0.91 | +0.12 | +
| disease | +null | +W4 | +Naive ‘ever early PVI’ | +V4_within | +0.59 | +1.48 | +0.00 | +-0.89 | +0.12 | +1.48 | +1.49 | +0.98 | +0.85 | +0.03 | +
| disease | +null | +W4 | +Landmark at 6 months | +V1_ignore | +-0.02 | +-0.05 | +0.00 | +0.03 | +0.06 | +-0.05 | +1.10 | +0.99 | +0.96 | +0.05 | +
| disease | +null | +W4 | +Landmark at 6 months | +V2_cluster | +-0.02 | +-0.05 | +0.00 | +0.03 | +0.06 | +-0.05 | +1.10 | +0.99 | +0.96 | +0.04 | +
| disease | +null | +W4 | +Landmark at 6 months | +V3_random | +0.04 | +-0.05 | +0.00 | +0.09 | +0.05 | +-0.05 | +1.12 | +0.99 | +0.94 | +0.06 | +
| disease | +null | +W4 | +Landmark at 6 months | +V4_within | +-0.15 | +-0.05 | +0.00 | +-0.10 | +0.08 | +-0.05 | +1.35 | +1.01 | +0.92 | +0.08 | +
| disease | +null | +W4 | +Sequential trials, ITT | +V1_ignore | +0.06 | +0.00 | +0.00 | +0.06 | +0.10 | +0.00 | +1.04 | +1.00 | +0.96 | +0.04 | +
| disease | +null | +W4 | +Sequential trials, ITT | +V2_cluster | +0.06 | +0.00 | +0.00 | +0.06 | +0.10 | +0.00 | +1.04 | +1.00 | +0.96 | +0.04 | +
| disease | +null | +W4 | +Sequential trials, ITT | +V3_random | +0.07 | +0.00 | +0.00 | +0.07 | +0.11 | +0.00 | +1.06 | +1.00 | +0.97 | +0.03 | +
| disease | +null | +W4 | +Sequential trials, ITT | +V4_within | +-0.05 | +0.00 | +0.00 | +-0.05 | +0.12 | +0.00 | +1.23 | +1.03 | +0.94 | +0.06 | +
| disease | +null | +W4 | +CCW, A vs B2 | +V1_ignore | +0.22 | +0.00 | +0.00 | +0.22 | +0.21 | +0.00 | +2.10 | +1.09 | +0.94 | +0.06 | +
| disease | +null | +W4 | +CCW, A vs B2 | +V2_cluster | +0.22 | +0.00 | +0.00 | +0.22 | +0.21 | +0.00 | +2.10 | +1.10 | +0.94 | +0.06 | +
| disease | +null | +W4 | +CCW, A vs B2 | +V3_random | +0.30 | +0.00 | +0.00 | +0.30 | +0.22 | +0.00 | +2.15 | +1.10 | +0.95 | +0.05 | +
| disease | +null | +W4 | +CCW, A vs B2 | +V4_within | +0.24 | +0.00 | +0.00 | +0.24 | +0.25 | +0.00 | +2.52 | +1.12 | +0.92 | +0.08 | +
| disease | +null | +W4 | +CCW, A vs B1 (reference) | +V1_ignore | +0.25 | +0.00 | +0.00 | +0.25 | +0.21 | +0.00 | +2.11 | +1.09 | +0.95 | +0.05 | +
| disease | +null | +W4 | +CCW, A vs B1 (reference) | +V2_cluster | +0.25 | +0.00 | +0.00 | +0.25 | +0.21 | +0.00 | +2.11 | +1.09 | +0.94 | +0.06 | +
| disease | +null | +W4 | +CCW, A vs B1 (reference) | +V3_random | +0.28 | +0.00 | +0.00 | +0.28 | +0.22 | +0.00 | +2.16 | +1.09 | +0.95 | +0.05 | +
| disease | +null | +W4 | +CCW, A vs B1 (reference) | +V4_within | +0.23 | +0.00 | +0.00 | +0.23 | +0.25 | +0.00 | +2.52 | +1.12 | +0.92 | +0.08 | +
| disease | +null | +W5 | +Naive ‘ever early PVI’ | +V1_ignore | +5.06 | +1.33 | +0.00 | +3.73 | +0.13 | +1.33 | +0.98 | +1.03 | +0.00 | +1.00 | +
| disease | +null | +W5 | +Naive ‘ever early PVI’ | +V2_cluster | +5.06 | +1.33 | +0.00 | +3.73 | +0.13 | +1.33 | +0.98 | +1.03 | +0.01 | +1.00 | +
| disease | +null | +W5 | +Naive ‘ever early PVI’ | +V3_random | +5.13 | +1.33 | +0.00 | +3.80 | +0.13 | +1.33 | +0.99 | +1.05 | +0.00 | +1.00 | +
| disease | +null | +W5 | +Naive ‘ever early PVI’ | +V4_within | +4.76 | +1.33 | +0.00 | +3.43 | +0.14 | +1.33 | +1.15 | +1.08 | +0.15 | +0.98 | +
| disease | +null | +W5 | +Landmark at 6 months | +V1_ignore | +2.80 | +-0.34 | +0.00 | +3.14 | +0.08 | +-0.34 | +0.94 | +1.08 | +0.06 | +0.83 | +
| disease | +null | +W5 | +Landmark at 6 months | +V2_cluster | +2.80 | +-0.34 | +0.00 | +3.14 | +0.08 | +-0.34 | +0.94 | +1.07 | +0.07 | +0.82 | +
| disease | +null | +W5 | +Landmark at 6 months | +V3_random | +2.82 | +-0.34 | +0.00 | +3.16 | +0.08 | +-0.34 | +0.95 | +1.08 | +0.06 | +0.81 | +
| disease | +null | +W5 | +Landmark at 6 months | +V4_within | +2.77 | +-0.34 | +0.00 | +3.11 | +0.10 | +-0.34 | +1.15 | +1.10 | +0.25 | +0.62 | +
| disease | +null | +W5 | +Sequential trials, ITT | +V1_ignore | +3.43 | +0.00 | +0.00 | +3.43 | +0.09 | +0.00 | +0.92 | +1.07 | +0.05 | +0.95 | +
| disease | +null | +W5 | +Sequential trials, ITT | +V2_cluster | +3.43 | +0.00 | +0.00 | +3.43 | +0.09 | +0.00 | +0.92 | +1.07 | +0.04 | +0.96 | +
| disease | +null | +W5 | +Sequential trials, ITT | +V3_random | +3.43 | +0.00 | +0.00 | +3.43 | +0.09 | +0.00 | +0.92 | +1.09 | +0.05 | +0.95 | +
| disease | +null | +W5 | +Sequential trials, ITT | +V4_within | +3.40 | +0.00 | +0.00 | +3.40 | +0.11 | +0.00 | +1.08 | +1.12 | +0.10 | +0.90 | +
| disease | +null | +W5 | +CCW, A vs B2 | +V1_ignore | +2.89 | +0.00 | +0.00 | +2.89 | +0.22 | +0.00 | +2.20 | +0.99 | +0.77 | +0.23 | +
| disease | +null | +W5 | +CCW, A vs B2 | +V2_cluster | +2.89 | +0.00 | +0.00 | +2.89 | +0.22 | +0.00 | +2.20 | +0.99 | +0.76 | +0.24 | +
| disease | +null | +W5 | +CCW, A vs B2 | +V3_random | +2.91 | +0.00 | +0.00 | +2.91 | +0.22 | +0.00 | +2.25 | +0.98 | +0.78 | +0.22 | +
| disease | +null | +W5 | +CCW, A vs B2 | +V4_within | +2.95 | +0.00 | +0.00 | +2.95 | +0.27 | +0.00 | +2.67 | +1.00 | +0.85 | +0.15 | +
| disease | +null | +W5 | +CCW, A vs B1 (reference) | +V1_ignore | +2.89 | +0.00 | +0.00 | +2.89 | +0.22 | +0.00 | +2.20 | +0.99 | +0.77 | +0.23 | +
| disease | +null | +W5 | +CCW, A vs B1 (reference) | +V2_cluster | +2.89 | +0.00 | +0.00 | +2.89 | +0.22 | +0.00 | +2.20 | +0.99 | +0.76 | +0.24 | +
| disease | +null | +W5 | +CCW, A vs B1 (reference) | +V3_random | +2.91 | +0.00 | +0.00 | +2.91 | +0.22 | +0.00 | +2.25 | +0.98 | +0.78 | +0.22 | +
| disease | +null | +W5 | +CCW, A vs B1 (reference) | +V4_within | +2.95 | +0.00 | +0.00 | +2.95 | +0.27 | +0.00 | +2.67 | +1.00 | +0.84 | +0.16 | +
| disease | +null | +WR | +Naive ‘ever early PVI’ | +V1_ignore | +5.59 | +10.57 | +0.00 | +-4.98 | +0.82 | +10.57 | +1.21 | +0.95 | +0.03 | +1.00 | +
| disease | +null | +WR | +Naive ‘ever early PVI’ | +V2_cluster | +5.59 | +10.57 | +0.00 | +-4.98 | +0.82 | +10.57 | +1.21 | +0.95 | +0.03 | +1.00 | +
| disease | +null | +WR | +Naive ‘ever early PVI’ | +V3_random | +6.18 | +10.57 | +0.00 | +-4.39 | +0.80 | +10.57 | +1.60 | +0.99 | +0.20 | +0.99 | +
| disease | +null | +WR | +Naive ‘ever early PVI’ | +V4_within | +4.61 | +10.57 | +0.00 | +-5.96 | +0.84 | +10.57 | +1.71 | +0.98 | +0.07 | +0.83 | +
| disease | +null | +WR | +Landmark at 6 months | +V1_ignore | +3.44 | +0.03 | +0.00 | +3.40 | +0.40 | +0.03 | +1.11 | +1.02 | +0.08 | +0.92 | +
| disease | +null | +WR | +Landmark at 6 months | +V2_cluster | +3.44 | +0.03 | +0.00 | +3.40 | +0.40 | +0.03 | +1.11 | +1.01 | +0.07 | +0.93 | +
| disease | +null | +WR | +Landmark at 6 months | +V3_random | +2.98 | +0.03 | +0.00 | +2.95 | +0.37 | +0.03 | +1.52 | +0.95 | +0.43 | +0.57 | +
| disease | +null | +WR | +Landmark at 6 months | +V4_within | +2.56 | +0.03 | +0.00 | +2.53 | +0.38 | +0.03 | +1.79 | +0.95 | +0.69 | +0.31 | +
| disease | +null | +WR | +Sequential trials, ITT | +V1_ignore | +4.01 | +0.00 | +0.00 | +4.01 | +0.12 | +0.00 | +1.15 | +0.95 | +0.03 | +0.97 | +
| disease | +null | +WR | +Sequential trials, ITT | +V2_cluster | +4.01 | +0.00 | +0.00 | +4.01 | +0.12 | +0.00 | +1.15 | +0.95 | +0.03 | +0.97 | +
| disease | +null | +WR | +Sequential trials, ITT | +V3_random | +3.63 | +0.00 | +0.00 | +3.63 | +0.14 | +0.00 | +1.44 | +0.98 | +0.23 | +0.77 | +
| disease | +null | +WR | +Sequential trials, ITT | +V4_within | +3.30 | +0.00 | +0.00 | +3.30 | +0.16 | +0.00 | +1.61 | +0.98 | +0.40 | +0.60 | +
| disease | +null | +WR | +CCW, A vs B2 | +V1_ignore | +2.84 | +0.00 | +0.00 | +2.84 | +0.25 | +0.00 | +2.52 | +1.00 | +0.85 | +0.15 | +
| disease | +null | +WR | +CCW, A vs B2 | +V2_cluster | +2.84 | +0.00 | +0.00 | +2.84 | +0.25 | +0.00 | +2.52 | +1.00 | +0.85 | +0.15 | +
| disease | +null | +WR | +CCW, A vs B2 | +V3_random | +2.61 | +0.00 | +0.00 | +2.61 | +0.31 | +0.00 | +3.06 | +0.96 | +0.91 | +0.09 | +
| disease | +null | +WR | +CCW, A vs B2 | +V4_within | +2.31 | +0.00 | +0.00 | +2.31 | +0.32 | +0.00 | +3.20 | +0.99 | +0.91 | +0.09 | +
| disease | +null | +WR | +CCW, A vs B1 (reference) | +V1_ignore | +2.80 | +0.00 | +0.00 | +2.80 | +0.25 | +0.00 | +2.53 | +1.00 | +0.85 | +0.15 | +
| disease | +null | +WR | +CCW, A vs B1 (reference) | +V2_cluster | +2.80 | +0.00 | +0.00 | +2.80 | +0.25 | +0.00 | +2.53 | +1.00 | +0.85 | +0.15 | +
| disease | +null | +WR | +CCW, A vs B1 (reference) | +V3_random | +2.55 | +0.00 | +0.00 | +2.55 | +0.31 | +0.00 | +3.07 | +0.95 | +0.91 | +0.09 | +
| disease | +null | +WR | +CCW, A vs B1 (reference) | +V4_within | +2.21 | +0.00 | +0.00 | +2.21 | +0.32 | +0.00 | +3.22 | +0.98 | +0.91 | +0.09 | +
| male | +benefit_harm | +W0 | +Naive ‘ever early PVI’ | +V1_ignore | +20.48 | +20.59 | +17.36 | +-0.11 | +0.09 | +3.23 | +1.68 | +1.13 | +0.98 | +1.00 | +
| male | +benefit_harm | +W0 | +Naive ‘ever early PVI’ | +V2_cluster | +20.48 | +20.59 | +17.36 | +-0.11 | +0.09 | +3.23 | +1.68 | +1.13 | +0.97 | +1.00 | +
| male | +benefit_harm | +W0 | +Naive ‘ever early PVI’ | +V3_random | +20.54 | +20.59 | +17.36 | +-0.04 | +0.09 | +3.23 | +1.74 | +1.11 | +0.97 | +1.00 | +
| male | +benefit_harm | +W0 | +Naive ‘ever early PVI’ | +V4_within | +19.70 | +20.59 | +17.36 | +-0.89 | +0.17 | +3.23 | +2.39 | +1.00 | +0.90 | +1.00 | +
| male | +benefit_harm | +W0 | +Landmark at 6 months | +V1_ignore | +21.06 | +20.76 | +17.36 | +0.29 | +0.24 | +3.40 | +5.88 | +0.91 | +0.91 | +0.99 | +
| male | +benefit_harm | +W0 | +Landmark at 6 months | +V2_cluster | +21.06 | +20.76 | +17.36 | +0.29 | +0.24 | +3.40 | +5.88 | +0.90 | +0.92 | +0.99 | +
| male | +benefit_harm | +W0 | +Landmark at 6 months | +V3_random | +21.03 | +20.76 | +17.36 | +0.27 | +0.24 | +3.40 | +5.92 | +0.90 | +0.92 | +0.99 | +
| male | +benefit_harm | +W0 | +Landmark at 6 months | +V4_within | +20.97 | +20.76 | +17.36 | +0.21 | +0.60 | +3.40 | +8.37 | +0.84 | +0.90 | +0.90 | +
| male | +benefit_harm | +W0 | +Sequential trials, ITT | +V1_ignore | +19.52 | +19.27 | +17.36 | +0.26 | +0.17 | +1.91 | +1.66 | +1.09 | +0.98 | +1.00 | +
| male | +benefit_harm | +W0 | +Sequential trials, ITT | +V2_cluster | +19.52 | +19.27 | +17.36 | +0.26 | +0.17 | +1.91 | +1.66 | +1.08 | +0.98 | +1.00 | +
| male | +benefit_harm | +W0 | +Sequential trials, ITT | +V3_random | +19.44 | +19.27 | +17.36 | +0.17 | +0.17 | +1.91 | +1.73 | +1.06 | +0.97 | +1.00 | +
| male | +benefit_harm | +W0 | +Sequential trials, ITT | +V4_within | +18.97 | +19.27 | +17.36 | +-0.29 | +0.23 | +1.91 | +2.33 | +0.93 | +0.94 | +1.00 | +
| male | +benefit_harm | +W0 | +CCW, A vs B2 | +V1_ignore | +17.71 | +17.55 | +17.36 | +0.16 | +0.44 | +0.19 | +4.39 | +0.93 | +0.92 | +1.00 | +
| male | +benefit_harm | +W0 | +CCW, A vs B2 | +V2_cluster | +17.71 | +17.55 | +17.36 | +0.16 | +0.44 | +0.19 | +4.39 | +0.92 | +0.92 | +1.00 | +
| male | +benefit_harm | +W0 | +CCW, A vs B2 | +V3_random | +17.71 | +17.55 | +17.36 | +0.15 | +0.44 | +0.19 | +4.39 | +0.93 | +0.91 | +1.00 | +
| male | +benefit_harm | +W0 | +CCW, A vs B2 | +V4_within | +17.57 | +17.55 | +17.36 | +0.02 | +0.49 | +0.19 | +4.91 | +0.98 | +0.93 | +0.99 | +
| male | +benefit_harm | +W0 | +CCW, A vs B1 (reference) | +V1_ignore | +17.52 | +17.36 | +17.36 | +0.17 | +0.44 | +0.00 | +4.39 | +0.92 | +0.92 | +1.00 | +
| male | +benefit_harm | +W0 | +CCW, A vs B1 (reference) | +V2_cluster | +17.52 | +17.36 | +17.36 | +0.17 | +0.44 | +0.00 | +4.39 | +0.92 | +0.92 | +1.00 | +
| male | +benefit_harm | +W0 | +CCW, A vs B1 (reference) | +V3_random | +17.52 | +17.36 | +17.36 | +0.16 | +0.44 | +0.00 | +4.40 | +0.93 | +0.91 | +1.00 | +
| male | +benefit_harm | +W0 | +CCW, A vs B1 (reference) | +V4_within | +17.37 | +17.36 | +17.36 | +0.01 | +0.49 | +0.00 | +4.91 | +0.98 | +0.93 | +0.98 | +
| male | +benefit_harm | +W1 | +Naive ‘ever early PVI’ | +V1_ignore | +25.03 | +22.76 | +19.95 | +2.27 | +0.13 | +2.81 | +2.25 | +0.88 | +0.82 | +1.00 | +
| male | +benefit_harm | +W1 | +Naive ‘ever early PVI’ | +V2_cluster | +25.03 | +22.76 | +19.95 | +2.27 | +0.13 | +2.81 | +2.25 | +0.97 | +0.85 | +1.00 | +
| male | +benefit_harm | +W1 | +Naive ‘ever early PVI’ | +V3_random | +24.49 | +22.76 | +19.95 | +1.73 | +0.10 | +2.81 | +2.17 | +0.99 | +0.90 | +1.00 | +
| male | +benefit_harm | +W1 | +Naive ‘ever early PVI’ | +V4_within | +22.92 | +22.76 | +19.95 | +0.16 | +0.14 | +2.81 | +2.55 | +1.02 | +0.96 | +1.00 | +
| male | +benefit_harm | +W1 | +Landmark at 6 months | +V1_ignore | +25.57 | +21.61 | +19.95 | +3.96 | +0.28 | +1.67 | +6.35 | +0.88 | +0.85 | +0.98 | +
| male | +benefit_harm | +W1 | +Landmark at 6 months | +V2_cluster | +25.57 | +21.61 | +19.95 | +3.96 | +0.28 | +1.67 | +6.35 | +0.90 | +0.86 | +0.98 | +
| male | +benefit_harm | +W1 | +Landmark at 6 months | +V3_random | +25.36 | +21.61 | +19.95 | +3.74 | +0.26 | +1.67 | +6.30 | +0.90 | +0.86 | +0.98 | +
| male | +benefit_harm | +W1 | +Landmark at 6 months | +V4_within | +23.70 | +21.61 | +19.95 | +2.09 | +0.59 | +1.67 | +8.40 | +0.85 | +0.90 | +0.91 | +
| male | +benefit_harm | +W1 | +Sequential trials, ITT | +V1_ignore | +24.20 | +21.75 | +19.95 | +2.45 | +0.22 | +1.80 | +2.20 | +0.86 | +0.74 | +1.00 | +
| male | +benefit_harm | +W1 | +Sequential trials, ITT | +V2_cluster | +24.20 | +21.75 | +19.95 | +2.45 | +0.22 | +1.80 | +2.20 | +0.95 | +0.80 | +1.00 | +
| male | +benefit_harm | +W1 | +Sequential trials, ITT | +V3_random | +23.51 | +21.75 | +19.95 | +1.76 | +0.21 | +1.80 | +2.13 | +0.97 | +0.88 | +1.00 | +
| male | +benefit_harm | +W1 | +Sequential trials, ITT | +V4_within | +22.30 | +21.75 | +19.95 | +0.54 | +0.24 | +1.80 | +2.44 | +0.99 | +0.94 | +1.00 | +
| male | +benefit_harm | +W1 | +CCW, A vs B2 | +V1_ignore | +22.36 | +20.21 | +19.95 | +2.15 | +0.47 | +0.26 | +4.70 | +0.89 | +0.85 | +1.00 | +
| male | +benefit_harm | +W1 | +CCW, A vs B2 | +V2_cluster | +22.36 | +20.21 | +19.95 | +2.15 | +0.47 | +0.26 | +4.70 | +0.91 | +0.87 | +1.00 | +
| male | +benefit_harm | +W1 | +CCW, A vs B2 | +V3_random | +21.91 | +20.21 | +19.95 | +1.70 | +0.47 | +0.26 | +4.74 | +0.91 | +0.88 | +1.00 | +
| male | +benefit_harm | +W1 | +CCW, A vs B2 | +V4_within | +20.98 | +20.21 | +19.95 | +0.77 | +0.56 | +0.26 | +5.59 | +0.89 | +0.87 | +1.00 | +
| male | +benefit_harm | +W1 | +CCW, A vs B1 (reference) | +V1_ignore | +22.10 | +19.95 | +19.95 | +2.15 | +0.47 | +0.00 | +4.70 | +0.89 | +0.85 | +1.00 | +
| male | +benefit_harm | +W1 | +CCW, A vs B1 (reference) | +V2_cluster | +22.10 | +19.95 | +19.95 | +2.15 | +0.47 | +0.00 | +4.70 | +0.91 | +0.87 | +1.00 | +
| male | +benefit_harm | +W1 | +CCW, A vs B1 (reference) | +V3_random | +21.65 | +19.95 | +19.95 | +1.70 | +0.47 | +0.00 | +4.75 | +0.91 | +0.88 | +1.00 | +
| male | +benefit_harm | +W1 | +CCW, A vs B1 (reference) | +V4_within | +20.69 | +19.95 | +19.95 | +0.74 | +0.56 | +0.00 | +5.59 | +0.89 | +0.87 | +0.99 | +
| male | +benefit_harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V1_ignore | +23.81 | +24.02 | +20.65 | +-0.21 | +0.12 | +3.37 | +1.86 | +1.05 | +0.93 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V2_cluster | +23.81 | +24.02 | +20.65 | +-0.21 | +0.12 | +3.37 | +1.86 | +1.15 | +0.98 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V3_random | +23.95 | +24.02 | +20.65 | +-0.08 | +0.09 | +3.37 | +1.92 | +1.12 | +0.96 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V4_within | +23.34 | +24.02 | +20.65 | +-0.68 | +0.14 | +3.37 | +2.58 | +1.03 | +0.94 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +Landmark at 6 months | +V1_ignore | +25.30 | +23.91 | +20.65 | +1.40 | +0.29 | +3.25 | +6.00 | +0.92 | +0.93 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +Landmark at 6 months | +V2_cluster | +25.30 | +23.91 | +20.65 | +1.40 | +0.29 | +3.25 | +6.00 | +0.93 | +0.94 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +Landmark at 6 months | +V3_random | +25.19 | +23.91 | +20.65 | +1.28 | +0.28 | +3.25 | +6.00 | +0.93 | +0.92 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +Landmark at 6 months | +V4_within | +23.47 | +23.91 | +20.65 | +-0.44 | +0.64 | +3.25 | +8.29 | +0.91 | +0.91 | +0.89 | +
| male | +benefit_harm | +W1_rho0 | +Sequential trials, ITT | +V1_ignore | +22.93 | +22.55 | +20.65 | +0.39 | +0.18 | +1.89 | +1.84 | +1.02 | +0.96 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +Sequential trials, ITT | +V2_cluster | +22.93 | +22.55 | +20.65 | +0.39 | +0.18 | +1.89 | +1.84 | +1.12 | +0.98 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +Sequential trials, ITT | +V3_random | +22.93 | +22.55 | +20.65 | +0.39 | +0.19 | +1.89 | +1.90 | +1.09 | +0.98 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +Sequential trials, ITT | +V4_within | +22.61 | +22.55 | +20.65 | +0.06 | +0.25 | +1.89 | +2.47 | +0.98 | +0.94 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +CCW, A vs B2 | +V1_ignore | +21.33 | +20.89 | +20.65 | +0.44 | +0.43 | +0.24 | +4.28 | +0.98 | +0.98 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +CCW, A vs B2 | +V2_cluster | +21.33 | +20.89 | +20.65 | +0.44 | +0.43 | +0.24 | +4.28 | +1.00 | +0.98 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +CCW, A vs B2 | +V3_random | +21.44 | +20.89 | +20.65 | +0.54 | +0.45 | +0.24 | +4.46 | +0.98 | +0.94 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +CCW, A vs B2 | +V4_within | +21.43 | +20.89 | +20.65 | +0.54 | +0.54 | +0.24 | +5.43 | +0.96 | +0.94 | +0.99 | +
| male | +benefit_harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V1_ignore | +21.09 | +20.65 | +20.65 | +0.44 | +0.43 | +0.00 | +4.28 | +0.98 | +0.98 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V2_cluster | +21.09 | +20.65 | +20.65 | +0.44 | +0.43 | +0.00 | +4.28 | +1.00 | +0.98 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V3_random | +21.20 | +20.65 | +20.65 | +0.54 | +0.45 | +0.00 | +4.46 | +0.98 | +0.94 | +1.00 | +
| male | +benefit_harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V4_within | +21.17 | +20.65 | +20.65 | +0.52 | +0.54 | +0.00 | +5.43 | +0.96 | +0.94 | +0.99 | +
| male | +benefit_harm | +W2 | +Naive ‘ever early PVI’ | +V1_ignore | +21.59 | +27.04 | +17.96 | +-5.46 | +0.83 | +9.09 | +1.98 | +0.97 | +0.23 | +1.00 | +
| male | +benefit_harm | +W2 | +Naive ‘ever early PVI’ | +V2_cluster | +21.59 | +27.04 | +17.96 | +-5.46 | +0.83 | +9.09 | +1.98 | +0.97 | +0.22 | +1.00 | +
| male | +benefit_harm | +W2 | +Naive ‘ever early PVI’ | +V3_random | +22.12 | +27.04 | +17.96 | +-4.92 | +0.84 | +9.09 | +2.99 | +0.99 | +0.53 | +1.00 | +
| male | +benefit_harm | +W2 | +Naive ‘ever early PVI’ | +V4_within | +19.76 | +27.04 | +17.96 | +-7.28 | +0.89 | +9.09 | +3.56 | +0.99 | +0.42 | +1.00 | +
| male | +benefit_harm | +W2 | +Landmark at 6 months | +V1_ignore | +21.61 | +18.83 | +17.96 | +2.77 | +1.07 | +0.87 | +5.12 | +1.05 | +0.94 | +0.98 | +
| male | +benefit_harm | +W2 | +Landmark at 6 months | +V2_cluster | +21.61 | +18.83 | +17.96 | +2.77 | +1.07 | +0.87 | +5.12 | +1.04 | +0.92 | +0.99 | +
| male | +benefit_harm | +W2 | +Landmark at 6 months | +V3_random | +22.09 | +18.83 | +17.96 | +3.26 | +1.01 | +0.87 | +5.51 | +1.05 | +0.92 | +0.97 | +
| male | +benefit_harm | +W2 | +Landmark at 6 months | +V4_within | +21.17 | +18.83 | +17.96 | +2.34 | +1.15 | +0.87 | +8.19 | +0.92 | +0.92 | +0.89 | +
| male | +benefit_harm | +W2 | +Sequential trials, ITT | +V1_ignore | +20.53 | +19.92 | +17.96 | +0.62 | +0.19 | +1.96 | +1.93 | +0.95 | +0.94 | +1.00 | +
| male | +benefit_harm | +W2 | +Sequential trials, ITT | +V2_cluster | +20.53 | +19.92 | +17.96 | +0.62 | +0.19 | +1.96 | +1.93 | +0.94 | +0.94 | +1.00 | +
| male | +benefit_harm | +W2 | +Sequential trials, ITT | +V3_random | +19.88 | +19.92 | +17.96 | +-0.04 | +0.27 | +1.96 | +2.66 | +0.95 | +0.92 | +1.00 | +
| male | +benefit_harm | +W2 | +Sequential trials, ITT | +V4_within | +19.07 | +19.92 | +17.96 | +-0.84 | +0.30 | +1.96 | +2.97 | +0.94 | +0.91 | +1.00 | +
| male | +benefit_harm | +W2 | +CCW, A vs B2 | +V1_ignore | +18.59 | +18.22 | +17.96 | +0.36 | +0.41 | +0.27 | +4.11 | +1.03 | +0.96 | +1.00 | +
| male | +benefit_harm | +W2 | +CCW, A vs B2 | +V2_cluster | +18.59 | +18.22 | +17.96 | +0.36 | +0.41 | +0.27 | +4.11 | +1.01 | +0.96 | +1.00 | +
| male | +benefit_harm | +W2 | +CCW, A vs B2 | +V3_random | +18.73 | +18.22 | +17.96 | +0.50 | +0.59 | +0.27 | +5.91 | +0.95 | +0.90 | +0.96 | +
| male | +benefit_harm | +W2 | +CCW, A vs B2 | +V4_within | +18.88 | +18.22 | +17.96 | +0.65 | +0.75 | +0.27 | +7.46 | +0.86 | +0.90 | +0.91 | +
| male | +benefit_harm | +W2 | +CCW, A vs B1 (reference) | +V1_ignore | +18.37 | +17.96 | +17.96 | +0.41 | +0.41 | +0.00 | +4.11 | +1.03 | +0.97 | +1.00 | +
| male | +benefit_harm | +W2 | +CCW, A vs B1 (reference) | +V2_cluster | +18.37 | +17.96 | +17.96 | +0.41 | +0.41 | +0.00 | +4.11 | +1.02 | +0.96 | +1.00 | +
| male | +benefit_harm | +W2 | +CCW, A vs B1 (reference) | +V3_random | +18.47 | +17.96 | +17.96 | +0.52 | +0.59 | +0.00 | +5.90 | +0.95 | +0.90 | +0.96 | +
| male | +benefit_harm | +W2 | +CCW, A vs B1 (reference) | +V4_within | +18.41 | +17.96 | +17.96 | +0.45 | +0.75 | +0.00 | +7.46 | +0.86 | +0.91 | +0.89 | +
| male | +benefit_harm | +W3 | +Naive ‘ever early PVI’ | +V1_ignore | +23.34 | +21.85 | +11.26 | +1.48 | +0.86 | +10.59 | +2.35 | +0.83 | +0.80 | +1.00 | +
| male | +benefit_harm | +W3 | +Naive ‘ever early PVI’ | +V2_cluster | +23.34 | +21.85 | +11.26 | +1.48 | +0.86 | +10.59 | +2.35 | +0.90 | +0.83 | +1.00 | +
| male | +benefit_harm | +W3 | +Naive ‘ever early PVI’ | +V3_random | +18.80 | +21.85 | +11.26 | +-3.05 | +0.79 | +10.59 | +3.02 | +0.96 | +0.76 | +1.00 | +
| male | +benefit_harm | +W3 | +Naive ‘ever early PVI’ | +V4_within | +15.60 | +21.85 | +11.26 | +-6.25 | +0.84 | +10.59 | +3.44 | +0.96 | +0.44 | +0.99 | +
| male | +benefit_harm | +W3 | +Landmark at 6 months | +V1_ignore | +21.76 | +14.64 | +11.26 | +7.12 | +0.84 | +3.38 | +5.55 | +0.97 | +0.80 | +0.98 | +
| male | +benefit_harm | +W3 | +Landmark at 6 months | +V2_cluster | +21.76 | +14.64 | +11.26 | +7.12 | +0.84 | +3.38 | +5.55 | +0.97 | +0.78 | +0.98 | +
| male | +benefit_harm | +W3 | +Landmark at 6 months | +V3_random | +19.73 | +14.64 | +11.26 | +5.09 | +0.72 | +3.38 | +5.99 | +0.92 | +0.84 | +0.97 | +
| male | +benefit_harm | +W3 | +Landmark at 6 months | +V4_within | +17.68 | +14.64 | +11.26 | +3.03 | +0.84 | +3.38 | +9.04 | +0.76 | +0.85 | +0.74 | +
| male | +benefit_harm | +W3 | +Sequential trials, ITT | +V1_ignore | +22.17 | +12.63 | +11.26 | +9.54 | +0.22 | +1.37 | +2.21 | +0.84 | +0.00 | +1.00 | +
| male | +benefit_harm | +W3 | +Sequential trials, ITT | +V2_cluster | +22.17 | +12.63 | +11.26 | +9.54 | +0.22 | +1.37 | +2.21 | +0.92 | +0.00 | +1.00 | +
| male | +benefit_harm | +W3 | +Sequential trials, ITT | +V3_random | +16.25 | +12.63 | +11.26 | +3.62 | +0.25 | +1.37 | +2.49 | +0.96 | +0.68 | +1.00 | +
| male | +benefit_harm | +W3 | +Sequential trials, ITT | +V4_within | +14.82 | +12.63 | +11.26 | +2.19 | +0.28 | +1.37 | +2.78 | +0.94 | +0.88 | +1.00 | +
| male | +benefit_harm | +W3 | +CCW, A vs B2 | +V1_ignore | +18.63 | +11.57 | +11.26 | +7.07 | +0.45 | +0.30 | +4.45 | +0.96 | +0.65 | +1.00 | +
| male | +benefit_harm | +W3 | +CCW, A vs B2 | +V2_cluster | +18.63 | +11.57 | +11.26 | +7.07 | +0.45 | +0.30 | +4.45 | +0.96 | +0.64 | +1.00 | +
| male | +benefit_harm | +W3 | +CCW, A vs B2 | +V3_random | +14.81 | +11.57 | +11.26 | +3.24 | +0.58 | +0.30 | +5.79 | +0.92 | +0.86 | +0.84 | +
| male | +benefit_harm | +W3 | +CCW, A vs B2 | +V4_within | +14.02 | +11.57 | +11.26 | +2.46 | +0.67 | +0.30 | +6.67 | +0.87 | +0.87 | +0.70 | +
| male | +benefit_harm | +W3 | +CCW, A vs B1 (reference) | +V1_ignore | +18.40 | +11.26 | +11.26 | +7.14 | +0.45 | +0.00 | +4.45 | +0.96 | +0.64 | +1.00 | +
| male | +benefit_harm | +W3 | +CCW, A vs B1 (reference) | +V2_cluster | +18.40 | +11.26 | +11.26 | +7.14 | +0.45 | +0.00 | +4.45 | +0.96 | +0.64 | +1.00 | +
| male | +benefit_harm | +W3 | +CCW, A vs B1 (reference) | +V3_random | +14.52 | +11.26 | +11.26 | +3.26 | +0.58 | +0.00 | +5.80 | +0.92 | +0.86 | +0.81 | +
| male | +benefit_harm | +W3 | +CCW, A vs B1 (reference) | +V4_within | +13.48 | +11.26 | +11.26 | +2.22 | +0.67 | +0.00 | +6.68 | +0.87 | +0.88 | +0.66 | +
| male | +benefit_harm | +W4 | +Naive ‘ever early PVI’ | +V1_ignore | +19.23 | +19.51 | +16.42 | +-0.29 | +0.10 | +3.10 | +1.76 | +1.08 | +0.95 | +1.00 | +
| male | +benefit_harm | +W4 | +Naive ‘ever early PVI’ | +V2_cluster | +19.23 | +19.51 | +16.42 | +-0.29 | +0.10 | +3.10 | +1.76 | +1.08 | +0.94 | +1.00 | +
| male | +benefit_harm | +W4 | +Naive ‘ever early PVI’ | +V3_random | +19.37 | +19.51 | +16.42 | +-0.14 | +0.09 | +3.10 | +1.81 | +1.08 | +0.96 | +1.00 | +
| male | +benefit_harm | +W4 | +Naive ‘ever early PVI’ | +V4_within | +18.72 | +19.51 | +16.42 | +-0.80 | +0.15 | +3.10 | +2.25 | +1.08 | +0.95 | +1.00 | +
| male | +benefit_harm | +W4 | +Landmark at 6 months | +V1_ignore | +19.24 | +19.15 | +16.42 | +0.09 | +0.22 | +2.73 | +5.57 | +0.94 | +0.95 | +0.99 | +
| male | +benefit_harm | +W4 | +Landmark at 6 months | +V2_cluster | +19.24 | +19.15 | +16.42 | +0.09 | +0.22 | +2.73 | +5.57 | +0.94 | +0.94 | +0.99 | +
| male | +benefit_harm | +W4 | +Landmark at 6 months | +V3_random | +19.18 | +19.15 | +16.42 | +0.03 | +0.21 | +2.73 | +5.53 | +0.95 | +0.93 | +0.99 | +
| male | +benefit_harm | +W4 | +Landmark at 6 months | +V4_within | +17.59 | +19.15 | +16.42 | +-1.56 | +0.51 | +2.73 | +8.20 | +0.84 | +0.87 | +0.78 | +
| male | +benefit_harm | +W4 | +Sequential trials, ITT | +V1_ignore | +18.28 | +18.34 | +16.42 | +-0.06 | +0.17 | +1.92 | +1.73 | +1.05 | +0.95 | +1.00 | +
| male | +benefit_harm | +W4 | +Sequential trials, ITT | +V2_cluster | +18.28 | +18.34 | +16.42 | +-0.06 | +0.17 | +1.92 | +1.73 | +1.05 | +0.96 | +1.00 | +
| male | +benefit_harm | +W4 | +Sequential trials, ITT | +V3_random | +18.29 | +18.34 | +16.42 | +-0.05 | +0.18 | +1.92 | +1.78 | +1.05 | +0.97 | +1.00 | +
| male | +benefit_harm | +W4 | +Sequential trials, ITT | +V4_within | +18.04 | +18.34 | +16.42 | +-0.30 | +0.22 | +1.92 | +2.16 | +1.02 | +0.94 | +1.00 | +
| male | +benefit_harm | +W4 | +CCW, A vs B2 | +V1_ignore | +16.90 | +17.50 | +16.42 | +-0.60 | +0.39 | +1.08 | +3.88 | +1.03 | +0.92 | +1.00 | +
| male | +benefit_harm | +W4 | +CCW, A vs B2 | +V2_cluster | +16.90 | +17.50 | +16.42 | +-0.60 | +0.39 | +1.08 | +3.88 | +1.02 | +0.93 | +1.00 | +
| male | +benefit_harm | +W4 | +CCW, A vs B2 | +V3_random | +16.95 | +17.50 | +16.42 | +-0.55 | +0.39 | +1.08 | +3.91 | +1.03 | +0.93 | +1.00 | +
| male | +benefit_harm | +W4 | +CCW, A vs B2 | +V4_within | +16.52 | +17.50 | +16.42 | +-0.98 | +0.47 | +1.08 | +4.66 | +1.00 | +0.91 | +0.97 | +
| male | +benefit_harm | +W4 | +CCW, A vs B1 (reference) | +V1_ignore | +15.86 | +16.42 | +16.42 | +-0.55 | +0.39 | +0.00 | +3.86 | +1.03 | +0.93 | +1.00 | +
| male | +benefit_harm | +W4 | +CCW, A vs B1 (reference) | +V2_cluster | +15.86 | +16.42 | +16.42 | +-0.55 | +0.39 | +0.00 | +3.86 | +1.03 | +0.93 | +1.00 | +
| male | +benefit_harm | +W4 | +CCW, A vs B1 (reference) | +V3_random | +15.86 | +16.42 | +16.42 | +-0.56 | +0.39 | +0.00 | +3.90 | +1.04 | +0.93 | +1.00 | +
| male | +benefit_harm | +W4 | +CCW, A vs B1 (reference) | +V4_within | +15.35 | +16.42 | +16.42 | +-1.07 | +0.47 | +0.00 | +4.66 | +1.00 | +0.91 | +0.95 | +
| male | +benefit_harm | +W5 | +Naive ‘ever early PVI’ | +V1_ignore | +26.90 | +20.55 | +17.36 | +6.35 | +0.20 | +3.20 | +1.42 | +0.98 | +0.00 | +1.00 | +
| male | +benefit_harm | +W5 | +Naive ‘ever early PVI’ | +V2_cluster | +26.90 | +20.55 | +17.36 | +6.35 | +0.20 | +3.20 | +1.42 | +0.98 | +0.00 | +1.00 | +
| male | +benefit_harm | +W5 | +Naive ‘ever early PVI’ | +V3_random | +26.91 | +20.55 | +17.36 | +6.36 | +0.19 | +3.20 | +1.46 | +0.97 | +0.00 | +1.00 | +
| male | +benefit_harm | +W5 | +Naive ‘ever early PVI’ | +V4_within | +26.61 | +20.55 | +17.36 | +6.06 | +0.20 | +3.20 | +1.77 | +0.96 | +0.05 | +1.00 | +
| male | +benefit_harm | +W5 | +Landmark at 6 months | +V1_ignore | +27.21 | +21.13 | +17.36 | +6.08 | +0.58 | +3.77 | +1.41 | +1.01 | +0.00 | +1.00 | +
| male | +benefit_harm | +W5 | +Landmark at 6 months | +V2_cluster | +27.21 | +21.13 | +17.36 | +6.08 | +0.58 | +3.77 | +1.41 | +1.01 | +0.00 | +1.00 | +
| male | +benefit_harm | +W5 | +Landmark at 6 months | +V3_random | +27.17 | +21.13 | +17.36 | +6.04 | +0.58 | +3.77 | +1.44 | +1.01 | +0.00 | +1.00 | +
| male | +benefit_harm | +W5 | +Landmark at 6 months | +V4_within | +27.07 | +21.13 | +17.36 | +5.94 | +0.61 | +3.77 | +1.80 | +0.97 | +0.09 | +1.00 | +
| male | +benefit_harm | +W5 | +Sequential trials, ITT | +V1_ignore | +25.01 | +19.27 | +17.36 | +5.75 | +0.15 | +1.91 | +1.52 | +0.95 | +0.02 | +1.00 | +
| male | +benefit_harm | +W5 | +Sequential trials, ITT | +V2_cluster | +25.01 | +19.27 | +17.36 | +5.75 | +0.15 | +1.91 | +1.52 | +0.95 | +0.02 | +1.00 | +
| male | +benefit_harm | +W5 | +Sequential trials, ITT | +V3_random | +24.96 | +19.27 | +17.36 | +5.70 | +0.16 | +1.91 | +1.57 | +0.94 | +0.03 | +1.00 | +
| male | +benefit_harm | +W5 | +Sequential trials, ITT | +V4_within | +24.72 | +19.27 | +17.36 | +5.45 | +0.19 | +1.91 | +1.93 | +0.91 | +0.13 | +1.00 | +
| male | +benefit_harm | +W5 | +CCW, A vs B2 | +V1_ignore | +22.72 | +17.55 | +17.36 | +5.17 | +0.33 | +0.19 | +3.34 | +0.97 | +0.62 | +1.00 | +
| male | +benefit_harm | +W5 | +CCW, A vs B2 | +V2_cluster | +22.72 | +17.55 | +17.36 | +5.17 | +0.33 | +0.19 | +3.34 | +0.97 | +0.63 | +1.00 | +
| male | +benefit_harm | +W5 | +CCW, A vs B2 | +V3_random | +22.87 | +17.55 | +17.36 | +5.31 | +0.34 | +0.19 | +3.36 | +0.98 | +0.58 | +1.00 | +
| male | +benefit_harm | +W5 | +CCW, A vs B2 | +V4_within | +23.15 | +17.55 | +17.36 | +5.60 | +0.41 | +0.19 | +4.12 | +0.95 | +0.67 | +1.00 | +
| male | +benefit_harm | +W5 | +CCW, A vs B1 (reference) | +V1_ignore | +22.54 | +17.36 | +17.36 | +5.18 | +0.33 | +0.00 | +3.34 | +0.97 | +0.62 | +1.00 | +
| male | +benefit_harm | +W5 | +CCW, A vs B1 (reference) | +V2_cluster | +22.54 | +17.36 | +17.36 | +5.18 | +0.33 | +0.00 | +3.34 | +0.97 | +0.63 | +1.00 | +
| male | +benefit_harm | +W5 | +CCW, A vs B1 (reference) | +V3_random | +22.68 | +17.36 | +17.36 | +5.33 | +0.34 | +0.00 | +3.36 | +0.98 | +0.58 | +1.00 | +
| male | +benefit_harm | +W5 | +CCW, A vs B1 (reference) | +V4_within | +22.95 | +17.36 | +17.36 | +5.59 | +0.41 | +0.00 | +4.12 | +0.95 | +0.67 | +1.00 | +
| male | +benefit_harm | +WR | +Naive ‘ever early PVI’ | +V1_ignore | +34.09 | +25.32 | +13.73 | +8.78 | +1.05 | +11.59 | +2.19 | +0.73 | +0.00 | +1.00 | +
| male | +benefit_harm | +WR | +Naive ‘ever early PVI’ | +V2_cluster | +34.09 | +25.32 | +13.73 | +8.78 | +1.05 | +11.59 | +2.19 | +1.05 | +0.01 | +1.00 | +
| male | +benefit_harm | +WR | +Naive ‘ever early PVI’ | +V3_random | +28.65 | +25.32 | +13.73 | +3.33 | +1.00 | +11.59 | +2.05 | +1.09 | +0.73 | +1.00 | +
| male | +benefit_harm | +WR | +Naive ‘ever early PVI’ | +V4_within | +26.55 | +25.32 | +13.73 | +1.23 | +1.02 | +11.59 | +2.26 | +1.11 | +0.94 | +1.00 | +
| male | +benefit_harm | +WR | +Landmark at 6 months | +V1_ignore | +34.42 | +17.84 | +13.73 | +16.58 | +1.10 | +4.11 | +2.22 | +0.74 | +0.00 | +1.00 | +
| male | +benefit_harm | +WR | +Landmark at 6 months | +V2_cluster | +34.42 | +17.84 | +13.73 | +16.58 | +1.10 | +4.11 | +2.22 | +1.05 | +0.00 | +1.00 | +
| male | +benefit_harm | +WR | +Landmark at 6 months | +V3_random | +28.31 | +17.84 | +13.73 | +10.48 | +1.09 | +4.11 | +2.10 | +1.09 | +0.00 | +1.00 | +
| male | +benefit_harm | +WR | +Landmark at 6 months | +V4_within | +27.20 | +17.84 | +13.73 | +9.36 | +1.10 | +4.11 | +2.34 | +1.11 | +0.01 | +1.00 | +
| male | +benefit_harm | +WR | +Sequential trials, ITT | +V1_ignore | +32.48 | +15.12 | +13.73 | +17.36 | +0.23 | +1.39 | +2.34 | +0.70 | +0.00 | +1.00 | +
| male | +benefit_harm | +WR | +Sequential trials, ITT | +V2_cluster | +32.48 | +15.12 | +13.73 | +17.36 | +0.23 | +1.39 | +2.34 | +1.00 | +0.00 | +1.00 | +
| male | +benefit_harm | +WR | +Sequential trials, ITT | +V3_random | +26.01 | +15.12 | +13.73 | +10.89 | +0.22 | +1.39 | +2.24 | +1.01 | +0.00 | +1.00 | +
| male | +benefit_harm | +WR | +Sequential trials, ITT | +V4_within | +24.59 | +15.12 | +13.73 | +9.48 | +0.24 | +1.39 | +2.44 | +1.02 | +0.01 | +1.00 | +
| male | +benefit_harm | +WR | +CCW, A vs B2 | +V1_ignore | +28.91 | +14.11 | +13.73 | +14.79 | +0.45 | +0.38 | +4.55 | +0.85 | +0.05 | +1.00 | +
| male | +benefit_harm | +WR | +CCW, A vs B2 | +V2_cluster | +28.91 | +14.11 | +13.73 | +14.79 | +0.45 | +0.38 | +4.55 | +0.91 | +0.07 | +1.00 | +
| male | +benefit_harm | +WR | +CCW, A vs B2 | +V3_random | +24.27 | +14.11 | +13.73 | +10.15 | +0.48 | +0.38 | +4.79 | +0.98 | +0.43 | +1.00 | +
| male | +benefit_harm | +WR | +CCW, A vs B2 | +V4_within | +23.96 | +14.11 | +13.73 | +9.85 | +0.54 | +0.38 | +5.42 | +0.97 | +0.53 | +1.00 | +
| male | +benefit_harm | +WR | +CCW, A vs B1 (reference) | +V1_ignore | +28.60 | +13.73 | +13.73 | +14.87 | +0.45 | +0.00 | +4.53 | +0.85 | +0.04 | +1.00 | +
| male | +benefit_harm | +WR | +CCW, A vs B1 (reference) | +V2_cluster | +28.60 | +13.73 | +13.73 | +14.87 | +0.45 | +0.00 | +4.53 | +0.91 | +0.07 | +1.00 | +
| male | +benefit_harm | +WR | +CCW, A vs B1 (reference) | +V3_random | +23.87 | +13.73 | +13.73 | +10.14 | +0.48 | +0.00 | +4.77 | +0.98 | +0.42 | +1.00 | +
| male | +benefit_harm | +WR | +CCW, A vs B1 (reference) | +V4_within | +23.20 | +13.73 | +13.73 | +9.47 | +0.54 | +0.00 | +5.38 | +0.97 | +0.56 | +1.00 | +
| male | +harm | +W0 | +Naive ‘ever early PVI’ | +V1_ignore | +23.13 | +23.33 | +20.68 | +-0.20 | +0.09 | +2.66 | +1.97 | +0.99 | +0.95 | +1.00 | +
| male | +harm | +W0 | +Naive ‘ever early PVI’ | +V2_cluster | +23.13 | +23.33 | +20.68 | +-0.20 | +0.09 | +2.66 | +1.97 | +0.98 | +0.94 | +1.00 | +
| male | +harm | +W0 | +Naive ‘ever early PVI’ | +V3_random | +23.27 | +23.33 | +20.68 | +-0.07 | +0.08 | +2.66 | +2.04 | +0.97 | +0.94 | +1.00 | +
| male | +harm | +W0 | +Naive ‘ever early PVI’ | +V4_within | +22.58 | +23.33 | +20.68 | +-0.75 | +0.15 | +2.66 | +2.44 | +1.01 | +0.93 | +1.00 | +
| male | +harm | +W0 | +Landmark at 6 months | +V1_ignore | +24.73 | +24.67 | +20.68 | +0.06 | +0.21 | +4.00 | +4.71 | +0.98 | +0.97 | +1.00 | +
| male | +harm | +W0 | +Landmark at 6 months | +V2_cluster | +24.73 | +24.67 | +20.68 | +0.06 | +0.21 | +4.00 | +4.71 | +0.98 | +0.97 | +1.00 | +
| male | +harm | +W0 | +Landmark at 6 months | +V3_random | +24.67 | +24.67 | +20.68 | +0.00 | +0.19 | +4.00 | +4.84 | +0.96 | +0.96 | +1.00 | +
| male | +harm | +W0 | +Landmark at 6 months | +V4_within | +24.17 | +24.67 | +20.68 | +-0.50 | +0.38 | +4.00 | +6.49 | +0.89 | +0.92 | +0.96 | +
| male | +harm | +W0 | +Sequential trials, ITT | +V1_ignore | +22.15 | +22.23 | +20.68 | +-0.07 | +0.19 | +1.55 | +1.89 | +0.98 | +0.93 | +1.00 | +
| male | +harm | +W0 | +Sequential trials, ITT | +V2_cluster | +22.15 | +22.23 | +20.68 | +-0.07 | +0.19 | +1.55 | +1.89 | +0.98 | +0.94 | +1.00 | +
| male | +harm | +W0 | +Sequential trials, ITT | +V3_random | +22.16 | +22.23 | +20.68 | +-0.07 | +0.20 | +1.55 | +2.01 | +0.95 | +0.94 | +1.00 | +
| male | +harm | +W0 | +Sequential trials, ITT | +V4_within | +21.81 | +22.23 | +20.68 | +-0.41 | +0.24 | +1.55 | +2.40 | +0.95 | +0.93 | +1.00 | +
| male | +harm | +W0 | +CCW, A vs B2 | +V1_ignore | +21.22 | +20.98 | +20.68 | +0.24 | +0.43 | +0.30 | +4.35 | +0.97 | +0.95 | +1.00 | +
| male | +harm | +W0 | +CCW, A vs B2 | +V2_cluster | +21.22 | +20.98 | +20.68 | +0.24 | +0.43 | +0.30 | +4.35 | +0.97 | +0.92 | +1.00 | +
| male | +harm | +W0 | +CCW, A vs B2 | +V3_random | +21.23 | +20.98 | +20.68 | +0.25 | +0.45 | +0.30 | +4.54 | +0.95 | +0.96 | +1.00 | +
| male | +harm | +W0 | +CCW, A vs B2 | +V4_within | +21.40 | +20.98 | +20.68 | +0.42 | +0.55 | +0.30 | +5.51 | +0.94 | +0.91 | +1.00 | +
| male | +harm | +W0 | +CCW, A vs B1 (reference) | +V1_ignore | +20.93 | +20.68 | +20.68 | +0.25 | +0.44 | +0.00 | +4.35 | +0.97 | +0.94 | +1.00 | +
| male | +harm | +W0 | +CCW, A vs B1 (reference) | +V2_cluster | +20.93 | +20.68 | +20.68 | +0.25 | +0.44 | +0.00 | +4.35 | +0.97 | +0.92 | +1.00 | +
| male | +harm | +W0 | +CCW, A vs B1 (reference) | +V3_random | +20.94 | +20.68 | +20.68 | +0.26 | +0.45 | +0.00 | +4.54 | +0.95 | +0.96 | +1.00 | +
| male | +harm | +W0 | +CCW, A vs B1 (reference) | +V4_within | +21.08 | +20.68 | +20.68 | +0.41 | +0.55 | +0.00 | +5.52 | +0.94 | +0.91 | +1.00 | +
| male | +harm | +W1 | +Naive ‘ever early PVI’ | +V1_ignore | +25.95 | +24.73 | +21.55 | +1.22 | +0.12 | +3.18 | +1.80 | +1.12 | +0.95 | +1.00 | +
| male | +harm | +W1 | +Naive ‘ever early PVI’ | +V2_cluster | +25.95 | +24.73 | +21.55 | +1.22 | +0.12 | +3.18 | +1.80 | +1.17 | +0.95 | +1.00 | +
| male | +harm | +W1 | +Naive ‘ever early PVI’ | +V3_random | +25.62 | +24.73 | +21.55 | +0.89 | +0.10 | +3.18 | +1.87 | +1.13 | +0.97 | +1.00 | +
| male | +harm | +W1 | +Naive ‘ever early PVI’ | +V4_within | +24.39 | +24.73 | +21.55 | +-0.34 | +0.18 | +3.18 | +2.62 | +1.01 | +0.95 | +1.00 | +
| male | +harm | +W1 | +Landmark at 6 months | +V1_ignore | +41.61 | +37.41 | +21.55 | +4.19 | +0.35 | +15.87 | +10.29 | +0.61 | +0.88 | +0.99 | +
| male | +harm | +W1 | +Landmark at 6 months | +V2_cluster | +41.61 | +37.41 | +21.55 | +4.19 | +0.35 | +15.87 | +10.29 | +0.63 | +0.88 | +0.99 | +
| male | +harm | +W1 | +Landmark at 6 months | +V3_random | +40.37 | +37.41 | +21.55 | +2.96 | +0.29 | +15.87 | +10.37 | +0.61 | +0.86 | +0.99 | +
| male | +harm | +W1 | +Landmark at 6 months | +V4_within | +38.71 | +37.41 | +21.55 | +1.30 | +0.49 | +15.87 | +11.36 | +0.62 | +0.83 | +1.00 | +
| male | +harm | +W1 | +Sequential trials, ITT | +V1_ignore | +25.03 | +23.04 | +21.55 | +1.99 | +0.17 | +1.49 | +1.75 | +1.09 | +0.89 | +1.00 | +
| male | +harm | +W1 | +Sequential trials, ITT | +V2_cluster | +25.03 | +23.04 | +21.55 | +1.99 | +0.17 | +1.49 | +1.75 | +1.15 | +0.92 | +1.00 | +
| male | +harm | +W1 | +Sequential trials, ITT | +V3_random | +24.55 | +23.04 | +21.55 | +1.51 | +0.18 | +1.49 | +1.80 | +1.12 | +0.94 | +1.00 | +
| male | +harm | +W1 | +Sequential trials, ITT | +V4_within | +23.55 | +23.04 | +21.55 | +0.51 | +0.24 | +1.49 | +2.35 | +1.01 | +0.95 | +1.00 | +
| male | +harm | +W1 | +CCW, A vs B2 | +V1_ignore | +23.52 | +21.89 | +21.55 | +1.63 | +0.44 | +0.34 | +4.35 | +0.97 | +0.92 | +1.00 | +
| male | +harm | +W1 | +CCW, A vs B2 | +V2_cluster | +23.52 | +21.89 | +21.55 | +1.63 | +0.44 | +0.34 | +4.35 | +0.98 | +0.91 | +1.00 | +
| male | +harm | +W1 | +CCW, A vs B2 | +V3_random | +23.10 | +21.89 | +21.55 | +1.21 | +0.44 | +0.34 | +4.41 | +0.97 | +0.92 | +1.00 | +
| male | +harm | +W1 | +CCW, A vs B2 | +V4_within | +22.41 | +21.89 | +21.55 | +0.52 | +0.52 | +0.34 | +5.16 | +0.96 | +0.91 | +0.99 | +
| male | +harm | +W1 | +CCW, A vs B1 (reference) | +V1_ignore | +23.19 | +21.55 | +21.55 | +1.65 | +0.44 | +0.00 | +4.35 | +0.98 | +0.92 | +1.00 | +
| male | +harm | +W1 | +CCW, A vs B1 (reference) | +V2_cluster | +23.19 | +21.55 | +21.55 | +1.65 | +0.44 | +0.00 | +4.35 | +0.98 | +0.91 | +1.00 | +
| male | +harm | +W1 | +CCW, A vs B1 (reference) | +V3_random | +22.77 | +21.55 | +21.55 | +1.22 | +0.44 | +0.00 | +4.41 | +0.97 | +0.92 | +1.00 | +
| male | +harm | +W1 | +CCW, A vs B1 (reference) | +V4_within | +22.04 | +21.55 | +21.55 | +0.49 | +0.52 | +0.00 | +5.16 | +0.96 | +0.91 | +0.99 | +
| male | +harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V1_ignore | +24.83 | +25.06 | +22.33 | +-0.23 | +0.10 | +2.74 | +1.74 | +1.14 | +0.99 | +1.00 | +
| male | +harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V2_cluster | +24.83 | +25.06 | +22.33 | +-0.23 | +0.10 | +2.74 | +1.74 | +1.18 | +0.99 | +1.00 | +
| male | +harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V3_random | +24.96 | +25.06 | +22.33 | +-0.10 | +0.09 | +2.74 | +1.79 | +1.16 | +0.99 | +1.00 | +
| male | +harm | +W1_rho0 | +Naive ‘ever early PVI’ | +V4_within | +24.13 | +25.06 | +22.33 | +-0.94 | +0.17 | +2.74 | +2.30 | +1.12 | +0.97 | +1.00 | +
| male | +harm | +W1_rho0 | +Landmark at 6 months | +V1_ignore | +39.19 | +37.80 | +22.33 | +1.39 | +0.31 | +15.47 | +10.02 | +0.65 | +0.83 | +0.99 | +
| male | +harm | +W1_rho0 | +Landmark at 6 months | +V2_cluster | +39.19 | +37.80 | +22.33 | +1.39 | +0.31 | +15.47 | +10.02 | +0.67 | +0.84 | +0.99 | +
| male | +harm | +W1_rho0 | +Landmark at 6 months | +V3_random | +38.75 | +37.80 | +22.33 | +0.95 | +0.26 | +15.47 | +10.06 | +0.66 | +0.83 | +0.99 | +
| male | +harm | +W1_rho0 | +Landmark at 6 months | +V4_within | +38.02 | +37.80 | +22.33 | +0.22 | +0.54 | +15.47 | +11.71 | +0.65 | +0.80 | +1.00 | +
| male | +harm | +W1_rho0 | +Sequential trials, ITT | +V1_ignore | +23.90 | +23.92 | +22.33 | +-0.02 | +0.17 | +1.59 | +1.69 | +1.13 | +0.99 | +1.00 | +
| male | +harm | +W1_rho0 | +Sequential trials, ITT | +V2_cluster | +23.90 | +23.92 | +22.33 | +-0.02 | +0.17 | +1.59 | +1.69 | +1.18 | +0.99 | +1.00 | +
| male | +harm | +W1_rho0 | +Sequential trials, ITT | +V3_random | +23.88 | +23.92 | +22.33 | +-0.03 | +0.17 | +1.59 | +1.73 | +1.16 | +0.98 | +1.00 | +
| male | +harm | +W1_rho0 | +Sequential trials, ITT | +V4_within | +23.32 | +23.92 | +22.33 | +-0.59 | +0.22 | +1.59 | +2.16 | +1.10 | +0.99 | +1.00 | +
| male | +harm | +W1_rho0 | +CCW, A vs B2 | +V1_ignore | +22.90 | +22.65 | +22.33 | +0.25 | +0.45 | +0.32 | +4.46 | +0.95 | +0.92 | +1.00 | +
| male | +harm | +W1_rho0 | +CCW, A vs B2 | +V2_cluster | +22.90 | +22.65 | +22.33 | +0.25 | +0.45 | +0.32 | +4.46 | +0.96 | +0.93 | +1.00 | +
| male | +harm | +W1_rho0 | +CCW, A vs B2 | +V3_random | +22.91 | +22.65 | +22.33 | +0.26 | +0.45 | +0.32 | +4.54 | +0.96 | +0.92 | +1.00 | +
| male | +harm | +W1_rho0 | +CCW, A vs B2 | +V4_within | +22.24 | +22.65 | +22.33 | +-0.41 | +0.53 | +0.32 | +5.33 | +0.93 | +0.91 | +1.00 | +
| male | +harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V1_ignore | +22.58 | +22.33 | +22.33 | +0.25 | +0.45 | +0.00 | +4.46 | +0.95 | +0.92 | +1.00 | +
| male | +harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V2_cluster | +22.58 | +22.33 | +22.33 | +0.25 | +0.45 | +0.00 | +4.46 | +0.96 | +0.92 | +1.00 | +
| male | +harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V3_random | +22.59 | +22.33 | +22.33 | +0.26 | +0.45 | +0.00 | +4.54 | +0.96 | +0.92 | +1.00 | +
| male | +harm | +W1_rho0 | +CCW, A vs B1 (reference) | +V4_within | +21.89 | +22.33 | +22.33 | +-0.44 | +0.53 | +0.00 | +5.33 | +0.93 | +0.91 | +1.00 | +
| male | +harm | +W2 | +Naive ‘ever early PVI’ | +V1_ignore | +24.52 | +32.00 | +21.28 | +-7.47 | +0.84 | +10.71 | +2.14 | +0.92 | +0.07 | +1.00 | +
| male | +harm | +W2 | +Naive ‘ever early PVI’ | +V2_cluster | +24.52 | +32.00 | +21.28 | +-7.47 | +0.84 | +10.71 | +2.14 | +0.94 | +0.07 | +1.00 | +
| male | +harm | +W2 | +Naive ‘ever early PVI’ | +V3_random | +25.44 | +32.00 | +21.28 | +-6.56 | +0.79 | +10.71 | +2.89 | +1.06 | +0.32 | +1.00 | +
| male | +harm | +W2 | +Naive ‘ever early PVI’ | +V4_within | +22.93 | +32.00 | +21.28 | +-9.07 | +0.86 | +10.71 | +3.58 | +0.99 | +0.24 | +1.00 | +
| male | +harm | +W2 | +Landmark at 6 months | +V1_ignore | +25.59 | +26.09 | +21.28 | +-0.51 | +0.90 | +4.81 | +6.01 | +0.79 | +0.90 | +0.99 | +
| male | +harm | +W2 | +Landmark at 6 months | +V2_cluster | +25.59 | +26.09 | +21.28 | +-0.51 | +0.90 | +4.81 | +6.01 | +0.79 | +0.88 | +0.99 | +
| male | +harm | +W2 | +Landmark at 6 months | +V3_random | +25.11 | +26.09 | +21.28 | +-0.98 | +0.79 | +4.81 | +6.76 | +0.84 | +0.87 | +0.98 | +
| male | +harm | +W2 | +Landmark at 6 months | +V4_within | +23.80 | +26.09 | +21.28 | +-2.29 | +0.84 | +4.81 | +8.40 | +0.80 | +0.81 | +0.93 | +
| male | +harm | +W2 | +Sequential trials, ITT | +V1_ignore | +23.45 | +22.93 | +21.28 | +0.53 | +0.20 | +1.64 | +2.02 | +0.93 | +0.93 | +1.00 | +
| male | +harm | +W2 | +Sequential trials, ITT | +V2_cluster | +23.45 | +22.93 | +21.28 | +0.53 | +0.20 | +1.64 | +2.02 | +0.94 | +0.92 | +1.00 | +
| male | +harm | +W2 | +Sequential trials, ITT | +V3_random | +23.21 | +22.93 | +21.28 | +0.28 | +0.25 | +1.64 | +2.55 | +1.01 | +0.98 | +1.00 | +
| male | +harm | +W2 | +Sequential trials, ITT | +V4_within | +22.33 | +22.93 | +21.28 | +-0.59 | +0.29 | +1.64 | +2.89 | +0.99 | +0.94 | +1.00 | +
| male | +harm | +W2 | +CCW, A vs B2 | +V1_ignore | +21.92 | +21.68 | +21.28 | +0.24 | +0.48 | +0.39 | +4.84 | +0.91 | +0.92 | +1.00 | +
| male | +harm | +W2 | +CCW, A vs B2 | +V2_cluster | +21.92 | +21.68 | +21.28 | +0.24 | +0.48 | +0.39 | +4.84 | +0.89 | +0.90 | +1.00 | +
| male | +harm | +W2 | +CCW, A vs B2 | +V3_random | +22.13 | +21.68 | +21.28 | +0.46 | +0.66 | +0.39 | +6.65 | +0.86 | +0.88 | +0.97 | +
| male | +harm | +W2 | +CCW, A vs B2 | +V4_within | +21.69 | +21.68 | +21.28 | +0.02 | +0.75 | +0.39 | +7.53 | +0.83 | +0.92 | +0.91 | +
| male | +harm | +W2 | +CCW, A vs B1 (reference) | +V1_ignore | +21.60 | +21.28 | +21.28 | +0.32 | +0.48 | +0.00 | +4.84 | +0.91 | +0.91 | +1.00 | +
| male | +harm | +W2 | +CCW, A vs B1 (reference) | +V2_cluster | +21.60 | +21.28 | +21.28 | +0.32 | +0.48 | +0.00 | +4.84 | +0.89 | +0.92 | +1.00 | +
| male | +harm | +W2 | +CCW, A vs B1 (reference) | +V3_random | +21.76 | +21.28 | +21.28 | +0.48 | +0.67 | +0.00 | +6.65 | +0.86 | +0.87 | +0.97 | +
| male | +harm | +W2 | +CCW, A vs B1 (reference) | +V4_within | +21.04 | +21.28 | +21.28 | +-0.25 | +0.75 | +0.00 | +7.54 | +0.83 | +0.92 | +0.90 | +
| male | +harm | +W3 | +Naive ‘ever early PVI’ | +V1_ignore | +25.39 | +22.52 | +14.23 | +2.86 | +0.85 | +8.30 | +2.24 | +0.90 | +0.67 | +1.00 | +
| male | +harm | +W3 | +Naive ‘ever early PVI’ | +V2_cluster | +25.39 | +22.52 | +14.23 | +2.86 | +0.85 | +8.30 | +2.24 | +0.94 | +0.70 | +1.00 | +
| male | +harm | +W3 | +Naive ‘ever early PVI’ | +V3_random | +20.57 | +22.52 | +14.23 | +-1.96 | +0.77 | +8.30 | +2.93 | +0.99 | +0.87 | +1.00 | +
| male | +harm | +W3 | +Naive ‘ever early PVI’ | +V4_within | +17.19 | +22.52 | +14.23 | +-5.34 | +0.84 | +8.30 | +3.22 | +0.99 | +0.58 | +1.00 | +
| male | +harm | +W3 | +Landmark at 6 months | +V1_ignore | +26.39 | +16.51 | +14.23 | +9.88 | +0.72 | +2.28 | +4.38 | +1.06 | +0.40 | +1.00 | +
| male | +harm | +W3 | +Landmark at 6 months | +V2_cluster | +26.39 | +16.51 | +14.23 | +9.88 | +0.72 | +2.28 | +4.38 | +1.06 | +0.38 | +1.00 | +
| male | +harm | +W3 | +Landmark at 6 months | +V3_random | +20.39 | +16.51 | +14.23 | +3.88 | +0.59 | +2.28 | +5.75 | +0.88 | +0.83 | +0.98 | +
| male | +harm | +W3 | +Landmark at 6 months | +V4_within | +18.26 | +16.51 | +14.23 | +1.75 | +0.64 | +2.28 | +6.87 | +0.85 | +0.90 | +0.88 | +
| male | +harm | +W3 | +Sequential trials, ITT | +V1_ignore | +24.40 | +15.28 | +14.23 | +9.12 | +0.22 | +1.05 | +2.19 | +0.88 | +0.00 | +1.00 | +
| male | +harm | +W3 | +Sequential trials, ITT | +V2_cluster | +24.40 | +15.28 | +14.23 | +9.12 | +0.22 | +1.05 | +2.19 | +0.93 | +0.01 | +1.00 | +
| male | +harm | +W3 | +Sequential trials, ITT | +V3_random | +18.25 | +15.28 | +14.23 | +2.97 | +0.26 | +1.05 | +2.56 | +0.94 | +0.72 | +1.00 | +
| male | +harm | +W3 | +Sequential trials, ITT | +V4_within | +16.65 | +15.28 | +14.23 | +1.37 | +0.29 | +1.05 | +2.92 | +0.90 | +0.91 | +1.00 | +
| male | +harm | +W3 | +CCW, A vs B2 | +V1_ignore | +22.67 | +14.65 | +14.23 | +8.02 | +0.45 | +0.43 | +4.54 | +0.99 | +0.57 | +1.00 | +
| male | +harm | +W3 | +CCW, A vs B2 | +V2_cluster | +22.67 | +14.65 | +14.23 | +8.02 | +0.45 | +0.43 | +4.54 | +1.00 | +0.59 | +1.00 | +
| male | +harm | +W3 | +CCW, A vs B2 | +V3_random | +17.12 | +14.65 | +14.23 | +2.47 | +0.53 | +0.43 | +5.26 | +1.00 | +0.92 | +0.93 | +
| male | +harm | +W3 | +CCW, A vs B2 | +V4_within | +16.27 | +14.65 | +14.23 | +1.62 | +0.60 | +0.43 | +5.98 | +0.96 | +0.92 | +0.86 | +
| male | +harm | +W3 | +CCW, A vs B1 (reference) | +V1_ignore | +22.34 | +14.23 | +14.23 | +8.12 | +0.45 | +0.00 | +4.53 | +0.99 | +0.57 | +1.00 | +
| male | +harm | +W3 | +CCW, A vs B1 (reference) | +V2_cluster | +22.34 | +14.23 | +14.23 | +8.12 | +0.45 | +0.00 | +4.53 | +1.00 | +0.59 | +1.00 | +
| male | +harm | +W3 | +CCW, A vs B1 (reference) | +V3_random | +16.72 | +14.23 | +14.23 | +2.50 | +0.53 | +0.00 | +5.27 | +1.00 | +0.92 | +0.93 | +
| male | +harm | +W3 | +CCW, A vs B1 (reference) | +V4_within | +15.51 | +14.23 | +14.23 | +1.29 | +0.60 | +0.00 | +6.00 | +0.96 | +0.90 | +0.83 | +
| male | +harm | +W4 | +Naive ‘ever early PVI’ | +V1_ignore | +21.37 | +21.46 | +18.95 | +-0.09 | +0.09 | +2.51 | +1.92 | +1.01 | +0.94 | +1.00 | +
| male | +harm | +W4 | +Naive ‘ever early PVI’ | +V2_cluster | +21.37 | +21.46 | +18.95 | +-0.09 | +0.09 | +2.51 | +1.92 | +1.00 | +0.93 | +1.00 | +
| male | +harm | +W4 | +Naive ‘ever early PVI’ | +V3_random | +21.46 | +21.46 | +18.95 | +-0.00 | +0.08 | +2.51 | +2.05 | +0.97 | +0.92 | +1.00 | +
| male | +harm | +W4 | +Naive ‘ever early PVI’ | +V4_within | +20.37 | +21.46 | +18.95 | +-1.09 | +0.16 | +2.51 | +2.73 | +0.91 | +0.92 | +1.00 | +
| male | +harm | +W4 | +Landmark at 6 months | +V1_ignore | +22.73 | +22.70 | +18.95 | +0.03 | +0.26 | +3.75 | +4.69 | +1.01 | +0.92 | +0.98 | +
| male | +harm | +W4 | +Landmark at 6 months | +V2_cluster | +22.73 | +22.70 | +18.95 | +0.03 | +0.26 | +3.75 | +4.69 | +1.01 | +0.92 | +0.98 | +
| male | +harm | +W4 | +Landmark at 6 months | +V3_random | +22.83 | +22.70 | +18.95 | +0.13 | +0.22 | +3.75 | +4.92 | +0.98 | +0.92 | +0.99 | +
| male | +harm | +W4 | +Landmark at 6 months | +V4_within | +22.49 | +22.70 | +18.95 | +-0.22 | +0.41 | +3.75 | +6.65 | +0.93 | +0.91 | +0.98 | +
| male | +harm | +W4 | +Sequential trials, ITT | +V1_ignore | +20.43 | +20.53 | +18.95 | +-0.10 | +0.19 | +1.58 | +1.87 | +0.99 | +0.96 | +1.00 | +
| male | +harm | +W4 | +Sequential trials, ITT | +V2_cluster | +20.43 | +20.53 | +18.95 | +-0.10 | +0.19 | +1.58 | +1.87 | +0.98 | +0.96 | +1.00 | +
| male | +harm | +W4 | +Sequential trials, ITT | +V3_random | +20.36 | +20.53 | +18.95 | +-0.17 | +0.20 | +1.58 | +2.00 | +0.94 | +0.96 | +1.00 | +
| male | +harm | +W4 | +Sequential trials, ITT | +V4_within | +19.72 | +20.53 | +18.95 | +-0.82 | +0.26 | +1.58 | +2.60 | +0.86 | +0.89 | +1.00 | +
| male | +harm | +W4 | +CCW, A vs B2 | +V1_ignore | +20.89 | +20.93 | +18.95 | +-0.05 | +0.42 | +1.98 | +4.25 | +1.01 | +0.93 | +1.00 | +
| male | +harm | +W4 | +CCW, A vs B2 | +V2_cluster | +20.89 | +20.93 | +18.95 | +-0.05 | +0.42 | +1.98 | +4.25 | +1.00 | +0.93 | +1.00 | +
| male | +harm | +W4 | +CCW, A vs B2 | +V3_random | +20.96 | +20.93 | +18.95 | +0.03 | +0.42 | +1.98 | +4.25 | +1.02 | +0.94 | +1.00 | +
| male | +harm | +W4 | +CCW, A vs B2 | +V4_within | +20.84 | +20.93 | +18.95 | +-0.09 | +0.50 | +1.98 | +4.99 | +1.00 | +0.95 | +1.00 | +
| male | +harm | +W4 | +CCW, A vs B1 (reference) | +V1_ignore | +19.00 | +18.95 | +18.95 | +0.05 | +0.43 | +0.00 | +4.27 | +1.00 | +0.94 | +0.99 | +
| male | +harm | +W4 | +CCW, A vs B1 (reference) | +V2_cluster | +19.00 | +18.95 | +18.95 | +0.05 | +0.43 | +0.00 | +4.27 | +1.00 | +0.93 | +0.99 | +
| male | +harm | +W4 | +CCW, A vs B1 (reference) | +V3_random | +18.99 | +18.95 | +18.95 | +0.04 | +0.43 | +0.00 | +4.26 | +1.02 | +0.94 | +1.00 | +
| male | +harm | +W4 | +CCW, A vs B1 (reference) | +V4_within | +18.71 | +18.95 | +18.95 | +-0.24 | +0.50 | +0.00 | +4.99 | +1.00 | +0.94 | +0.99 | +
| male | +harm | +W5 | +Naive ‘ever early PVI’ | +V1_ignore | +30.43 | +23.61 | +20.68 | +6.83 | +0.16 | +2.93 | +1.40 | +1.01 | +0.00 | +1.00 | +
| male | +harm | +W5 | +Naive ‘ever early PVI’ | +V2_cluster | +30.43 | +23.61 | +20.68 | +6.83 | +0.16 | +2.93 | +1.40 | +1.01 | +0.00 | +1.00 | +
| male | +harm | +W5 | +Naive ‘ever early PVI’ | +V3_random | +30.52 | +23.61 | +20.68 | +6.92 | +0.15 | +2.93 | +1.39 | +1.04 | +0.00 | +1.00 | +
| male | +harm | +W5 | +Naive ‘ever early PVI’ | +V4_within | +30.35 | +23.61 | +20.68 | +6.74 | +0.16 | +2.93 | +1.57 | +1.10 | +0.02 | +1.00 | +
| male | +harm | +W5 | +Landmark at 6 months | +V1_ignore | +28.38 | +24.51 | +20.68 | +3.88 | +0.46 | +3.83 | +1.52 | +1.00 | +0.25 | +1.00 | +
| male | +harm | +W5 | +Landmark at 6 months | +V2_cluster | +28.38 | +24.51 | +20.68 | +3.88 | +0.46 | +3.83 | +1.52 | +1.00 | +0.27 | +1.00 | +
| male | +harm | +W5 | +Landmark at 6 months | +V3_random | +28.44 | +24.51 | +20.68 | +3.93 | +0.46 | +3.83 | +1.51 | +1.03 | +0.23 | +1.00 | +
| male | +harm | +W5 | +Landmark at 6 months | +V4_within | +28.38 | +24.51 | +20.68 | +3.87 | +0.46 | +3.83 | +1.74 | +1.07 | +0.46 | +1.00 | +
| male | +harm | +W5 | +Sequential trials, ITT | +V1_ignore | +28.40 | +22.23 | +20.68 | +6.18 | +0.15 | +1.55 | +1.49 | +1.00 | +0.00 | +1.00 | +
| male | +harm | +W5 | +Sequential trials, ITT | +V2_cluster | +28.40 | +22.23 | +20.68 | +6.18 | +0.15 | +1.55 | +1.49 | +1.00 | +0.00 | +1.00 | +
| male | +harm | +W5 | +Sequential trials, ITT | +V3_random | +28.42 | +22.23 | +20.68 | +6.19 | +0.15 | +1.55 | +1.49 | +1.02 | +0.00 | +1.00 | +
| male | +harm | +W5 | +Sequential trials, ITT | +V4_within | +28.30 | +22.23 | +20.68 | +6.07 | +0.17 | +1.55 | +1.70 | +1.05 | +0.09 | +1.00 | +
| male | +harm | +W5 | +CCW, A vs B2 | +V1_ignore | +27.11 | +20.98 | +20.68 | +6.14 | +0.30 | +0.30 | +3.00 | +1.12 | +0.55 | +1.00 | +
| male | +harm | +W5 | +CCW, A vs B2 | +V2_cluster | +27.11 | +20.98 | +20.68 | +6.14 | +0.30 | +0.30 | +3.00 | +1.13 | +0.55 | +1.00 | +
| male | +harm | +W5 | +CCW, A vs B2 | +V3_random | +27.26 | +20.98 | +20.68 | +6.28 | +0.30 | +0.30 | +3.00 | +1.14 | +0.56 | +1.00 | +
| male | +harm | +W5 | +CCW, A vs B2 | +V4_within | +27.54 | +20.98 | +20.68 | +6.57 | +0.38 | +0.30 | +3.82 | +1.05 | +0.58 | +1.00 | +
| male | +harm | +W5 | +CCW, A vs B1 (reference) | +V1_ignore | +26.83 | +20.68 | +20.68 | +6.15 | +0.30 | +0.00 | +3.00 | +1.12 | +0.56 | +1.00 | +
| male | +harm | +W5 | +CCW, A vs B1 (reference) | +V2_cluster | +26.83 | +20.68 | +20.68 | +6.15 | +0.30 | +0.00 | +3.00 | +1.13 | +0.54 | +1.00 | +
| male | +harm | +W5 | +CCW, A vs B1 (reference) | +V3_random | +26.98 | +20.68 | +20.68 | +6.30 | +0.30 | +0.00 | +3.01 | +1.14 | +0.56 | +1.00 | +
| male | +harm | +W5 | +CCW, A vs B1 (reference) | +V4_within | +27.23 | +20.68 | +20.68 | +6.56 | +0.38 | +0.00 | +3.82 | +1.05 | +0.58 | +1.00 | +
| male | +harm | +WR | +Naive ‘ever early PVI’ | +V1_ignore | +33.93 | +23.60 | +14.48 | +10.32 | +0.89 | +9.12 | +2.19 | +0.73 | +0.00 | +1.00 | +
| male | +harm | +WR | +Naive ‘ever early PVI’ | +V2_cluster | +33.93 | +23.60 | +14.48 | +10.32 | +0.89 | +9.12 | +2.19 | +0.98 | +0.00 | +1.00 | +
| male | +harm | +WR | +Naive ‘ever early PVI’ | +V3_random | +28.96 | +23.60 | +14.48 | +5.35 | +0.87 | +9.12 | +2.34 | +0.93 | +0.34 | +1.00 | +
| male | +harm | +WR | +Naive ‘ever early PVI’ | +V4_within | +26.99 | +23.60 | +14.48 | +3.39 | +0.89 | +9.12 | +2.54 | +0.96 | +0.72 | +1.00 | +
| male | +harm | +WR | +Landmark at 6 months | +V1_ignore | +32.12 | +25.25 | +14.48 | +6.87 | +1.13 | +10.76 | +2.34 | +0.73 | +0.07 | +1.00 | +
| male | +harm | +WR | +Landmark at 6 months | +V2_cluster | +32.12 | +25.25 | +14.48 | +6.87 | +1.13 | +10.76 | +2.34 | +0.96 | +0.11 | +1.00 | +
| male | +harm | +WR | +Landmark at 6 months | +V3_random | +26.34 | +25.25 | +14.48 | +1.09 | +1.15 | +10.76 | +2.35 | +0.97 | +0.93 | +1.00 | +
| male | +harm | +WR | +Landmark at 6 months | +V4_within | +24.97 | +25.25 | +14.48 | +-0.28 | +1.17 | +10.76 | +2.65 | +0.99 | +0.96 | +1.00 | +
| male | +harm | +WR | +Sequential trials, ITT | +V1_ignore | +32.28 | +15.51 | +14.48 | +16.77 | +0.22 | +1.03 | +2.23 | +0.74 | +0.00 | +1.00 | +
| male | +harm | +WR | +Sequential trials, ITT | +V2_cluster | +32.28 | +15.51 | +14.48 | +16.77 | +0.22 | +1.03 | +2.23 | +0.99 | +0.00 | +1.00 | +
| male | +harm | +WR | +Sequential trials, ITT | +V3_random | +26.26 | +15.51 | +14.48 | +10.75 | +0.23 | +1.03 | +2.31 | +0.95 | +0.00 | +1.00 | +
| male | +harm | +WR | +Sequential trials, ITT | +V4_within | +24.74 | +15.51 | +14.48 | +9.23 | +0.25 | +1.03 | +2.54 | +0.95 | +0.03 | +1.00 | +
| male | +harm | +WR | +CCW, A vs B2 | +V1_ignore | +29.38 | +14.99 | +14.48 | +14.40 | +0.47 | +0.50 | +4.66 | +0.84 | +0.07 | +1.00 | +
| male | +harm | +WR | +CCW, A vs B2 | +V2_cluster | +29.38 | +14.99 | +14.48 | +14.40 | +0.47 | +0.50 | +4.66 | +0.88 | +0.08 | +1.00 | +
| male | +harm | +WR | +CCW, A vs B2 | +V3_random | +24.96 | +14.99 | +14.48 | +9.98 | +0.53 | +0.50 | +5.34 | +0.88 | +0.49 | +1.00 | +
| male | +harm | +WR | +CCW, A vs B2 | +V4_within | +24.54 | +14.99 | +14.48 | +9.55 | +0.58 | +0.50 | +5.82 | +0.90 | +0.59 | +1.00 | +
| male | +harm | +WR | +CCW, A vs B1 (reference) | +V1_ignore | +28.98 | +14.48 | +14.48 | +14.49 | +0.46 | +0.00 | +4.64 | +0.84 | +0.07 | +1.00 | +
| male | +harm | +WR | +CCW, A vs B1 (reference) | +V2_cluster | +28.98 | +14.48 | +14.48 | +14.49 | +0.46 | +0.00 | +4.64 | +0.88 | +0.08 | +1.00 | +
| male | +harm | +WR | +CCW, A vs B1 (reference) | +V3_random | +24.46 | +14.48 | +14.48 | +9.98 | +0.53 | +0.00 | +5.35 | +0.88 | +0.48 | +1.00 | +
| male | +harm | +WR | +CCW, A vs B1 (reference) | +V4_within | +23.60 | +14.48 | +14.48 | +9.12 | +0.58 | +0.00 | +5.84 | +0.90 | +0.60 | +1.00 | +
| male | +null | +W0 | +Naive ‘ever early PVI’ | +V1_ignore | +16.02 | +16.18 | +14.23 | +-0.16 | +0.09 | +1.95 | +1.70 | +1.06 | +0.93 | +1.00 | +
| male | +null | +W0 | +Naive ‘ever early PVI’ | +V2_cluster | +16.02 | +16.18 | +14.23 | +-0.16 | +0.09 | +1.95 | +1.70 | +1.05 | +0.93 | +1.00 | +
| male | +null | +W0 | +Naive ‘ever early PVI’ | +V3_random | +16.13 | +16.18 | +14.23 | +-0.05 | +0.08 | +1.95 | +1.73 | +1.06 | +0.96 | +1.00 | +
| male | +null | +W0 | +Naive ‘ever early PVI’ | +V4_within | +15.50 | +16.18 | +14.23 | +-0.68 | +0.17 | +1.95 | +2.28 | +1.01 | +0.94 | +1.00 | +
| male | +null | +W0 | +Landmark at 6 months | +V1_ignore | +14.79 | +14.68 | +14.23 | +0.11 | +0.09 | +0.45 | +1.78 | +1.00 | +0.95 | +1.00 | +
| male | +null | +W0 | +Landmark at 6 months | +V2_cluster | +14.79 | +14.68 | +14.23 | +0.11 | +0.09 | +0.45 | +1.78 | +1.00 | +0.94 | +1.00 | +
| male | +null | +W0 | +Landmark at 6 months | +V3_random | +14.86 | +14.68 | +14.23 | +0.19 | +0.08 | +0.45 | +1.82 | +0.99 | +0.93 | +1.00 | +
| male | +null | +W0 | +Landmark at 6 months | +V4_within | +14.59 | +14.68 | +14.23 | +-0.09 | +0.15 | +0.45 | +2.38 | +0.96 | +0.93 | +1.00 | +
| male | +null | +W0 | +Sequential trials, ITT | +V1_ignore | +15.07 | +15.06 | +14.23 | +0.01 | +0.17 | +0.84 | +1.69 | +1.01 | +0.96 | +1.00 | +
| male | +null | +W0 | +Sequential trials, ITT | +V2_cluster | +15.07 | +15.06 | +14.23 | +0.01 | +0.17 | +0.84 | +1.69 | +1.00 | +0.96 | +1.00 | +
| male | +null | +W0 | +Sequential trials, ITT | +V3_random | +15.06 | +15.06 | +14.23 | +-0.00 | +0.17 | +0.84 | +1.75 | +0.99 | +0.94 | +1.00 | +
| male | +null | +W0 | +Sequential trials, ITT | +V4_within | +14.84 | +15.06 | +14.23 | +-0.22 | +0.22 | +0.84 | +2.15 | +0.96 | +0.93 | +1.00 | +
| male | +null | +W0 | +CCW, A vs B2 | +V1_ignore | +14.32 | +14.47 | +14.23 | +-0.15 | +0.40 | +0.24 | +3.98 | +0.95 | +0.93 | +0.97 | +
| male | +null | +W0 | +CCW, A vs B2 | +V2_cluster | +14.32 | +14.47 | +14.23 | +-0.15 | +0.40 | +0.24 | +3.98 | +0.95 | +0.93 | +0.98 | +
| male | +null | +W0 | +CCW, A vs B2 | +V3_random | +14.49 | +14.47 | +14.23 | +0.02 | +0.40 | +0.24 | +3.98 | +0.97 | +0.94 | +0.98 | +
| male | +null | +W0 | +CCW, A vs B2 | +V4_within | +14.70 | +14.47 | +14.23 | +0.24 | +0.46 | +0.24 | +4.57 | +1.01 | +0.93 | +0.95 | +
| male | +null | +W0 | +CCW, A vs B1 (reference) | +V1_ignore | +14.09 | +14.23 | +14.23 | +-0.14 | +0.40 | +0.00 | +3.98 | +0.95 | +0.93 | +0.97 | +
| male | +null | +W0 | +CCW, A vs B1 (reference) | +V2_cluster | +14.09 | +14.23 | +14.23 | +-0.14 | +0.40 | +0.00 | +3.98 | +0.95 | +0.93 | +0.97 | +
| male | +null | +W0 | +CCW, A vs B1 (reference) | +V3_random | +14.26 | +14.23 | +14.23 | +0.03 | +0.40 | +0.00 | +3.98 | +0.97 | +0.94 | +0.97 | +
| male | +null | +W0 | +CCW, A vs B1 (reference) | +V4_within | +14.45 | +14.23 | +14.23 | +0.22 | +0.46 | +0.00 | +4.57 | +1.01 | +0.93 | +0.95 | +
| male | +null | +W1 | +Naive ‘ever early PVI’ | +V1_ignore | +16.45 | +15.62 | +13.86 | +0.83 | +0.11 | +1.76 | +2.09 | +0.88 | +0.92 | +1.00 | +
| male | +null | +W1 | +Naive ‘ever early PVI’ | +V2_cluster | +16.45 | +15.62 | +13.86 | +0.83 | +0.11 | +1.76 | +2.09 | +0.90 | +0.93 | +1.00 | +
| male | +null | +W1 | +Naive ‘ever early PVI’ | +V3_random | +16.28 | +15.62 | +13.86 | +0.66 | +0.09 | +1.76 | +2.15 | +0.89 | +0.94 | +1.00 | +
| male | +null | +W1 | +Naive ‘ever early PVI’ | +V4_within | +15.25 | +15.62 | +13.86 | +-0.37 | +0.16 | +1.76 | +2.48 | +0.95 | +0.92 | +1.00 | +
| male | +null | +W1 | +Landmark at 6 months | +V1_ignore | +15.04 | +13.92 | +13.86 | +1.12 | +0.09 | +0.05 | +1.96 | +0.92 | +0.90 | +1.00 | +
| male | +null | +W1 | +Landmark at 6 months | +V2_cluster | +15.04 | +13.92 | +13.86 | +1.12 | +0.09 | +0.05 | +1.96 | +0.94 | +0.92 | +1.00 | +
| male | +null | +W1 | +Landmark at 6 months | +V3_random | +14.80 | +13.92 | +13.86 | +0.89 | +0.08 | +0.05 | +1.96 | +0.94 | +0.93 | +1.00 | +
| male | +null | +W1 | +Landmark at 6 months | +V4_within | +14.10 | +13.92 | +13.86 | +0.18 | +0.15 | +0.05 | +2.39 | +0.95 | +0.94 | +1.00 | +
| male | +null | +W1 | +Sequential trials, ITT | +V1_ignore | +15.43 | +14.62 | +13.86 | +0.80 | +0.19 | +0.76 | +1.92 | +0.90 | +0.91 | +1.00 | +
| male | +null | +W1 | +Sequential trials, ITT | +V2_cluster | +15.43 | +14.62 | +13.86 | +0.80 | +0.19 | +0.76 | +1.92 | +0.92 | +0.92 | +1.00 | +
| male | +null | +W1 | +Sequential trials, ITT | +V3_random | +15.10 | +14.62 | +13.86 | +0.47 | +0.20 | +0.76 | +1.96 | +0.91 | +0.95 | +1.00 | +
| male | +null | +W1 | +Sequential trials, ITT | +V4_within | +14.47 | +14.62 | +13.86 | +-0.15 | +0.23 | +0.76 | +2.31 | +0.92 | +0.91 | +1.00 | +
| male | +null | +W1 | +CCW, A vs B2 | +V1_ignore | +14.86 | +14.12 | +13.86 | +0.74 | +0.41 | +0.25 | +4.12 | +0.96 | +0.94 | +0.99 | +
| male | +null | +W1 | +CCW, A vs B2 | +V2_cluster | +14.86 | +14.12 | +13.86 | +0.74 | +0.41 | +0.25 | +4.12 | +0.97 | +0.94 | +0.99 | +
| male | +null | +W1 | +CCW, A vs B2 | +V3_random | +14.51 | +14.12 | +13.86 | +0.39 | +0.41 | +0.25 | +4.13 | +0.97 | +0.93 | +0.99 | +
| male | +null | +W1 | +CCW, A vs B2 | +V4_within | +14.43 | +14.12 | +13.86 | +0.31 | +0.48 | +0.25 | +4.84 | +0.96 | +0.94 | +0.94 | +
| male | +null | +W1 | +CCW, A vs B1 (reference) | +V1_ignore | +14.61 | +13.86 | +13.86 | +0.75 | +0.41 | +0.00 | +4.12 | +0.96 | +0.94 | +0.99 | +
| male | +null | +W1 | +CCW, A vs B1 (reference) | +V2_cluster | +14.61 | +13.86 | +13.86 | +0.75 | +0.41 | +0.00 | +4.12 | +0.97 | +0.94 | +0.99 | +
| male | +null | +W1 | +CCW, A vs B1 (reference) | +V3_random | +14.26 | +13.86 | +13.86 | +0.40 | +0.41 | +0.00 | +4.13 | +0.97 | +0.92 | +0.99 | +
| male | +null | +W1 | +CCW, A vs B1 (reference) | +V4_within | +14.15 | +13.86 | +13.86 | +0.29 | +0.48 | +0.00 | +4.84 | +0.96 | +0.94 | +0.93 | +
| male | +null | +W1_rho0 | +Naive ‘ever early PVI’ | +V1_ignore | +16.29 | +16.39 | +14.77 | +-0.10 | +0.09 | +1.62 | +1.74 | +1.05 | +0.96 | +1.00 | +
| male | +null | +W1_rho0 | +Naive ‘ever early PVI’ | +V2_cluster | +16.29 | +16.39 | +14.77 | +-0.10 | +0.09 | +1.62 | +1.74 | +1.07 | +0.97 | +1.00 | +
| male | +null | +W1_rho0 | +Naive ‘ever early PVI’ | +V3_random | +16.44 | +16.39 | +14.77 | +0.05 | +0.08 | +1.62 | +1.81 | +1.05 | +0.97 | +1.00 | +
| male | +null | +W1_rho0 | +Naive ‘ever early PVI’ | +V4_within | +15.88 | +16.39 | +14.77 | +-0.51 | +0.14 | +1.62 | +2.17 | +1.07 | +0.95 | +1.00 | +
| male | +null | +W1_rho0 | +Landmark at 6 months | +V1_ignore | +15.01 | +14.92 | +14.77 | +0.09 | +0.10 | +0.15 | +1.64 | +1.10 | +0.98 | +1.00 | +
| male | +null | +W1_rho0 | +Landmark at 6 months | +V2_cluster | +15.01 | +14.92 | +14.77 | +0.09 | +0.10 | +0.15 | +1.64 | +1.12 | +0.98 | +1.00 | +
| male | +null | +W1_rho0 | +Landmark at 6 months | +V3_random | +15.11 | +14.92 | +14.77 | +0.19 | +0.08 | +0.15 | +1.69 | +1.11 | +0.98 | +1.00 | +
| male | +null | +W1_rho0 | +Landmark at 6 months | +V4_within | +14.90 | +14.92 | +14.77 | +-0.03 | +0.13 | +0.15 | +2.01 | +1.15 | +0.98 | +1.00 | +
| male | +null | +W1_rho0 | +Sequential trials, ITT | +V1_ignore | +15.36 | +15.62 | +14.77 | +-0.26 | +0.17 | +0.84 | +1.65 | +1.05 | +0.98 | +1.00 | +
| male | +null | +W1_rho0 | +Sequential trials, ITT | +V2_cluster | +15.36 | +15.62 | +14.77 | +-0.26 | +0.17 | +0.84 | +1.65 | +1.07 | +0.98 | +1.00 | +
| male | +null | +W1_rho0 | +Sequential trials, ITT | +V3_random | +15.35 | +15.62 | +14.77 | +-0.27 | +0.17 | +0.84 | +1.71 | +1.05 | +0.97 | +1.00 | +
| male | +null | +W1_rho0 | +Sequential trials, ITT | +V4_within | +15.16 | +15.62 | +14.77 | +-0.45 | +0.20 | +0.84 | +2.00 | +1.08 | +0.95 | +1.00 | +
| male | +null | +W1_rho0 | +CCW, A vs B2 | +V1_ignore | +14.99 | +15.02 | +14.77 | +-0.03 | +0.33 | +0.25 | +3.25 | +1.20 | +0.98 | +1.00 | +
| male | +null | +W1_rho0 | +CCW, A vs B2 | +V2_cluster | +14.99 | +15.02 | +14.77 | +-0.03 | +0.33 | +0.25 | +3.25 | +1.21 | +0.99 | +1.00 | +
| male | +null | +W1_rho0 | +CCW, A vs B2 | +V3_random | +14.95 | +15.02 | +14.77 | +-0.07 | +0.34 | +0.25 | +3.41 | +1.16 | +0.97 | +1.00 | +
| male | +null | +W1_rho0 | +CCW, A vs B2 | +V4_within | +14.83 | +15.02 | +14.77 | +-0.19 | +0.40 | +0.25 | +4.03 | +1.14 | +0.96 | +0.96 | +
| male | +null | +W1_rho0 | +CCW, A vs B1 (reference) | +V1_ignore | +14.75 | +14.77 | +14.77 | +-0.02 | +0.33 | +0.00 | +3.25 | +1.20 | +0.98 | +1.00 | +
| male | +null | +W1_rho0 | +CCW, A vs B1 (reference) | +V2_cluster | +14.75 | +14.77 | +14.77 | +-0.02 | +0.33 | +0.00 | +3.25 | +1.21 | +0.98 | +1.00 | +
| male | +null | +W1_rho0 | +CCW, A vs B1 (reference) | +V3_random | +14.71 | +14.77 | +14.77 | +-0.06 | +0.34 | +0.00 | +3.41 | +1.16 | +0.97 | +0.98 | +
| male | +null | +W1_rho0 | +CCW, A vs B1 (reference) | +V4_within | +14.57 | +14.77 | +14.77 | +-0.20 | +0.40 | +0.00 | +4.03 | +1.14 | +0.96 | +0.96 | +
| male | +null | +W2 | +Naive ‘ever early PVI’ | +V1_ignore | +17.43 | +26.14 | +14.83 | +-8.72 | +0.99 | +11.32 | +1.84 | +1.02 | +0.02 | +1.00 | +
| male | +null | +W2 | +Naive ‘ever early PVI’ | +V2_cluster | +17.43 | +26.14 | +14.83 | +-8.72 | +0.99 | +11.32 | +1.84 | +1.03 | +0.01 | +1.00 | +
| male | +null | +W2 | +Naive ‘ever early PVI’ | +V3_random | +18.38 | +26.14 | +14.83 | +-7.76 | +0.97 | +11.32 | +2.92 | +1.06 | +0.26 | +1.00 | +
| male | +null | +W2 | +Naive ‘ever early PVI’ | +V4_within | +15.80 | +26.14 | +14.83 | +-10.34 | +1.06 | +11.32 | +3.66 | +0.97 | +0.16 | +1.00 | +
| male | +null | +W2 | +Landmark at 6 months | +V1_ignore | +16.05 | +16.06 | +14.83 | +-0.00 | +0.54 | +1.23 | +1.80 | +1.02 | +0.95 | +1.00 | +
| male | +null | +W2 | +Landmark at 6 months | +V2_cluster | +16.05 | +16.06 | +14.83 | +-0.00 | +0.54 | +1.23 | +1.80 | +1.03 | +0.95 | +1.00 | +
| male | +null | +W2 | +Landmark at 6 months | +V3_random | +15.72 | +16.06 | +14.83 | +-0.34 | +0.50 | +1.23 | +2.91 | +0.99 | +0.95 | +1.00 | +
| male | +null | +W2 | +Landmark at 6 months | +V4_within | +14.82 | +16.06 | +14.83 | +-1.24 | +0.53 | +1.23 | +3.83 | +0.93 | +0.87 | +0.99 | +
| male | +null | +W2 | +Sequential trials, ITT | +V1_ignore | +16.34 | +15.74 | +14.83 | +0.60 | +0.17 | +0.91 | +1.73 | +1.02 | +0.94 | +1.00 | +
| male | +null | +W2 | +Sequential trials, ITT | +V2_cluster | +16.34 | +15.74 | +14.83 | +0.60 | +0.17 | +0.91 | +1.73 | +1.02 | +0.95 | +1.00 | +
| male | +null | +W2 | +Sequential trials, ITT | +V3_random | +15.84 | +15.74 | +14.83 | +0.10 | +0.25 | +0.91 | +2.54 | +0.96 | +0.96 | +1.00 | +
| male | +null | +W2 | +Sequential trials, ITT | +V4_within | +15.04 | +15.74 | +14.83 | +-0.70 | +0.30 | +0.91 | +2.97 | +0.90 | +0.91 | +1.00 | +
| male | +null | +W2 | +CCW, A vs B2 | +V1_ignore | +15.65 | +15.14 | +14.83 | +0.51 | +0.42 | +0.31 | +4.19 | +0.99 | +0.93 | +1.00 | +
| male | +null | +W2 | +CCW, A vs B2 | +V2_cluster | +15.65 | +15.14 | +14.83 | +0.51 | +0.42 | +0.31 | +4.19 | +0.98 | +0.93 | +1.00 | +
| male | +null | +W2 | +CCW, A vs B2 | +V3_random | +15.80 | +15.14 | +14.83 | +0.66 | +0.64 | +0.31 | +6.38 | +0.85 | +0.96 | +0.91 | +
| male | +null | +W2 | +CCW, A vs B2 | +V4_within | +15.42 | +15.14 | +14.83 | +0.28 | +0.75 | +0.31 | +7.49 | +0.78 | +0.94 | +0.79 | +
| male | +null | +W2 | +CCW, A vs B1 (reference) | +V1_ignore | +15.39 | +14.83 | +14.83 | +0.57 | +0.42 | +0.00 | +4.19 | +0.99 | +0.93 | +1.00 | +
| male | +null | +W2 | +CCW, A vs B1 (reference) | +V2_cluster | +15.39 | +14.83 | +14.83 | +0.57 | +0.42 | +0.00 | +4.19 | +0.98 | +0.93 | +1.00 | +
| male | +null | +W2 | +CCW, A vs B1 (reference) | +V3_random | +15.51 | +14.83 | +14.83 | +0.68 | +0.64 | +0.00 | +6.38 | +0.85 | +0.96 | +0.91 | +
| male | +null | +W2 | +CCW, A vs B1 (reference) | +V4_within | +14.89 | +14.83 | +14.83 | +0.06 | +0.75 | +0.00 | +7.49 | +0.78 | +0.95 | +0.76 | +
| male | +null | +W3 | +Naive ‘ever early PVI’ | +V1_ignore | +18.46 | +17.59 | +7.97 | +0.88 | +0.71 | +9.62 | +2.03 | +0.93 | +0.91 | +1.00 | +
| male | +null | +W3 | +Naive ‘ever early PVI’ | +V2_cluster | +18.46 | +17.59 | +7.97 | +0.88 | +0.71 | +9.62 | +2.03 | +1.01 | +0.94 | +1.00 | +
| male | +null | +W3 | +Naive ‘ever early PVI’ | +V3_random | +14.04 | +17.59 | +7.97 | +-3.55 | +0.67 | +9.62 | +2.84 | +0.95 | +0.70 | +0.99 | +
| male | +null | +W3 | +Naive ‘ever early PVI’ | +V4_within | +10.77 | +17.59 | +7.97 | +-6.82 | +0.73 | +9.62 | +2.97 | +0.97 | +0.32 | +0.98 | +
| male | +null | +W3 | +Landmark at 6 months | +V1_ignore | +16.96 | +8.32 | +7.97 | +8.65 | +0.43 | +0.34 | +1.99 | +0.94 | +0.00 | +1.00 | +
| male | +null | +W3 | +Landmark at 6 months | +V2_cluster | +16.96 | +8.32 | +7.97 | +8.65 | +0.43 | +0.34 | +1.99 | +1.03 | +0.00 | +1.00 | +
| male | +null | +W3 | +Landmark at 6 months | +V3_random | +11.32 | +8.32 | +7.97 | +3.01 | +0.35 | +0.34 | +2.41 | +0.99 | +0.77 | +0.99 | +
| male | +null | +W3 | +Landmark at 6 months | +V4_within | +9.67 | +8.32 | +7.97 | +1.35 | +0.37 | +0.34 | +2.91 | +0.96 | +0.93 | +0.93 | +
| male | +null | +W3 | +Sequential trials, ITT | +V1_ignore | +17.39 | +8.27 | +7.97 | +9.12 | +0.20 | +0.29 | +2.01 | +0.89 | +0.00 | +1.00 | +
| male | +null | +W3 | +Sequential trials, ITT | +V2_cluster | +17.39 | +8.27 | +7.97 | +9.12 | +0.20 | +0.29 | +2.01 | +0.98 | +0.00 | +1.00 | +
| male | +null | +W3 | +Sequential trials, ITT | +V3_random | +11.54 | +8.27 | +7.97 | +3.28 | +0.23 | +0.29 | +2.32 | +0.94 | +0.73 | +1.00 | +
| male | +null | +W3 | +Sequential trials, ITT | +V4_within | +10.24 | +8.27 | +7.97 | +1.97 | +0.26 | +0.29 | +2.59 | +0.92 | +0.83 | +1.00 | +
| male | +null | +W3 | +CCW, A vs B2 | +V1_ignore | +14.62 | +8.33 | +7.97 | +6.29 | +0.41 | +0.36 | +4.06 | +0.99 | +0.70 | +0.98 | +
| male | +null | +W3 | +CCW, A vs B2 | +V2_cluster | +14.62 | +8.33 | +7.97 | +6.29 | +0.41 | +0.36 | +4.06 | +1.01 | +0.70 | +0.97 | +
| male | +null | +W3 | +CCW, A vs B2 | +V3_random | +10.29 | +8.33 | +7.97 | +1.96 | +0.47 | +0.36 | +4.70 | +1.00 | +0.94 | +0.59 | +
| male | +null | +W3 | +CCW, A vs B2 | +V4_within | +9.53 | +8.33 | +7.97 | +1.20 | +0.50 | +0.36 | +4.96 | +1.03 | +0.93 | +0.49 | +
| male | +null | +W3 | +CCW, A vs B1 (reference) | +V1_ignore | +14.34 | +7.97 | +7.97 | +6.37 | +0.41 | +0.00 | +4.06 | +0.99 | +0.68 | +0.98 | +
| male | +null | +W3 | +CCW, A vs B1 (reference) | +V2_cluster | +14.34 | +7.97 | +7.97 | +6.37 | +0.41 | +0.00 | +4.06 | +1.01 | +0.66 | +0.97 | +
| male | +null | +W3 | +CCW, A vs B1 (reference) | +V3_random | +9.95 | +7.97 | +7.97 | +1.98 | +0.47 | +0.00 | +4.69 | +1.00 | +0.94 | +0.59 | +
| male | +null | +W3 | +CCW, A vs B1 (reference) | +V4_within | +8.90 | +7.97 | +7.97 | +0.92 | +0.49 | +0.00 | +4.94 | +1.03 | +0.93 | +0.40 | +
| male | +null | +W4 | +Naive ‘ever early PVI’ | +V1_ignore | +14.52 | +14.94 | +12.85 | +-0.41 | +0.10 | +2.08 | +1.72 | +1.06 | +0.97 | +1.00 | +
| male | +null | +W4 | +Naive ‘ever early PVI’ | +V2_cluster | +14.52 | +14.94 | +12.85 | +-0.41 | +0.10 | +2.08 | +1.72 | +1.06 | +0.96 | +1.00 | +
| male | +null | +W4 | +Naive ‘ever early PVI’ | +V3_random | +14.69 | +14.94 | +12.85 | +-0.25 | +0.10 | +2.08 | +1.79 | +1.05 | +0.96 | +1.00 | +
| male | +null | +W4 | +Naive ‘ever early PVI’ | +V4_within | +14.02 | +14.94 | +12.85 | +-0.92 | +0.15 | +2.08 | +2.27 | +1.06 | +0.90 | +1.00 | +
| male | +null | +W4 | +Landmark at 6 months | +V1_ignore | +13.33 | +13.36 | +12.85 | +-0.03 | +0.09 | +0.51 | +1.62 | +1.12 | +0.99 | +1.00 | +
| male | +null | +W4 | +Landmark at 6 months | +V2_cluster | +13.33 | +13.36 | +12.85 | +-0.03 | +0.09 | +0.51 | +1.62 | +1.11 | +0.99 | +1.00 | +
| male | +null | +W4 | +Landmark at 6 months | +V3_random | +13.45 | +13.36 | +12.85 | +0.09 | +0.08 | +0.51 | +1.67 | +1.11 | +1.00 | +1.00 | +
| male | +null | +W4 | +Landmark at 6 months | +V4_within | +13.06 | +13.36 | +12.85 | +-0.30 | +0.13 | +0.51 | +2.18 | +1.10 | +0.99 | +1.00 | +
| male | +null | +W4 | +Sequential trials, ITT | +V1_ignore | +13.65 | +13.71 | +12.85 | +-0.07 | +0.16 | +0.86 | +1.61 | +1.07 | +0.97 | +1.00 | +
| male | +null | +W4 | +Sequential trials, ITT | +V2_cluster | +13.65 | +13.71 | +12.85 | +-0.07 | +0.16 | +0.86 | +1.61 | +1.07 | +0.97 | +1.00 | +
| male | +null | +W4 | +Sequential trials, ITT | +V3_random | +13.69 | +13.71 | +12.85 | +-0.02 | +0.16 | +0.86 | +1.64 | +1.08 | +0.98 | +1.00 | +
| male | +null | +W4 | +Sequential trials, ITT | +V4_within | +13.39 | +13.71 | +12.85 | +-0.32 | +0.20 | +0.86 | +2.00 | +1.07 | +0.98 | +1.00 | +
| male | +null | +W4 | +CCW, A vs B2 | +V1_ignore | +15.25 | +14.41 | +12.85 | +0.84 | +0.39 | +1.56 | +3.95 | +1.02 | +0.95 | +1.00 | +
| male | +null | +W4 | +CCW, A vs B2 | +V2_cluster | +15.25 | +14.41 | +12.85 | +0.84 | +0.39 | +1.56 | +3.95 | +1.01 | +0.95 | +0.99 | +
| male | +null | +W4 | +CCW, A vs B2 | +V3_random | +15.29 | +14.41 | +12.85 | +0.88 | +0.39 | +1.56 | +3.93 | +1.03 | +0.94 | +1.00 | +
| male | +null | +W4 | +CCW, A vs B2 | +V4_within | +14.79 | +14.41 | +12.85 | +0.38 | +0.44 | +1.56 | +4.45 | +1.07 | +0.98 | +0.93 | +
| male | +null | +W4 | +CCW, A vs B1 (reference) | +V1_ignore | +13.76 | +12.85 | +12.85 | +0.91 | +0.39 | +0.00 | +3.94 | +1.02 | +0.95 | +0.98 | +
| male | +null | +W4 | +CCW, A vs B1 (reference) | +V2_cluster | +13.76 | +12.85 | +12.85 | +0.91 | +0.39 | +0.00 | +3.94 | +1.01 | +0.95 | +0.99 | +
| male | +null | +W4 | +CCW, A vs B1 (reference) | +V3_random | +13.73 | +12.85 | +12.85 | +0.88 | +0.39 | +0.00 | +3.93 | +1.03 | +0.94 | +0.99 | +
| male | +null | +W4 | +CCW, A vs B1 (reference) | +V4_within | +13.19 | +12.85 | +12.85 | +0.34 | +0.44 | +0.00 | +4.37 | +1.08 | +0.98 | +0.87 | +
| male | +null | +W5 | +Naive ‘ever early PVI’ | +V1_ignore | +21.97 | +16.04 | +14.23 | +5.94 | +0.16 | +1.81 | +1.30 | +1.05 | +0.01 | +1.00 | +
| male | +null | +W5 | +Naive ‘ever early PVI’ | +V2_cluster | +21.97 | +16.04 | +14.23 | +5.94 | +0.16 | +1.81 | +1.30 | +1.05 | +0.01 | +1.00 | +
| male | +null | +W5 | +Naive ‘ever early PVI’ | +V3_random | +22.06 | +16.04 | +14.23 | +6.02 | +0.16 | +1.81 | +1.31 | +1.06 | +0.00 | +1.00 | +
| male | +null | +W5 | +Naive ‘ever early PVI’ | +V4_within | +21.85 | +16.04 | +14.23 | +5.81 | +0.17 | +1.81 | +1.50 | +1.12 | +0.03 | +1.00 | +
| male | +null | +W5 | +Landmark at 6 months | +V1_ignore | +19.28 | +14.39 | +14.23 | +4.89 | +0.15 | +0.16 | +1.34 | +1.11 | +0.04 | +1.00 | +
| male | +null | +W5 | +Landmark at 6 months | +V2_cluster | +19.28 | +14.39 | +14.23 | +4.89 | +0.15 | +0.16 | +1.34 | +1.10 | +0.04 | +1.00 | +
| male | +null | +W5 | +Landmark at 6 months | +V3_random | +19.34 | +14.39 | +14.23 | +4.95 | +0.15 | +0.16 | +1.39 | +1.09 | +0.06 | +1.00 | +
| male | +null | +W5 | +Landmark at 6 months | +V4_within | +19.35 | +14.39 | +14.23 | +4.96 | +0.18 | +0.16 | +1.76 | +1.05 | +0.20 | +1.00 | +
| male | +null | +W5 | +Sequential trials, ITT | +V1_ignore | +20.21 | +15.06 | +14.23 | +5.14 | +0.13 | +0.84 | +1.30 | +1.08 | +0.03 | +1.00 | +
| male | +null | +W5 | +Sequential trials, ITT | +V2_cluster | +20.21 | +15.06 | +14.23 | +5.14 | +0.13 | +0.84 | +1.30 | +1.08 | +0.03 | +1.00 | +
| male | +null | +W5 | +Sequential trials, ITT | +V3_random | +20.24 | +15.06 | +14.23 | +5.17 | +0.13 | +0.84 | +1.30 | +1.11 | +0.03 | +1.00 | +
| male | +null | +W5 | +Sequential trials, ITT | +V4_within | +20.23 | +15.06 | +14.23 | +5.16 | +0.15 | +0.84 | +1.51 | +1.15 | +0.14 | +1.00 | +
| male | +null | +W5 | +CCW, A vs B2 | +V1_ignore | +18.57 | +14.47 | +14.23 | +4.10 | +0.30 | +0.24 | +3.05 | +1.04 | +0.75 | +1.00 | +
| male | +null | +W5 | +CCW, A vs B2 | +V2_cluster | +18.57 | +14.47 | +14.23 | +4.10 | +0.30 | +0.24 | +3.05 | +1.04 | +0.75 | +1.00 | +
| male | +null | +W5 | +CCW, A vs B2 | +V3_random | +18.55 | +14.47 | +14.23 | +4.09 | +0.32 | +0.24 | +3.20 | +1.01 | +0.76 | +1.00 | +
| male | +null | +W5 | +CCW, A vs B2 | +V4_within | +18.36 | +14.47 | +14.23 | +3.89 | +0.39 | +0.24 | +3.92 | +0.98 | +0.87 | +1.00 | +
| male | +null | +W5 | +CCW, A vs B1 (reference) | +V1_ignore | +18.34 | +14.23 | +14.23 | +4.11 | +0.31 | +0.00 | +3.05 | +1.04 | +0.75 | +1.00 | +
| male | +null | +W5 | +CCW, A vs B1 (reference) | +V2_cluster | +18.34 | +14.23 | +14.23 | +4.11 | +0.31 | +0.00 | +3.05 | +1.04 | +0.74 | +1.00 | +
| male | +null | +W5 | +CCW, A vs B1 (reference) | +V3_random | +18.32 | +14.23 | +14.23 | +4.10 | +0.32 | +0.00 | +3.21 | +1.00 | +0.76 | +1.00 | +
| male | +null | +W5 | +CCW, A vs B1 (reference) | +V4_within | +18.11 | +14.23 | +14.23 | +3.88 | +0.39 | +0.00 | +3.93 | +0.98 | +0.87 | +0.99 | +
| male | +null | +WR | +Naive ‘ever early PVI’ | +V1_ignore | +22.69 | +16.38 | +6.68 | +6.31 | +0.79 | +9.70 | +2.09 | +0.72 | +0.06 | +1.00 | +
| male | +null | +WR | +Naive ‘ever early PVI’ | +V2_cluster | +22.69 | +16.38 | +6.68 | +6.31 | +0.79 | +9.70 | +2.09 | +0.90 | +0.10 | +1.00 | +
| male | +null | +WR | +Naive ‘ever early PVI’ | +V3_random | +18.05 | +16.38 | +6.68 | +1.67 | +0.76 | +9.70 | +2.16 | +0.89 | +0.83 | +1.00 | +
| male | +null | +WR | +Naive ‘ever early PVI’ | +V4_within | +16.09 | +16.38 | +6.68 | +-0.29 | +0.79 | +9.70 | +2.39 | +0.88 | +0.89 | +1.00 | +
| male | +null | +WR | +Landmark at 6 months | +V1_ignore | +20.28 | +7.01 | +6.68 | +13.27 | +0.47 | +0.33 | +2.24 | +0.72 | +0.00 | +1.00 | +
| male | +null | +WR | +Landmark at 6 months | +V2_cluster | +20.28 | +7.01 | +6.68 | +13.27 | +0.47 | +0.33 | +2.24 | +0.89 | +0.00 | +1.00 | +
| male | +null | +WR | +Landmark at 6 months | +V3_random | +14.69 | +7.01 | +6.68 | +7.68 | +0.41 | +0.33 | +2.28 | +0.86 | +0.05 | +1.00 | +
| male | +null | +WR | +Landmark at 6 months | +V4_within | +13.64 | +7.01 | +6.68 | +6.63 | +0.42 | +0.33 | +2.62 | +0.86 | +0.18 | +1.00 | +
| male | +null | +WR | +Sequential trials, ITT | +V1_ignore | +21.09 | +6.88 | +6.68 | +14.21 | +0.22 | +0.20 | +2.16 | +0.71 | +0.00 | +1.00 | +
| male | +null | +WR | +Sequential trials, ITT | +V2_cluster | +21.09 | +6.88 | +6.68 | +14.21 | +0.22 | +0.20 | +2.16 | +0.89 | +0.00 | +1.00 | +
| male | +null | +WR | +Sequential trials, ITT | +V3_random | +15.40 | +6.88 | +6.68 | +8.52 | +0.21 | +0.20 | +2.06 | +0.91 | +0.00 | +1.00 | +
| male | +null | +WR | +Sequential trials, ITT | +V4_within | +14.30 | +6.88 | +6.68 | +7.42 | +0.23 | +0.20 | +2.30 | +0.89 | +0.09 | +1.00 | +
| male | +null | +WR | +CCW, A vs B2 | +V1_ignore | +18.57 | +7.05 | +6.68 | +11.52 | +0.39 | +0.37 | +3.90 | +0.92 | +0.10 | +1.00 | +
| male | +null | +WR | +CCW, A vs B2 | +V2_cluster | +18.57 | +7.05 | +6.68 | +11.52 | +0.39 | +0.37 | +3.90 | +0.96 | +0.11 | +1.00 | +
| male | +null | +WR | +CCW, A vs B2 | +V3_random | +14.24 | +7.05 | +6.68 | +7.19 | +0.47 | +0.37 | +4.68 | +0.86 | +0.63 | +0.97 | +
| male | +null | +WR | +CCW, A vs B2 | +V4_within | +13.73 | +7.05 | +6.68 | +6.68 | +0.51 | +0.37 | +5.08 | +0.85 | +0.72 | +0.92 | +
| male | +null | +WR | +CCW, A vs B1 (reference) | +V1_ignore | +18.26 | +6.68 | +6.68 | +11.58 | +0.39 | +0.00 | +3.89 | +0.92 | +0.10 | +1.00 | +
| male | +null | +WR | +CCW, A vs B1 (reference) | +V2_cluster | +18.26 | +6.68 | +6.68 | +11.58 | +0.39 | +0.00 | +3.89 | +0.96 | +0.11 | +1.00 | +
| male | +null | +WR | +CCW, A vs B1 (reference) | +V3_random | +13.86 | +6.68 | +6.68 | +7.18 | +0.47 | +0.00 | +4.68 | +0.86 | +0.63 | +0.97 | +
| male | +null | +WR | +CCW, A vs B1 (reference) | +V4_within | +13.01 | +6.68 | +6.68 | +6.33 | +0.51 | +0.00 | +5.07 | +0.85 | +0.74 | +0.90 | +